Drug, bio-affecting and body treating compositions patents - Monitor Patents
FreshPatents.com Logo    FreshPatents.com icons
Monitor Keywords Patent Organizer File a Provisional Patent Browse Inventors Browse Industry Browse Agents



USPTO Class 514  |  Browse by Industry: Previous - Next | All     monitor keywords
10/2012 | Recent  |  14: Jul | Jun | May | Apr | Mar | Feb | Jan | 13: Dec | Nov | Oct | Sep | Aug | Jul | Jun | May | Apr | Mar | Feb | Jan | 12: Dec | Nov | Oct | Sep | Aug | July | June | May | April | Mar | Feb | Jan | 11: Dec | Nov | Oct | Sep | Aug | Jul | Jun | May | Apr | Mar | Feb | Jan | 10: Dec | Nov | Oct | Sep | Aug | Jul | Jun | May | Apr | Mar | Feb | Jan |  | 09: Dec | Nov | Oct | Sep | Aug | Jl | Jn | May | Apr | Mar | Fb | Jn |  | 2008 | 2007 |

Drug, bio-affecting and body treating compositions October categorized by USPTO classification 10/12

Below are recently published patent applications awaiting approval from the USPTO. Recent week's RSS XML file available below.
Listing for abstract view: USPTO application #, Title, Abstract excerpt,Patent Agent. Listing format for list view: USPTO National Class full category number, title of the patent application.
  
10/25/2012 > 191 patent applications in 147 patent subcategories. categorized by USPTO classification

20120270766 - Early programming of brain function through soy protein feeding: Disclosed are methods for improving memory and/or cognition in an infant by administering soy protein to the infant's mother during pregnancy, and further administering soy protein to the infant after delivery. The soy protein may be administered to the infant's mother during lactation if the infant is breastfed and/or may... Agent: Abbott Laboratories

20120270767 - Tumor activated prodrugs: The instant invention provides compositions comprising a prodrug, the prodrug comprising a therapeutically active drug; and a peptide selected from the group consisting of the sequences: Ser-Ser-Lys-Tyr-Gln (SEQ ID NO:1); Gly-Lys-Ser-Gln-Tyr-Gln (SEQ ID NO:2); and Gly-Ser-Ala-Lys-Tyr-Gln (SEQ ID NO:3) wherein the peptide is linked to the therapeutically active drug to... Agent:

20120270768 - Tumor activated prodrugs: The instant invention provides compositions comprising a prodrug, the prodrug comprising a therapeutically active drug; and a peptide selected from the group consisting of the sequences: Ser-Ser-Lys-Tyr-Gln (SEQ ID NO:1); Gly-Lys-Ser-Gln-Tyr-Gln (SEQ ID NO:2); and Gly-Ser-Ala-Lys-Tyr-Gln (SEQ ID NO:3) wherein the peptide is linked to the therapeutically active drug to... Agent:

20120270769 - Methods of using macrocyclic inhibitors of serine protease enzymes: The present invention relates to novel macrocyclic compounds and salts thereof that bind to and/or are inhibitors of serine protease enzymes and methods of using the compounds. The present invention also relates to intermediates of these compounds, pharmaceutical compositions containing these compounds and methods of using the same. These compounds... Agent:

20120270770 - Anti-angiogenic peptides and their uses: This invention relates to novel synthetic lytic peptide fragments of full-length peptides with the capacity to modulate angiogenic activity in mammals. The invention also relates to the use of such peptides in pharmaceutical compositions and in methods for treating diseases or disorders that are associated with angiogenic activity.... Agent:

20120270771 - Apolipoprotein a-1 mimic peptides, and therapeutic agent for treating hyperlipidemia and diseases related to hyperlipidemia comprising same: The present invention relates to apolipoprotein A-1 mimic peptides, and therapeutic agent for treating hyperlipidemia and diseases related to hyperlipidemia comprising the same. More specifically, the apolipoprotein A-1 mimic peptides of the present invention were manufactured by modifying hydrophilic or hydrophobic face of existing 4F amphipathic peptides to produce Apo... Agent: Snu R&db Foundation

20120270772 - Lipopeptide compositions and related methods: The present disclosure provides novel powder daptomycin formulations which have improved chemical stability and faster reconstitution times when in the solid state. Some examples of the compositions comprise daptomycin and sucrose.... Agent: Cubist Pharmaceuticals, Inc.

20120270773 - Trim5alpha mutants and uses thereof: New mutant forms of TRIM5α comprising one or more mutations at amino acid positions corresponding to amino acids 324, 328, 330, 333, 335, 336 and/or 337 of wild-type human TRIM5α and which inhibit retrovirus replication are described. These mutants may be used, for example, in gene therapy applications for the... Agent:

20120270774 - Macrocyclic compounds, compositions comprising them and methods for preventing or treating hiv infection: The present invention relates to backbone cyclized CD-4 mimetics and to compositions and methods comprising them for preventing and treating viral infection. In particular, the present invention relates to orally bio-available compounds and formulations for prevention and treatment of human HIV-1 infection.... Agent: Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd

20120270775 - Crystalline forms of a potent hcv inhibitor: This invention relates to novel crystalline forms of the following Compound (1), and the sodium salt thereof, and methods for the preparation thereof, pharmaceutical compositions thereof, and their use in the treatment of Hepatitis C Viral (HCV) infection:... Agent: Boehringer Ingelheim International Gmbh

20120270776 - Novel pesticidal toxins: A novel pesticidal toxin that is highly active against a wide range of lepidopteran insect pests is disclosed. The DNA encoding the pesticidal toxin can be used to transform various prokaryotic and eukaryotic organisms to express the pesticidal toxin. These recombinant organisms can be used to control lepidopteran insects in... Agent: Syngenta Participations Ag

20120270777 - Lactoferrin and gut neuronal health in adults and/or elderly: The present invention relates generally to the field of neuronal health and neuronal protection. One embodiment of the present invention relates to a composition that can be used for the protection of the enteric nervous system from neurodegeneration. Disorders linked to an impaired enteric nervous system can be treated or... Agent: Nestec S.a.

20120270778 - Compositions and methods for non-invasive treatment of chronic complications of diabetes: The present invention provides C-peptide compositions that permit the noninvasive or non-injectable administration of C-peptide via nasal or pulmonary routes, as well as methods for treating disease.... Agent: Aegis Therapeutics LLC

20120270779 - Dosing regimens for neural stem cell proliferating agents and differentiating agents for the treatment of neurological disorders: Effective dosing regimens for neural stem cell proliferating and differentiating agents, kits comprising effective dosing regimens for neural stem cell proliferating and differentiating agents, and uses thereof are provided herein. Such kits and methods can be utilized acutely or chronically to treat a neurodegenerative disease or condition. Furthermore, the compositions... Agent: Stem Cell Therapeutics Corp.

20120270780 - Method and composition for modulating erythropoiesis: The invention generally relates to compositions and methods of their use. More specifically, the invention relates to the use of a compound in modulating erythropoiesis in a subject by mediating the activity and/or quantity of a member present in the LPA3-mediated signaling pathway, such as lysophosphatidic acid receptor subtype 3... Agent:

20120270781 - Expression vectors and cell lines expressing vascular endothelial growth factor d, and method of treating melanomas: This invention relates to expression vectors comprising VEGF-D and its biologically active derivatives, cell lines stably expressing VEGF-D and its biologically active derivatives, and to a method of making a polypeptide using these expression vectors and host cells. The invention also relates to a method for treating and alleviating melanomas... Agent: Vegenics Pty Limited

20120270782 - Formulation for hgh and rhigf-1 combination: The present invention relates to pharmaceutical compositions. More particularly, the invention relates to formulations of growth hormone (GH) and insulin-like growth factor (IGF-1) combination compositions which provide stable pharmaceutical compositions without aggregation formation at a desirable pH, and to processes of preparation thereof.... Agent: Ipsen Pharma S.a.s.

20120270783 - Rapid opioid detoxification: Rapid opioid detoxification procedures are provided which include sedating a patient with an anesthetic agent having a short full recovery period. The patient is administered an opioid antagonist while sedated and can be revived to an ambulatory condition within eight hours of initiating therapy. The described methods for detoxification also... Agent:

20120270784 - Growth hormone releasing factor (grf) analogs and uses thereof: Novel GRF analogs having GRF activity are described herein, as well as uses thereof for example as a GRF receptor agonist, e.g., to induce growth hormone secretion in a subject or biological system.... Agent: Theratechnologies Inc.

20120270785 - Therapy and prevention of problem drinking: The present invention provides methods for the therapy and prevention of problem drinking in alcohol-dependent and non-dependent subjects and those at risk of developing problem drinking behavior, and compositions of matter comprising oxytocin or an analog or derivative thereof or an agonist or partial agonist of an oxytocin receptor that... Agent:

20120270786 - Intestine and muscle recovery: The present invention generally relates to the field of nutrition and health. In particular, the present invention provides a composition that allows it to treat, limit or prevent muscle atrophy. Embodiments of the present invention are directed at GLP-2 containing compositions and to compositions that stimulate the secretion of GLP-2... Agent: Nestec S.a.

20120270787 - Compounds having peptides conjugated to bone targeting moieties and methods of making and using thereof: Described herein are compositions having a peptide sequence that includes at least one bone targeting moiety, wherein the bone targeting moiety is bonded to the peptide sequence by a linker, wherein the peptide sequence is calcitonin, and wherein the composition is neutral or a pharmaceutically acceptable salt or ester thereof.... Agent: The Governors Of The University Of Alberta

20120270788 - Method of administering porcine b-domainless fviii: The present invention provides a method of administering porcine B-domainless factor VIII (OBI-1) to a patient having factor VIII deficiency to provide more rapid and effective protection against bleeding episodes, compared to formerly available methods, or to provide more effective protection to such patients during non-bleeding periods. This invention is... Agent: Emory University

20120270789 - Treatment of coagulopathy with hyperfibrinolysis: The present invention relates to the use of thrombomodulin analogues for the manufacture of a medicament for the treatment of coagulopathy with hyperfibrinolysis, such as haemophilia disorders. These thrombomodulin analogs exhibit at therapeutically effective dosages an antifibrinolytic effect. Novel protein modifications together with methods for their identification are disclosed.... Agent: Paion Deutschland Gmbh

20120270790 - Compositions and methods for the treatment of myocardial ischemia/reperfusion injury with annexin a1 short peptide: The present invention provides a method of treating, ameliorating or preventing myocardial ischemia/reperfusion injury in a subject in need thereof, by administering to the subject a therapeutically effective amount of an ANXA1short peptide (ANXA1sp).... Agent: Duke University

20120270791 - Methods and compositions for treating and diagnosing kidney disease: The invention relates to a method for diagnosing a kidney disease state. The method comprises the steps of administering to a patient a composition comprising a conjugate or complex of the general formula V-L-D where the group V comprises a vitamin receptor binding ligand that binds to kidney proximal tubule... Agent:

20120270793 - Methods of treating a patient receiving a cardiac stent implant: Methods of treating a patient receiving a cardiac stent implant including the steps of: (i) monitoring the circulating level of Tn I or CK-MB in the patient; and (ii) administering SERP-I to the patient in an amount sufficient to prevent the circulating level of Tn I or CK-MB from exceeding... Agent: Viron Therapeutics Inc.

20120270792 - Urocortin-iii and uses thereof: A search of the public human genome database identified a human EST, GenBank accession number AW293249, which has high homology to known pufferfish urocortin sequences. The full length sequence was amplified from human genomic DNA and sequenced. Sequence homology comparisons of the novel sequence with human urocortin I and urocortin... Agent:

20120270794 - Polymorphisms associated with parkinson's disease: The invention provides human polymorphisms that are associated with Parkinson's disease (PD). Also disclosed are compositions and methods for use in diagnostics, prognostics, prevention, treatment and/or study of PD.... Agent: 23andme, Inc.

20120270795 - Compounds for the treatment of diseases related to protein misfolding: The present invention relates to the field of protein misfolding diseases and thus to diseases which are associated with or induced by abnormal or pathogenic three-dimensional folding of proteins and/or peptides or which are linked to pathogenic conformational changes of proteins and/or peptides, such as Alzheimer's disease. Particularly, the present... Agent:

20120270796 - Suspension type topical formulations comprising cyclic depsipeptide: e

20120270798 - Compositions and methods for preventing or treating cancer: The present invention relates to a MUC1 cytoplasmic tail peptide or portion thereof. These peptides are useful for inducing an immune response to MUC1-expressing tumor cells and thus for preventing or treating cancer.... Agent:

20120270797 - Engineered proteins including mutant fibronectin domains: The present invention features engineered proteins that can include a genetically modified Fn domain; two or more such domains joined to one another; or at least one genetically modified Fn domain joined to a target-specific protein scaffold. One or more accessory sequences can be included in or added to any... Agent: Massachusetts Institute Of Technology

20120270800 - Bifunctional stapled polypeptides and uses thereof: The invention relates to bifunctional stapled or stiched peptides comprising a targeting domain, a linker moiety, and an effector domain, that can be used to tether, or to bring into close proximity, at least two cellular entities (e.g., proteins). Certain aspects relate to bifunctional stapled or stiched peptides that bind... Agent: President And Fellows Of Harvard College

20120270801 - Her3 binding polypeptides: The disclosure provides a HER3 binding polypeptide, comprising a HER3 binding motif, BM, which motif consists of the amino acid sequence selected from i) EX2X3X4A X6X7EIW X11LPNL X16X17X18QX20 X21AFIX25 X26LX28D, and ii) an N amino acid sequence which has at least 90% identity to the sequence defined in i), wherein... Agent: Affibody Ab

20120270799 - Method of identifying a candidate compound which may inhibit a9-nachr overexpression or estrogen receptor-dependent transcription in nicotine-derived-compound-induced breast cancer cells: The invention relates to methods of identifying a candidate compound which may inhibit estrogen receptor-dependent transcription or α9-nAChR overexpression and proliferation of nicotine-derived-compound-induced breast cancer cells by using an activating protein 1 (AP1) polypeptide. The invention found that α9-nAChR has an activating protein 1 (AP1)-binding site, that the α9-nAChR promoter... Agent: Taipei Medical University

20120270802 - Binding molecules for the treatment of myeloid cell malignancies: Provided is a human C-type lectin, binding molecules that specifically bind to the human C-type lectin, nucleic acid molecules encoding the binding molecules or the human C-type lectin, compositions comprising the binding molecules or the human C-type lectin and methods of identifying or producing the binding molecules. The human C-type... Agent:

20120270803 - Mitotic kinesin inhibitors and methods of use thereof: This invention relates to inhibitors of mitotic kinesins, particularly KSP, and methods for producing these inhibitors. The invention also provides pharmaceutical compositions comprising the inhibitors of the invention and methods of utilizing the inhibitors and pharmaceutical compositions in the treatment and prevention of various disorders.... Agent:

20120270805 - Cyclosporin compositions: A composition is disclosed herein comprising from about 0.001% to about 0.4% cyclosporin A, castor oil, and a surfactant selected from the group consisting of alcohol ethoxylates, alcohols, alkyl glycosides, alkyl polyglycosides, alkylphenol ethoxylates, amine oxides, block polymers, carboxylated alcohol or alkylphenol ethoxylates, carboxylic acids/fatty acids, cellulose derivatives, ethoxylated alcohols,... Agent: Allergan, Inc.

20120270804 - Methods for the treatment and prevention of ocular disorders: Provided herein are methods for treatment of ocular diseases. The methods comprise administering a compound of general Formula (I): wherein R1, R2, R3, R4 and Ak are as defined in the specification.... Agent:

20120270806 - Designer cyclic peptides - hiv gp120 antagonists and their applications: The present invention is concerned with a novel composition of matter—a cyclic peptide derived from computer modeling studies that modulates the structure and function of the HIV main envelope protein gp120. The compound is capable of binding to the CD4-binding region of gp120 (this defines it as a CD4 mimic),... Agent:

20120270807 - Macrocyclic inhibitors of serine protease enzymes: The present invention relates to novel macrocyclic compounds and salts thereof that bind to and/or are inhibitors of serine protease enzymes. The present invention also relates to intermediates of these compounds, pharmaceutical compositions containing these compounds and methods of using the compounds. These compounds are useful as therapeutics for treatment... Agent:

20120270808 - Compositions and methods related to synchronous selection of homing peptides for multiple tissues by in vivo phage display: Embodiments of the invention include methods for selecting in parallel (i.e., synchronously or simultaneously) peptides that target a number of organs, in which each peptide targets distinct tissues or organs. Typically, the methods of the invention provide for peptide selection in a Minimal number of subjects and still provides a... Agent:

20120270809 - Human transmembrane proteins: The invention provides human transmembrane proteins (HTMPN) and polynucleotides which identify and encode HTMPN. The invention also provides expression vectors, host cells, antibodies, agonists, and antagonists. The invention also provides methods for diagnosing, treating, or preventing disorders associated with expression of HTMPN.... Agent: Incyte Corporation

20120270810 - Modification of enzymatic crosslinkers for controlling properties of crosslinked matrices: Improved matrix or hydrogel that is formed by enzymatic crosslinking of polymers wherein the crosslinking enzyme molecules have been modified for the purpose of improving the crosslinking density, mechanical properties, or other properties of the matrix, and/or to provide improved control over the rate and/or extent of crosslinking, wherein the... Agent:

20120270811 - Conformations of divergent peptides with mineral binding affinity: A series of peptides with divergent confirmations including structures of formula (1A), (1B), (2) and (3) are provided. In the formula, wherein U, G, A, B, R1, R2 and T are as defined in the specification. The divergent peptides disclosed in the present invention are characterized in a mineral binding... Agent: Kaohsiung Medical University

20120270812 - Compositions, methods, and kits for determining an alkyl transferase: The present invention relates to novel compounds as well as to compositions, methods, and kits comprising the compounds for determining an alkyltransferase (ATase), in particular an alkylguanine-DNA alkyl transferase (AGT). In general, the novel compounds provide for determining ATase levels, in particular for in vivo applications including, but not limited... Agent: Duke University

20120270813 - Process for preparing peptide products for promoting cholecystokinin secretion and use of the peptide products: A process for producing a peptide product having cholecystokinin secretion promoting effect, said process comprising hydrolyzing soybean residues with one or more proteases so that the peptide product having cholecystokinin secretion promoting effect is obtained. Also disclosed is the composition containing the peptide product and the use thereof.... Agent: Food Industry Research And Development Institute

20120270814 - Compositions and methods for reducing or preventing obesity: Compositions useful for weight management in an animal are disclosed. The compositions comprise one or more isoflavones or isoflavone metabolites, and in some embodiments include conjugated linoleic acid, and/or L-carnitine. Also disclosed are methods useful for weight management in an animal utilizing compositions comprising one or more isoflavones, conjugated linoleic... Agent:

20120270815 - Modified-galactosyl ceramides for staining and stimulating natural killer t cells: Modified glycolipid compounds are provided. Also disclosed are methods for activating an NKT cell, methods of stimulating an immune response in a subject, and methods suitable for labeling NKT cells.... Agent: Brigham Young University

20120270817 - 6-substituted estradiol derivatives and methods of use: A method of inhibiting growth of cancer cells comprising contacting cancer cells with a 6-substituted estradiol derivative in an amount at least partially sufficient to inhibit said growth is disclosed. The compounds have the general formula depicted below, wherein R1, R2, R3, R4, R5, R6 and R7 are as defined... Agent:

20120270816 - Methods of diagnosing and treating migraine: The present invention provides methods of diagnosing migraine attacks and determining predisposition of an individual to the development of migraine based on sodium level in the cerebrospinal fluid (CSF) and/or brain extracellular fluid. The invention also provides methods of treating migraine, wherein the individual is selected for treatment based in... Agent:

20120270821 - Cdk5 inhibitors and therapeutic uses thereof: Natural occurring inhibitors of cyclin-dependent protein kinase 5 (Cdk5), isolated from the root of Rhodiola rosea are structurally different from the known Cdk inhibitors. They show selectivity among different Cdks and efficacy to inhibit Cdk via a mixed-type of inhibition, which should lead to less toxicity and side-effects. They are... Agent: The Hong Kong University Of Science And Technology

20120270818 - Hdac 6 inhibitor-based methods for treating cancer: This invention provides methods for treating a subject afflicted with cancer, comprising concurrently administering (i) an HDAC 6-selective inhibitor and (ii) a suitable cytotoxic agent such as SAHA, doxorubicin or etoposide. This invention also provides methods for inducing the death of a transformed cell such as a cancer cell, comprising... Agent:

20120270820 - Use of albiflorin for anti-depression: A pharmaceutical composition containing albiflorin and use thereof in manufacturing medicaments for preventing and treating depression are provided by the present invention.... Agent:

20120270819 - Use of compounds with sglt-1/sglt-2 inhibitor activity for producing medicaments for treatment of bone disease: Use of compounds with SGLT-1/SGLT-2 inhibitor activity for producing medicaments for treatment of bone diseases The invention relates to the use of compounds with SGLT-1/SGLT-2 inhibitor activity for producing medicaments for treatment of bone diseases like osteoporosis. Preferred is the use of compounds of the formula I in which the... Agent: Sanofi

20120270822 - Stabilized formulation for oral administration of therapeutic agents and related methods: Stable formulations for the oral administration of therapeutic agents, methods for administering therapeutic agents using the formulations, and methods for treating conditions and diseases using the formulations.... Agent: University Of British Columbia

20120270823 - Aureolic acid derivatives, the method for preparation thereof and the uses thereof: Aureolic acid derivatives, process for obtaining them and uses thereof. This invention provides a bacterial strain that produces compound belonging to the family of aureolic acids useful in the treatment of cancer or nervous system diseases.... Agent: Entrechem, S.l.

20120270824 - Mannose derivatives as antagonists of bacterial adhesion: Compounds of the formula (I) wherein n is 0, 1 or 2, R1 is aryl, heteroaryl or heterocyclyl, and R2 and R3 are hydrogen or a substituent as described in the specification, are useful for the prevention and treatment of bacterial infections, in particular of urinary infections caused by E.... Agent:

20120270825 - Salix extract, its use and formulations containing it: The extract of the invention is characterized by an high content in salicin derivatives, reduced content in high molecular tannins and a content in proanthocyanidins sufficient to inhibit some tissue metal proteases. The product is formulated in oils rich in ω-3 and ω-6 acids which provide a better absorption of... Agent:

20120270826 - Adult stem cells, molecular signatures, and applications in the evaluation, diagnosis, and therapy of mammalian conditions: The present invention relates to the identification of a stem cell-specific signature or signatures composed of protein and/or nucleic acid markers expressed by virtue of the position of a cell or cells in the time line of its/their development and the impact of the cells' environment on this signature as... Agent:

20120270827 - Indole antiviral compositions and methods: The present invention provides novel chemical compounds, and methods for their use. In particular, the present invention provides indole derivatives (e.g. as shown in Formula (I)) and related compounds and methods of using indole derivatives and related compounds as therapeutic agents to treat a number of conditions, including those associated... Agent: The Regents Of The University Of Michigan

20120270922 - Antiangiogenic agent and method for inhibition of angiogenesis: This invention provides an antiangiogenic agent having a higher treatment effect than those of conventional antiangiogenic agents, and a method for inhibiting angiogenesis using the same. An antiangiogenic agent comprising at least one miRNA type selected from the group consisting of miRNAs, pre-miRNAs, and pri-miRNAs, each having a miRNA activity... Agent:

20120270925 - Antisense molecules and methods for treating pathologies: An antisense molecule capable of binding to a selected target site to induce exon skipping in the dystrophin gene, as set forth in SEQ ID NO: 1 to 59.... Agent: The University Of Western Australia

20120270920 - Compositions and methods for treatment of pouchitis: The present invention relates methods of treating pouchitis by administering a pharmaceutical formulation suitable for rectal use, such as an enema or suppository, comprising an antisense oligonucleotide targeted to ICAM-1 to an individual... Agent: Isis Pharmaceuticals, Inc.

20120270921 - Lipid formulated compositions and methods for inhibiting expression of a gene from the ebola virus: The invention relates to lipid formulated double-stranded ribonucleic acid (dsRNA) for inhibiting the expression of a gene from the Ebola virus.... Agent: Alnylam Pharmaceuticals, Inc.

20120270923 - Natriuretic peptide receptor as a biomarker for diagnosis and prognosis of cancer: The invention pertains to biomarkers for clinical detection of malignancies, especially for early detection of cancers. More specifically, this invention pertains to the role of Natriuretic Peptide Receptor A (NPRA) in cancer (e.g., tumor) progression. Thus, the invention includes materials and methods for the detection and prognosis of malignancies. The... Agent: University Of South Florida

20120270924 - Oligomeric compounds for the modultion of hif-1a expression: Oligonucleotides directed against the hypoxia-inducible factor-1α (HIF-1α) gene are provided for modulating the expression of HIF-1α. The compositions comprise oligonucleotides, particularly antisense oligonucleotides, targeted to nucleic acids encoding the HIF-1α. Methods of using these compounds for modulation of HIF-1α expression and for the treatment of diseases associated with the hypoxia-inducible... Agent: Enzon Pharmaceuticals. Inc.

20120270927 - Polyamides for nucleic acid delivery: A new class of non-viral transduction vectors that can be used for both in vivo and in vitro applications, including, a gene transfer vector that has comparable efficiency to a viral vector without the potential for a life-threatening immune response is provided. Complexes including a cellular delivery molecule or agent... Agent:

20120270926 - Sirna targeting apoliprotein (apob): Efficient sequence specific gene silencing is possible through the use of siRNA technology. By selecting particular siRNAs by rational design, one can maximize the generation of an effective gene silencing reagent, as well as methods for silencing genes. Methods, compositions, and kits generated through rational design of siRNAs are disclosed... Agent: Dharmacon, Inc.

20120270930 - Methods and compositions for dysferlin exon-skipping: The disclosure provides methods and compositions for inducing exon-skipping in a dysferlin pre-mRNA useful, e.g., in restoring function in a dysferlin deficiency. The disclosure also provides improved methods and compositions for generally inducing exon-skipping in a pre-mRNA.... Agent: Academisch Ziekenhuis Leiden H.o.d.n. Lumc

20120270928 - Microrna compounds and methods for modulating mir-21 activity: Described herein are compositions and methods for the inhibition of miR-21 activity. The compositions have certain nucleoside modification patterns that yield potent inhibitors of miR-21 activity. The compositions may be used to inhibit miR-21, and also to treat diseases associated with abnormal expression of miR-21, such as fibrosis and cancer.... Agent: Regulus Therapeutics Inc.

20120270929 - Modulation of ttc39 expression to increase hdl: Provided herein are methods, compounds, and compositions for reducing expression of a TTC39 mRNA and protein in an animal. Also provided herein are methods, compounds, and compositions for increasing HDL and/or decreasing PCSK9 in an animal. Such methods, compounds, and compositions are useful to treat, prevent, delay, or ameliorate cardiovascular... Agent: Isis Pharmaceuticals, Inc.

20120270828 - Quadruple therapy useful for treating persons afflicted with the human immunodeficiency virus (hiv): o

20120270829 - Use of adenosine a3 receptor agonists for treatment of neuropathic pain: A method of treating neuropathic pain in a subject is provided. The method comprises administering to the subject a pharmaceutical composition comprising a therapeutically effective amount of an A3AR agonist.... Agent: Saint Louis University

20120270830 - Nutritional compositions including theanine and exogenous nucleotides: Nutritional compositions and methods of making and using the nutritional compositions are provided. In a general embodiment, the present disclosure provides a nutritional composition including theanine and one or more exogenous nucleotides. The nutritional compositions can be specifically used to treat functional bowel disorders, including inflammatory bowel syndrome.... Agent: Nestec S.a.

20120270831 - Method for treating hematopoietic neoplasms: This invention relates to methods for treating a hematopoietic neoplasm comprising administering a therapeutically effective amount of a combretastatin compound, or a pharmaceutically acceptable salt thereof, to a subject having a hematological malignancy, wherein the combretastatin compound comprises a catechol or quinone moiety and is capable of forming a reactive... Agent: Oxigene, Inc.

20120270832 - Ketone accumulation inhibitor: A ketone body accumulation inhibitor that inhibits the accumulation of ketone bodies caused by exercising is provided in the present invention. The ketone body accumulation inhibitor contains isomaltulose as an active ingredient.... Agent: Mitsui Sugar Co., Ltd.

20120270834 - Depolymerized glycosaminoglycan from thelenota ananas and preperation method thereof: Disclosed is a depolymerized glycosaminoglycan from Thelenota ananas (dTHG), weight average molecular weight of which is about 8000˜20000 Da, and monosaccharide components of which are acetylgalactosamine (GalNAc), glucuronic acid (GlcUA), fucose (Fuc) or their sulfates (expressed as —OSO3−), in which molar ratio of GalNAc:GlcUA:Fuc:—OSO3− is about 1:(1±0.3):(1±0.3):(3.5±0.5). Said dTHG is... Agent: Shenzhen Neptunus Pharmaceutical Co., Ltd.

20120270833 - Immune activation of green tea hydrolysate and method for preparing food composition containing the same: Disclosed are an immune-boosting food composition containing a green tea hydrolysate as an active component, and a method for preparing the same.... Agent: Bionic Trading Corporation

20120270835 - Medicinal cream made using hydrocortisone acetate and a process to make the same: The present invention relates to a composition for treating skin inflammation, along with skin rejuvenation. More particularly, the present invention relates to a pharmaceutical cream comprising a biopolymer, and a corticosteroid. It discloses a composition for treating skin inflammation, along with skin rejuvenation containing a) a biopolymer in the form... Agent: Apex Laboratories Private Limited

20120270836 - Therapeutic approaches for treating alzheimer's disease: The present invention relates to compositions and methods for the treatment of Alzheimer's disease and related disorders. More specifically, the present invention relates to novel combinatorial therapies of Alzheimer's disease and related disorders. In particular, the invention concerns compounds which, alone or in combination(s), can effectively modulate synapse function and/or... Agent: Pharnext

20120270837 - Compositions that treat or inhibit pathological conditions associated with inflammatory response: A natural formulation of compounds that would to modulate inflammation is disclosed. The formulation would also inhibit expression of COX-2, inhibit synthesis of prostaglandins selectively in target cells, and inhibit inflammatory response selectively in target cells. The compositions containing at least one fraction isolated or derived from hops. Other embodiments... Agent: Metaproteomics, LLC

20120270839 - Compositions and methods for cancer treatment: Bromoacetoxycalcidiol (B3CD), which is structurally related to calcidiol, exhibits cytotoxic and apoptotic activity toward cancer cells, including highly aggressive neuroblastoma cells. A series of small molecules designed around the structure of B3CD is expected to have growth inhibitory and apoptogenic activities toward a wide range of malignancies. B3CD shows no... Agent: Women And Infants Hospital Of Ri

20120270838 - Spiroimidazolone derivative: o

20120270840 - Proteasome inhibitors and processes for their preparation, purification and use:

20120270841 - Diazonamide analogs: Diazonamide analogs having anti-mitotic activity, useful for the treatment of cancer and other proliferative disorders, and related pharmaceutical compositions are provided.... Agent:

20120270842 - Inhibitors of diacylglycerol o-acyltransferase 1 (dgat-1) and uses thereof: The invention pertains to use of DGAT-1 inhibitors to treat and/or prevent overweight, obesity and various diseases and disorders associated therewith. Other conditions also can be ameliorated or avoided, such as high postprandial triglycerides or diet-related hypertriglyceridemia, cardiovascular risk associated with excessive triglycerides, and insulin resistance/glucose intolerance in overweight patients,... Agent: Metabasis Therapeutics, Inc.

20120270843 - Pesticide composition comprising propamocarb-fosetylate and an insecticidally active substance: The present invention relates to a pesticide composition intended for protecting plants, crops or seeds against phyto-pathogenic fungi or damaging insects, and the corresponding methods of treatment using the said composition. More precisely, the subject of the present invention is a pesticide composition based on propamocarb-fosetylate, an insecticide active substance... Agent: Bayer Cropscience

20120270844 - Methods for treating alzheimer's disease: Provided herein arc PAK inhibitors. Also provided herein are compositions and methods for treating an individual suffering from Alzheimer's disease.... Agent: Afraxis, Inc.

20120270845 - Compositions and methods for treating chronic inflammation and inflammatory diseases: The present specification discloses pharmaceutical compositions, methods of preparing such pharmaceutical compositions, and methods and uses of treating a chronic inflammation and/or an inflammatory disease in an individual using such pharmaceutical compositions.... Agent:

20120270846 - Preparation of an acetyl salicylic acid/glutamic acid complex for oral administration: The present invention refers to a pharmaceutical preparation comprising an ionic type complex of acetyl salicylic acid and L-glutamic acid for use in the prevention or reduction of side-effects on stomach tissue associated with an oral administration of acetyl salicylic acid.... Agent: King Saud University

20120270847 - Novel carbamate amino acid and peptide prodrugs of opiates and uses thereof: Carbamate linked prodrugs of meptazinol and other opioid analgesics are provided. The prodrug moiety may comprise a single amino acid or short peptide. Additionally, the present invention relates to methods for reducing gastrointestinal side effects in a subject, the gastrointestinal side effects being associated with the administration of an opioid... Agent: Shire LLC

20120270849 - Combinations of niacin, omega-3 and plant sterols/stanols for prevention cholesterol treatment: Provided herein are nutritional compositions, regimens and methods for the prevention, mitigation, and treatment of a cholesterol abnormality. In some embodiments, the invention comprises combinations of niacin (precursor), and at least one ingredient selected from the group consisting of: an Omega-3 fatty acid, Omega-3 fatty acid precursor, or Omega-3 fatty... Agent: Prosoft Software, Inc.

20120270848 - Novel compositions and therapeutic methods using same: The present invention includes compositions and methods for treating a subject in need of opioid therapy, wherein the opioid therapy produces or has the possibility of producing respiratory depression or a breathing control disorder in the subject.... Agent: Galleon Pharmaceuticals, Inc.

20120270850 - Metal delivery agents and therapeutic uses of the same: The present invention relates to metal complexes, processes for their preparation and their use as pharmaceutical or veterinary agents, in particular for the treatment of conditions in which metal delivery can prevent, alleviate or ameliorate the condition. There are a number of clinical conditions which are caused by or associated... Agent: University Of Medlbourne

20120270851 - Use of ferroquine in the treatment or prevention of malaria: The present invention relates to the use of ferroquine or its N-demethylated metabolite or any of the pharmaceutically acceptable salts thereof for treating and/or preventing infections caused by the parasite Plasmodium vivax and, more generally, a parasite of the genus Plasmodium, the life cycle of which includes a phase of... Agent: Sanofi

20120270853 - Arylpropionamide, arylacrylamide, arylpropynamide, or arylmethylurea analogs as factor xia inhibitors: or a stereoisomer, tautomer, pharmaceutically acceptable salt or solvate form thereof, wherein the variables A, L1, M and R11 are as defined herein. The compounds of Formula (I) are selective inhibitors of serine protease enzymes of the coagulation cascade and/or contact activation system; for example thrombin, factor Xa, factor XIa,... Agent: Bristol-myers Squibb Company

20120270852 - Phenyl or pyridinyl-ethynyl derivatives: or to a pharmaceutically acceptable acid addition salt, to a racemic mixture, or to its corresponding enantiomer and/or optical isomer and/or stereoisomer thereof. Compounds of formula I are positive allosteric modulators (PAM) of the metabotropic glutamate receptor subtype 5 (mGluR5).... Agent:

20120270854 - Antiviral compounds: Compounds and methods for preventing and treating viral infections are provided. In some embodiments, novel compounds broad-spectrum antiviral activity are provided. In more specific embodiments, the compounds and methods are effective against viruses such as Venezuelan Equine Encephalitis, West Nile Virus, and Hepatitis C.... Agent: Prosetta Antiviral Inc.

20120270856 - Heteroaryloxy quinazoline derivatives: m

20120270855 - Thieno- and furo-pyrimidine modulators of the histamine h4 receptor: Thieno- and furo-pyrimidine compounds are described, which are useful as H4 receptor modulators. Such compounds may be used in pharmaceutical compositions and methods for the modulation of histamine H4 receptor activity and for the treatment of disease states, disorders, and conditions mediated by H4 receptor activity, such as inflammation.... Agent:

20120270857 - 5-ht3 receptor modulators, methods of making, and use thereof: Novel 5-HT3 receptor modulators are disclosed. These compounds are used in the treatment of various disorders, including chemotherapy-induced nausea and vomiting, post-operative nausea and vomiting, and irritable bowel syndrome. Methods of making these compounds are also described in the present invention.... Agent: Albany Molecular Research, Inc.

20120270858 - Isoquinoline, quinoline, and quinazoline derivatives as inhibitors of hedgehog signaling: The invention provides isoquinoline, quinoline, and quinazoline derivatives to treat a variety of disorders, diseases and pathologic conditions, and more specifically to the use of isoquinoline, quinoline, and quinazoline derivatives to inhibit the hedgehog signaling pathway and to the use of those compounds to the treatment of hyperproliferative diseases and... Agent: California Capital Equity, LLC

20120270859 - Indoline derivatives and their use in treating disease-states such as cancer: e

20120270862 - 1,4-benzodiazepine-2,5-diones and related compounds with therapeutic properties: The present invention provides novel chemical compounds characterized as Rho kinase (ROCK) inhibitors, methods for their discovery, and their therapeutic, research, and diagnostic use. In particular, the present invention provides 1,4-benzo-diazepine-2,5-dione compounds and related compounds having ROCK inhibitory activity, and methods of using such compounds as therapeutic agents to treat... Agent: The Regents Of The University Of Michigan

20120270860 - Methods for treating or preventing alcohol-related disorders or craving-related disorders: The invention provides methods for treating or preventing alcohol-related disorders or craving-related disorders comprising administering an effective amount of N-acetylcysteine or a pharmaceutically acceptable salt thereof to a patient to treat or prevent the alcohol or craving disorders. Methods for enhancing drug delivery and improving treatment outcomes are also described.... Agent:

20120270861 - Primary amines and derivatives thereof as modulators of the 5-ht2a serotonin receptor useful for the treatment of disorders related thereto: The present invention pertains to certain compounds of Formula (Ia) and pharmaceutical compositions thereof that modulate the activity of the 5-HT2A serotonin receptor. Compounds and pharmaceutical compositions thereof are directed to methods useful in the treatment of platelet aggreagation, coronary artery disease, myocardial infarction, transient ischemic attack, angina, stroke, atrial... Agent:

20120270863 - Fused ring analogues of anti-fibrotic agents: The present invention relates to arylcarbonyl and heteroarylcarbonyl anthranilate compounds that may be useful as anti-fibrotic agents. The present invention also relates to methods for their preparation, pharmaceutical compositions containing these compounds and uses of these compounds in the treatment disorders.... Agent: Fibrotech Therapeutics Pty Ltd

20120270864 - 2-quinolinone and 2-quinoxalinone-derivatives and their use as antibacterial agents: e

20120270865 - Heterocyclic compound:

20120270866 - 8-ethyl-6-(aryl)pyrido[2,3-d]pyrimidin-7(8h)-ones for the treatment of cns disorders: Provided herein are PAK inhibitors and methods of utilizing PAK inhibitors for the treatment of CNS disorders such as neuropsychiatric disorders.... Agent: Afraxis Inc.

20120270867 - Novel (6-oxo-1,6-dihydropyrimidin-2-yl)amide derivatives, preparation thereof and pharmaceutical use thereof as akt(pkb) phosphorylation inhibitors: The invention relates to the novel materials of formula (I), where: R1 is an optionally substituted aryl or heteroaryl; R is an H or, when formed with R1, a 5- or 6-member ring fused with an aryl or heretoaryl group optionally containing one or more of O, S, N, NH,... Agent: Sanofi

20120270869 - Pyridyl derivatives as cftr modulators: The present invention relates to modulators of ATP-Binding Cassette (“ABC”) transporters or fragments thereof, including Cystic Fibrosis Transmembrane Conductance Regulator (“CFTR”), compositions thereof, and methods therewith. The present invention also relates to methods of treating ABC transporter mediated diseases using such modulators.... Agent: Vertex Pharmaceuticals Incorporated

20120270868 - Rho kinase inhibitors: e

20120270870 - Indazole and pyrazolopyridine compounds as ccr1 receptor antagonists:

20120270871 - Pyrrolopyridinylpyrimidin-2-ylamine derivatives: Pyrrolopyridinylpyrimidin-2-ylamine derivatives of the formula (I), in which R1-R6 and R1 have the meanings indicated in claim 1, are inhibitors of cell proliferation/cell vitality and can be employed for the treatment of tumours.... Agent: Merck Patent Gesellschaft Mit Beschrankter Haftung

20120270872 - Crystalline forms of n-[3-fluoro-4-(oxy)phenyl]-n'-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide: This invention relates to three crystalline forms of N—[3-fluoro-4-((6-(methyloxy)-7-[(3-morpholin-4-ylpropyl)oxy]quinolin-4-yl|oxy)phenyl]—N′—(4-fluorophenyl)cyclopropane-1,1-dicarboxamide. Compound (I), designated as Form A, Form B, and Form C. The invention provides methods for treatment of cancer by exploiting the modulation of protein kinase activity. The invention also provides pharmaceutical compositions containing a crystalline form of Compound (I) and... Agent: Exelixis, Inc.

20120270873 - Adamantyl diamide derivatives and uses of same: i

20120270874 - Biaryl compositions and methods for modulating a kinase cascade:

20120270875 - Pyrimidine amide compounds:

20120270876 - Treatment of conditions through pharmacological modulation of the autonomic nervous system: Methods are provided for treating a subject for a condition caused by an abnormality in the subject's autonomic nervous system. In accordance with the subject methods, at least a portion of a subject's autonomic nervous system is pharmacologically modulated with at least one beta-blocker in a manner that is effective... Agent:

20120270877 - Ire-1alpha inhibitors: The invention provides compounds which directly inhibit IRE-1α activity in vitro, prodrugs, and pharmaceutically acceptable salts thereof. Such compounds and prodrugs are useful for treating diseases associated with the unfolded protein response and can be used as single agents or in combination therapies.... Agent: Mannkind Corporation

20120270878 - Inhibition of p38 kinase using symmetrical and unsymmetrical diphenyl ureas: This invention relates to the use of a group of aryl ureas in treating cytokine mediated diseases and proteolytic enzyme mediated diseases, and pharmaceutical compositions for use in such therapy.... Agent: Bayer Healthercare LLC

20120270879 - Heterocyclic compounds as ccr1 receptor antagonists: Disclosed are CCR1 receptor antagonists of the formula (I) wherein Ar1, Ar2, R1-R3, X and L are disclosed herein. Also disclosed are compositions, methods of making and using compounds of the formula (I).... Agent: Boehringer Ingelheim International Gmbh

20120270880 - Pyrrolo [2,3-d] pyrazin-7-ylpyrimidine compounds: Pyrrolo[2,3-d]pyrazin-7-ylpyrimidine compounds are inhibitors of cell proliferation/cell vitality and can be employed for the treatment of tumours.... Agent: Merck Patent Gesellschaft Mit Beschrankter Haftung

20120270881 - Conformationally constrained, fully synthetic macrocyclic compounds: Conformationally restricted, spatially defined 12-30 membered macrocyclic ring systems of formulae Ia and Ib are constituted by three distinct molecular parts: Template A, conformation Modulator B and Bridge C. These macrocycles Ia and Ib are readily manufactured by parallel synthesis or combinatorial chemistry in solution or on solid phase. They... Agent: Polyphor Ag

20120270882 - Fluorinated derivates of 3-hydroxypyridin-4-ones: Provided are compounds of Formula I which are derivatives of 3-Hydroxypyridin-4-ones. The compounds may be used in treatment of a medical condition related to a toxic concentration of iron. The compounds may be used for preparation of a medicament for treatment of a medical condition related to a toxic concentration... Agent: Apotex Technologies Inc.

20120270883 - Use of a polymorph of flibanserin for treating disease: The invention relates to the polymorph A of flibanserin, to a technical process for the preparation thereof, as well as to the use thereof for preparing medicaments.... Agent: Sprout Pharmaceuticals, Inc.

20120270884 - Methods of treating aneurysmal dilatation, blood vessel wall weakness and specifically abdominal aortic and thoracic aneurysm using matrix metalloprotease-2 inhibitors: The present invention provides methods of treating aneurysmal dilatation, blood vessel wall weakness, and specifically abdominal aortic aneurysm and thoracic aneurysm by inhibiting MMPs and ADAM-IO. Such compounds are useful in the in vitro study of the role of MMPs and ADAM-10 (and its inhibition) in biological processes. The present... Agent: Symphony Evolution, Inc.

20120270885 - Chemical compounds: provided that both are not N; R1, R2, R3, R3a, R4, R8 and Ra are specified organic groups and n and p are independently 0, 1, 2, 3 or 4; or salts or N-oxides thereof or compositions containing them in controlling insects, acarines, nematodes or molluscs. Novel compounds are also... Agent: Syngenta Crop Protection LLC

20120270886 - Inhibitors of iap: The invention provides novel inhibitors of IAP that are useful as therapeutic agents for treating malignancies where the compounds have the general formula (I): wherein Q, X1, X2, Y, Z1, Z2, Z3, Z4, R1, R2, R3, R3′, R4, R4′, R5, R6, R6′, and n are as described herein.... Agent:

20120270887 - Method of inhibiting myopia and application of an adenylyl cyclase inhibitor as a drug for inhibiting myopia: Methods for inhibiting myopia are disclosed. A method for inhibiting myopia includes reducing a level of an intraocular cAMP in a subject. The level of the intraocular cAMP is reduced by injecting an adenylyl cyclase inhibitor to achieve the inhibition of myopia in the subject. In one method, the adenylyl... Agent: School Of Ophthalmology And Optometry, Wenzhou Medical College

20120270888 - Pharmaceutical compositions of raltegravir, methods of preparation and use thereof: Disclosed are pharmaceutical compositions comprising HIV integrase strand transfer inhibitor. More particularly, oral pharmaceutical compositions of raltegravir or its pharmaceutically acceptable salts and process for preparing and use of the same are disclosed.... Agent:

20120270889 - Compound, certain novel forms thereof, pharmaceutical compositions thereof and methods for preparation and use: Compound of Formula A and pharmaceutically acceptable salts thereof and crystalline Forms I and II of Compound of Formula A! Also, methods for the preparation of such compounds, pharmaceutical compositions comprising such compounds, and methods for their uses.... Agent:

20120270890 - Methods of pancreatic beta cell regeneration: Disclosed are new methods for pancreatic β-cell regeneration and the methods for identifying adult pancreatic endocrine stem cells and the methods for identifying the existence of differentiation processes from adult pancreatic endocrine stem cells toward pancreatic β-cell fate and a new animal model for pancreatic β-cell regeneration. The present invention... Agent:

20120270892 - Aminopyrimidine kinase inhibitors: Disclosed are compounds, pharmaceutical compositions containing those compounds, and uses of the compounds and compositions as modulators of casein kinase 1 (e.g., CK1γ), casein kinase 2 (CK2), Pim-1, Pim-2, Pim-3, the TGFβ pathway, the Wnt pathway, the JAK/STAT pathway, and/or the mTOR pathway. Uses are also disclosed for the treatment... Agent: Jasco Pharmaceuticals, LLC

20120270891 - Salts of 4-methyl-n-[3-(4-methyl-imidazol-1-yl)-5-trifluoromethyl-phenyl]-3-(4-pyridin-3-yl-pyrimidin-2-ylamino)-benzamide: Salts of 4-methyl-N-[3-(4-methyl-imidazol-1-yl)-5-trifluoromethyl-phenyl]-3-(4-pyridin-3-yl-pyrimidin-2-ylamino)-benzamide are prepared by various processes.... Agent:

20120270893 - Substituted acetyl-coa carboxylase inhibitors: l

20120270894 - Controlled release of phenolic opioids: A method of providing a patient with controlled release of a phenolic opioid using a prodrug capable, upon enzymatic activation, of releasing the phenolic opioid through intra-molecular cyclization leading to formation of a cyclic urea, carbamate or thiocarbamate.... Agent:

20120270895 - Intranasal opioid compositions: The present invention relates to pharmaceutical compositions for intranasal administration to a mammal that contain an effective amount of an opioid, a liquid nasal carrier for the opioid, and optionally a sweetener, flavoring agent or masking agent. In some embodiments of the present invention, the pharmaceutical compositions have improved bioavailability.... Agent: University Of Kentucky Research Foundation

20120270896 - Antineoplastic combinations containing hki-272 and vinorelbine: A combination of HKI-272 compound and a vinorelbine compound in the treatment of a neoplasm is provided. Regimens, kits, and methods for treatment of neoplasm, including breast cancer including metastatic breast cancer, and lung cancer, using this combination, optionally in combination with other anti-neoplastic agents, or immune modulators are also... Agent: Wyeth LLC

20120270897 - Acetylene derivatives of 5-phenyl-pyrazolopyridine, preparation thereof, and therapeutic use thereof: c

20120270898 - Sulfonamide compound and crystal thereof: (S)-1-(4-Chloro-5-isoquinolinesulfonyl)-3-(methylamino)pyrrolidine monohydrochloride and a crystal thereof, and a crystal of the aforementioned monohydrochloride having a major peak or peaks at one or more positions selected from the group consisting of positions where 2θs are about 13.9°, 21.5°, 21.7°, 22.4°, 22.8°, 24.5° and 35.0° in a powder X-ray diffraction spectrum, which... Agent:

20120270899 - Compositions and methods for treating cardiovascular diseases: The present specification discloses pharmaceutical compositions, methods of preparing such pharmaceutical compositions, and methods and uses of treating a cardiovascular disease in an individual using such pharmaceutical compositions.... Agent:

20120270900 - Novel method of treatment: The present application discloses a method for the treatment or for alleviating the symptoms of a cancer in a subject comprising the steps of a) determining the level of Nicotinic acid phosphoribosyltransferase (NAPRT) in said subject; and b) 1) in the event of a level of NAPRT which is lower... Agent: Topo Target A/s

20120270901 - Indene derivatives as pharmaceutical agents: e

20120270903 - Intranasal spray device containing pharmaceutical composition: An intranasnal spray device contains a composition for the intranasal delivery of fentanyl or a pharmaceutically acceptable salt thereof to an animal includes an aqueous solution of fentanyl or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable additive selected from (i) a pectin and (ii) a poloxamer and chitosan... Agent: Archimedes Development Limited

20120270902 - N-substituted benzene sulfonamides:

20120270904 - Co-crystal of 4-furan-2(5h)-one with oxalic acid and use thereof as pesticide: The invention relates to a new co-crystal of 4-{[(6-chloropyrid-3-yl)methyl](2,2-difluoroethyl)amino}furan-2(5H)-one with oxalic acid, and also to processes for preparation thereof and use.... Agent: Bayer Technology Services Gmbh

20120270905 - Fluorinated 2,6-dialkyl-3,5-dicyano-4-(1h-indazol-5-yl)-1,4-dihydropyridines and methods of use thereof: The present invention relates to novel fluorinated 2,6-dialkyl-3,5-dicyano-4-(1H-indazol-5-yl)-1,4-dihydropyridine derivatives having protein tyrosine kinase inhibitory activity, to a process for the manufacture thereof and to the use thereof for the treatment of c-Met-mediated diseases or c-Met-mediated conditions, particularly cancer and other proliferative disorders.... Agent: Bayer Pharma Aktiengesellschaft

20120270906 - Cyclohexane derivative and pharmaceutical use thereof: A method relieves both nociceptive pain and neuropathic pain and has fewer side effects. The compound includes cyclohexane derivatives represented by the following compound, or pharmaceutically acceptable salts thereof or prodrugs thereof.... Agent: Toray Industries, Inc.

20120270907 - Therapeutic uses of nicotine: The uses of nicotine, analogues, precursors or derivatives thereof for treatment of inflammatory, infectious, candidal or degenerative diseases of the joint, central nervous system, kidney, lung, and liver, depression, obesity, bone disease and the like are described. The various diseases, disorders or conditions can be improved by means of intensification... Agent:

20120270908 - Substituted 3 -hydrozypyridines and pharmaceutical compositions thereof: Therapeutic compounds of formula (I) wherein R1 is selected from the group consisting of C2-8alkyl, R2 is independently selected from the group consisting of C1-8alkyl, R3 is independently selected from the group consisting of H and C1-8alkyl, R4 is independently selected from the group consisting of C1-8alkyl or pharmaceutically acceptable... Agent:

20120270909 - Method of inhibiting harmful microorganisms and barrier-forming composition therefor: In an embodiment, the barrier-forming composition includes a carbohydrate gum, a humectant, and an antimicrobial agent. The composition furthermore meets the following requirements: about 0.01%≦C≦about 0.4%; about 4.5%≦H≦about 65%; and 0.050%<A; or about 0%≦C≦about 0.4%; about 55%≦H≦about 65%; and 0.050%<A. C is the carbohydrate gum; H is the humectant; and... Agent:

20120270911 - Novel salts and polymorphs of desazadesferrithiocin polyether analogues as metal chelation agents: Disclosed herein are new salts and polymorphs of desazadesferrithiocin polyether (DADFT-PE) analogues, as well as pharmaceutical compositions comprising them and their application as metal chelation agents for the treatment of disease. Methods of chelation of iron and other metals in a human or animal subject are also provided for the... Agent: Ferrokin Biosciences, Inc.

20120270910 - Pharmaceutical containing ppar-delta agonist: Provision of an agent for promoting proliferation of meibomian gland epithelial cells or corneal epithelial cells, and a therapeutic agent for ocular diseases such as meibomian gland dysfunction, dry eye and the like. A preparation containing [3-[2-[4-isopropyl-2-(4-trifluoroethyl)phenyl-5-thiazolyl]ethyl]-5-methyl-1,2-benzisoxazol-6-yl]oxyacetic acid, [4-[3-[2-(4-trifluoromethyl)phenyl-4-isopropyl-5-thiazolyl]propionyl]-2-methylphenoxy]acetic acid or [4-[3-[2-(2-hydroxy-4-chlorophenyl)-5-isopropyl-4-oxazolyl]propionyl]-2-methylphenoxy]acetic acid, or a pharmacologically acceptable salt thereof as... Agent: Nippon Chemiphar Co., Ltd.

20120270912 - Substituted indolealkanoic acids: Disclosed are substituted indolealkanoic acids useful in the treatment of chronic complications arising from diabetes mellitus. Also disclosed are pharmaceutical compositions containing the compounds and methods of treatment employing the compounds, as well as methods for their synthesis.... Agent:

20120270913 - Composition and method for controlling plant diseases: The present invention provides: a composition for controlling plant diseases comprising, as active ingredients, ethaboxam and penflufen; a method for controlling plant diseases which comprises applying effective amounts of ethaboxam and penflufen to a plant or soil for growing plant; and so on.... Agent:

20120270914 - Split-luciferase c-myc sensor and uses thereof: A split luciferase-based sensor system was developed to noninvasively monitor and image phosphorylation-mediated c-Myc activation, in which the complementation of the split FL is induced by phosphorylation-mediated interaction between GSK3β and c-Myc. The complemented luciferase activity resulting from this interaction is specific to c-Myc phosphorylation and correlated with the steady-state... Agent: The Board Of Trustees Of The Leland Stanford Junior University

20120270915 - Fatty acid amide hydrolase inhihibitors for treating pain: Compounds of Formula 1 are described herein. These compounds may be administered to a patient for treatment of suffering from pain or other FAAH mediated conditions.... Agent:

20120270916 - Topical formulations for treating neuropathy: Compositions for the topical or transdermal treatment of neuropathy. More particularly, transdermal or topical compositions including a combination of ingredients that provide a surprising degree of effective relief from the symptoms of peripheral neuropathy are described.... Agent: Taraxos Inc.

20120270917 - Adamantane analogs: Provided are compounds that are capable of modulating the activity of the influenza A virus via interaction with the M2 transmembrane protein. Also provided are methods for treating an influenza A-affected disease state or infection comprising administering a composition comprising one or more compounds that have been identified as being... Agent: The Trustees Of The University Of Pennsylvania

20120270918 - Pyrazole derivatives, preparation thereof, and therapeutic use thereof: o

20120270919 - Proteasome inhibitors: Disclosed herein are compounds of Formula (I) that include a sulfonate ester, ester or ether group. Compounds of Formula (I) can be included in pharmaceutical compositions, and can be used to treating and/or ameliorating a disease or condition, such as cancer, a microbial disease and/or inflammation.... Agent: Nereus Pharmaceuticals, Inc.

20120270932 - Personal care compositions with improved hyposensitivity: The present invention provides personal care compositions comprising a carrier and a mixture of essential oil components having specific levels of eucalyptol, terpene materials and auxiliary fragrance materials. The compositions herein gentle to skin and have a fragrance and activity similar if the composition were made using the pure extracted... Agent:

20120270931 - Stable pharmaceutical formulations comprising lubiprostone: Provided is a pharmaceutical formulation comprising lubiprostone and at least one propylene glycol ester. The propylene glycol ester is typically selected from the group consisting of: propylene glycol mono-ester of lauric acid, propylene glycol mono-ester of caprylic acid, propylene glycol mono-ester of capric acid, propylene glycol di-ester of lauric acid,... Agent:

20120270933 - Liquid statin formulation: The present invention relates to compositions and methods for liquid statin products suitable for use in a person or animal. The invention provides stable liquid formulations containing a statin and at least one solubilizer. Methods for the oral administration of statin formulations are also provided by the invention.... Agent: Madeira Therapeutics

20120270934 - Prostacyclin derivatives: This invention relates to novel prostacyclin derivatives and acceptable salts thereof. The invention also provides compositions comprising a compound of this invention and the use of such compositions in methods of treating diseases and conditions beneficially treated by prostacyclin, and in particular those diseases and conditions beneficially treated by dilators... Agent: Concert Pharmaceuticals, Inc.

20120270935 - Formulations: An antimicrobial and/or anti-acne formulation containing either usnic acid or an usnate, together with (a) a primary solvent or solvent system in which the usnic acid or usnate is at least partially dissolved; (b) a glycol; and (c) a hydrophobic fatty acid, fatty alcohol or derivative thereof. The formulation may... Agent: Evocutis PLC

20120270936 - Composition and method for treatment of inflamation and infections of the genitalia, contraceptive and the prophylaxis of sexually transmitted diseases: A composition, employed topically for its microbicidal, spermatocidal activity upon application to the human genitalia and/or anorectal area, and the relief from symptoms of local inflammation and infection incorporates L-Ascorbic acid in a concentration of about 2% to about 25% wt/vol, within an acidic range or pH level of about... Agent:

20120270937 - Linear self-eliminating oligomers: The present invention relates to a linear self-eliminating oligomer comprising one or more cleavable triggers, linker units, effector units and a carrier, and a pharmaceutical composition comprising said oligomer.... Agent: Ktb Tumorforschungsgesellschaft Mbh

20120270938 - Small molecules that covalently modify transthyretin: reacts chemoselectively with one or two of four Lys-15 ε-amino groups within the transthyretin tetramer. The crystal structure confirms the binding orientation of the compound substructure and the conjugating amide bond. A covalent transthyretin kinetic stabilizer exhibits superior amyloid inhibition potency, compared to a non-covalent counterpart, and inhibits cytotoxicity associated... Agent:

20120270939 - Formulations and methods for treating amyloidosis: Methods, formulations, and compositions for the treatment of amyloidosis are described.... Agent: Kiacta Sarl

20120270940 - Closthioamides: This invention relates to the field of biologically active compounds and specifically to closthioamides, pharmaceutical compositions comprising these compounds, and their use as antibiotic, antifungal, and/or cytotoxic agent.... Agent: Lelbuiz-institut Fur Naturstoff-forschung Und Infe

20120270941 - Topical application of travoprost for combating hair loss: Travoprost medicament compositions for non-daily topical application are useful for simulating or inducing the growth and/or decreasing the loss and/or increasing the density and/or reducing the heterogeneity in the diameter of human hair shafts/follicles, e.g., for the treatment of androgenic alopecia, such medicament compositions being at least twice applied over... Agent: Galderma Research & Development

20120270942 - Spreading active agricultural agents: Disclosed herein is a device for the application of agricultural active agents, wherein the device is suitable to be brought to the site of action in a manner temporally and spatially separated from the production process, and comprises a dispenser and non-water-soluble nanofibers and/or mesofibers charged with agricultural active agents.... Agent: Philipps-universitat Marburg

20120270943 - D-aspartic acid pro-nutrients with improved solubility characteristics: D-aspartic acid is prepared as its hydrochloride salt or as the hydrochloride salt of its diethyl ester, thereby providing soluble forms of D-aspartic acid that are readily taken up by a human body via its digestive tract. The D-aspartic acid is administered as pills, capsules, powdered drink mixes, beverages, confectionaries,... Agent:

20120270944 - Antioxidants and vegetable oils as stabilizers of insect semiochemicals: Semiochemicals are combined with oils and/or antioxidants in order to control and maintain the necessary threshold release rates of the semiochemicals (such as attractants or repellents) from release devices for optimal activity/performance, for the reduction or elimination of semiochemical oxidation, isomerization, breakdown and polymerization, and also for stabilizing and/or protecting... Agent: Sterling International Inc.

20120270945 - Method for modulating cytokine activity: The present invention relates to a method for modulating cytokine activity, immunomodulation or treating esophagitis comprising an administration of a fatty acid derivative to a mammalian subject. The present invention also relates to a composition for modulating cytokine activity, immunomodulation or treating esophagitis comprising a fatty acid derivative.... Agent: Sucampo Ag

20120270946 - Crystalline form of bimatoprost, preparation method and use thereof: The crystalline form A of Bimatoprost of formula I, its preparation method and use are provided. There are characteristic peaks where diffraction angles 2θ are 3.2+0.2°, 5.5+0.2°, 11.4+0.2°, 16.7+0.2°, 17.6+0.2°, 19.9+0.2°, 20.8±02° and 22.8+0.2° in the X-ray powder diffraction pattern of the crystalline form A.... Agent: Shanghai Techwell Biopharmaceutical Co., Ltd.

20120270947 - Short telomere length on chromosome 9p is strongly associated with breast cancer risk: Disclosed are compositions and methods related to assessing the risk of cancer, such as breast cancer, through analyzing the length of telomeres, such as chromosome 9p telomere, such as the short arm of the 9p telomere. If the 9p arm is shorter than normal, the risk of cancer is increased.... Agent: Georgetown University

20120270949 - Melt-granulated cinacalcet: The invention relates to an intermediate obtainable by the melt-extrusion of (i) cinacalcet or a pharmaceutically acceptable salt thereof with (ii) a matrix former, and oral dosage forms, especially tablets containing the intermediates of the invention. The invention further relates to a method of preparing the tablets of the invention.... Agent: Ratiopharm Gmbh

20120270948 - Polymorphisims in the human cyp2d6 gene promoter region and their use in diagnostic and therapeutic applications: Provided are polynucleotides of molecular variant promoters of the CYP2D6 gene which, for example, are associated with abnormal drug response or individual predisposition to several common diseases and disorders caused by drug under- or over-metabolization, and vectors comprising such polynucleotides. Furthermore, methods of diagnosing the status of disorders related to... Agent:

20120270950 - Alkaline decomposition product of hop extract and use thereof: According to the present invention, there are provided a food and a food additive obtained using an alkaline decomposition product of a hop extract, and an agent for suppressing fat accumulation or for suppressing weight gain comprising the same as an active ingredient.... Agent: Kirin Holdings Kabushiki Kaisha

20120270951 - Novel anti-inflammatory cyclooxygenase inhibitors: Disclosed is a pharmaceutical composition including a therapeutic quantity of a COX-2 inhibitor having an IC50-WHMA COX-2/COX-1 ratio ranging from about 0.23 to about 3.33 with reduced gastrointestinal and cardiovascular toxicity. Also disclosed are methods for treating osteoarthritis, rheumatoid arthritis or acute pain with less side-effects and faster onset of... Agent:

20120270952 - Method for enhancing the bioavailability of ospemifene: s

20120270953 - Methods and compositions for the treatment of infection or infectious colonization of the eyelid, ocular surface, skin or ear: The instant invention provides methods and compositions for the treatment of infection or infectious colonization of the eyelid and/or ocular surface for the treatment and prevention of ocular disorders and eyelid disorders.... Agent: Advanced Vision Research, Inc.

20120270954 - Methods for maintaining eye health and ameliorating opthalmic maladies in canines: The invention provides novel methods for maintaining eye health and ameliorating ophthalmic maladies in canines by administering to the canines an ophthalmic malady ameliorating amount of one or more carotenes. Generally, the carotenes are administered to the canines in amounts of from about 0.1 to about 5000 mg or in... Agent:

20120270955 - Ophthalmic composition with a viscosity enhancement system having two different viscosity enhancing agents: An ophthalmic composition is disclosed having a viscosity enhancement system comprised of two different viscosity enhancing agents. The aqueous composition contains a first viscosity enhancing agent that provides enhanced viscosity upon dispensing of the composition to the eye and a second viscosity agent that increases viscosity (e.g., gels or partially... Agent:

20120270956 - Use of protein satb2 as a marker for colorectal cancer: The invention provides new methods, means and uses in connection with detection, characterization and prognosis of colo-rectal cancer, via the identification of the SATB2 protein as a marker for this cancer type.... Agent:

  
10/18/2012 > 161 patent applications in 124 patent subcategories. categorized by USPTO classification

20120264675 - Cmv gene products promote cancer stem cell growth: The disclosure relates generally to compositions and methods useful for inhibiting the infection and propagation of viral particles, particularly members of the Herpesviridae family, and more particularly to cytomegalovirus (CMV) and methods of treating diseases and disorders, including cell proliferative disorders, associated with CMV infection.... Agent: Sutter West Bay Hospitals

20120264674 - Methods for preparing purified polypeptide compositions: The present invention relates to purified peptidomimetic macrocycles. The invention additionally provides methods of preparing and using such macrocycles, for example in therapeutic applications.... Agent: Aileron Therapeutics, Inc.

20120264676 - Multi-component antioxidant compounds, pharmaceutical compositions containing same and their use for reducing or preventing oxidative stress: An antioxidant compound is disclosed, along with pharmaceutical compositions and methods of treatment which utilize said compound. The compound is characterized by a peptide including at least three amino acid residues of which at least two are cysteine residues, and a first hydrophobic or non-charged moiety being attached to an... Agent: Yissum Research Development Company Of The Hebrew University Of Jerusalem

20120264677 - Oxidant resistant apolipoprotein a-1 and mimetic peptides: A purified polypeptide includes an ApoA1 mimetic or fragment thereof that are resistant to oxidation.... Agent:

20120264678 - Methods of using [3.2.0] heterocyclic compounds and analogs thereof for treating infectious diseases: Disclosed are methods of treating infectious diseases comprising administering to an animal, a therapeutically effective amount of a heterocyclic compound. The animal is a mammal, preferably a human or a rodent.... Agent: Nereus Pharmaceuticals, Inc.

20120264679 - 3-ether and 3-thioether substituted cyclosporin derivatives for the treatment and prevention of hepatitis c infection: s

20120264680 - Regulation of energy metabolism and obesity by modulating b cell activating factor (baff, blys) or baff signaling: Provided herein are methods and compositions for modulating energy metabolism and weight in mammals, in particular by modulating thermogenesis associated with brown fat, including thermogenesis by brown fat or brown fat cells, adaptive thermogenesis by brown fat or brown fat cells, thermogenic capacity of brown fat or brown fat cells,... Agent: Children's Hospital Medical Center

20120264681 - Buffered ophthalmic compositions and methods of use thereof: The present disclosure provides a buffered ophthalmic composition for formulation of topically administrable suspensions useful for treating eye disorders by promoting wound healing, delivery of pharmaceutically active agents, and lubricating the eye. In particular the ophthalmic composition includes a buffer solution compatible with application to a mammalian eye, wherein the... Agent: Healor Ltd.

20120264682 - Tissue protective peptides and uses thereof: Provided herein are tissue protective peptides derived from or sharing consensus sequences with portions of cytokine receptor ligands, including Erythropoietin (EPO), that are generally located on or within the region of the cytokine receptor ligand that faces away from a receptor complex while the ligand is bound to the receptor.... Agent: Araim Pharmaceuticals, Inc.

20120264683 - Use of an fgf-21 compound and a glp-1 compound for the treatment of obesity: The present invention provides methods of lowering body weight by administering an FGF-21 compound in combination with a GLP-1 compound. In addition, the present invention also provides methods to treat obesity by administering an FGF-21 compound in combination with a GLP-1 compound. The present invention also discloses combinations useful in... Agent: Eli Lilly And Company

20120264684 - Glycosylated form of antigenic glp-1 analogue: Disclosed is a glucagon-like peptide-1 (GLP-1) analogue which is obtained by ameliorating a highly antigenic GLP-1 analogue so that the GLP-1 analogue has reduced antigenicity without being lowered in the blood glucose suppressing activity. Specifically disclosed is a glycosylated form of an antigenic GLP-1 analogue, which has GLP-1 activity and... Agent:

20120264685 - Short chain peptidomimetics based orally active glp 1 agonist and glucagon receptor antagonist: The present invention provides novel short chain peptidomimetics, which act as GLP-1 receptors agonist and glucagon receptor antagonist. These dual acting peptidomimetics exhibit increased stability to proteolytic cleavage, especially against DPP-IV (Dipeptidyl peptidase-IV) enzyme, GIT enzymes such as pepsin and acidic stomach pH and also against liver microsomes (in vitro).... Agent:

20120264686 - Modified erythropoietin (epo) polypeptides that exhibit increased protease resistance and pharmaceutical compositions thereof: Modified erythropoietin (EPO) polypeptides and other modified therapeutic polypeptides are provided. The EPO polypeptides and other therapeutic polypeptides are modified to exhibit physical properties and activities that differ from the unmodified EPO polypeptides and other unmodified therapeutic polypeptides, respectively. Nucleic acid molecules encoding these polypeptides also are provided. Also provided... Agent: Hanall Biopharma Co. Ltd

20120264687 - Modified erythropoietin to which water-soluble long-chain molecule is added: An object of the invention is to provide a pharmaceutical composition that contains erythropoietin as the active ingredient and has, when administered in humans and/or animals, a hematopoietic effect that lasts for not less than seven days. The invention provides a pharmaceutical composition containing, in an amount equal to not... Agent: Kaneka Corporation

20120264688 - Process for the purification of recombinant human erythropoietin (epo), epo thus purified and pharmaceutical compositions comprising same: A procedure for the production of erythropoietin (EPO), in particular recombinant human EPO (rhEPO) with a defined composition of glycoforms in a highly pure form, i.e., with a high amount of O-glycosylated EPO isoforms is provided.... Agent:

20120264689 - Methods and compositions for skin regeneration: Compositions and methods for inducing tissue differentiation and growth within a localized area of application in humans or other animals are provided. Compositions comprising a biological or pharmacologically active agent such as Insulin-like Growth Factor-1 (IGF-1) and sustained-release nanoparticle formulations comprising IGF-1 and a matrix forming component such as hyaluronan... Agent: Genogen, Inc.

20120264690 - Methods of using basic fibroblast growth factor to prevent acute wound failure: Methods for preventing incisional hernia formation and acute wound failure are described. More particularly, methods are described for preventing incisional hernia formation and acute wound failure by administering a composition comprising basic fibroblast growth factor. In addition, a drug delivery device to administer basic fibroblast growth factor is described.... Agent: M-3 Biologics, LLC

20120264691 - Medical compositions containing ghrelin: It is provided a pharmaceutical composition stably containing ghrelin or its derivative, which is an endogenous growth hormone secretagogue (GHS) to a growth hormone secretagogue-receptor (GHS-R), comprising a aqueous solution containing the ghrelins having pH range of 2 to 7, wherein the aqueous solution having pH range of 2 to... Agent: Daiichi Sankyo Company, Limited

20120264692 - Genetic polymorphisms associated with venous thrombosis, methods of detection and uses thereof: The present invention is based on the discovery of genetic polymorphisms that are associated with venous thrombosis. In particular, the present invention relates to nucleic acid molecules containing the polymorphisms, variant proteins encoded by such nucleic acid molecules, reagents for detecting the polymorphic nucleic acid molecules and proteins, and methods... Agent: Celera Corporation

20120264693 - Compounds acting as peptide gap junction modulators, and uses thereof: Compounds capable of modulating intracellular gap junctional communication, as well as their use in the treatment of diseases associated with impaired gap junction intracellular communication (GJIC) 1 are disclosed.... Agent: The Research Foundation Of State Univesity Of New York

20120264694 - Composition comprising torasemide: A composition for the alleviation or treatment of one or more symptoms caused by one or more conditions or diseases selected from the group consisting of dilated cardiomyopathy, acquired or naturally occurring valvular disease, hypertrophic cardiomyopathy, hypertrophic obstructive cardiomyopathy, restrictive cardiomyopathy and unclassified cardiomyopathy and combinations thereof. Also disclosed is... Agent: Eurovet Animal Health B.v.

20120264695 - Non-porous film for culturing cells: The invention relates to collagenous polypeptide films on which cells are cultivated. In particular the invention relates to such films that are used to treat wounds such as severe burns or physical or chemical injury. The invention also related to methods for producing such films.... Agent: Fujifilm Manufacturing Europe B.v.

20120264696 - Prevention of cellular senescence in mammals by natural peptide complexes: Preventing skin aging by targeting multiple causes by a single bullet is of primal scientific and consumer interest. A treatment based on compositions of compound (I) for cellular senescence to control cellular degradation offers such a solution to multiple skin ailments including skin degradation from cancer, diabetes, radiation treatments, chemotherapy,... Agent: Island Kinetics Inc.

20120264697 - Uses of hypoxia-inducible factor inhibitors: The present invention relates to treating a hematologic cancer using a Hypoxia- Inducible Factor (HIF inhibitor). The invention also relates to inducing acute myeloid leukemia remission using the HIF inhibitor. The invention further relates to inhibiting a maintenance or survival function of a cancer stem cell (CSC) using the HIF... Agent: Oncoimmune Inc.

20120264698 - Method of using dopamine reuptake inhibitors and their analogs for treating autoimmune conditions and delaying or preventing autoimmune related pathologic progressions: Dopamine reuptake inhibitors, and their analogs, are disclosed for treating and delaying the progression of autoimmune diseases.... Agent:

20120264699 - Method of producing autogenous or allogenic blood serum and related logistics: A method of producing blood serum containing prophylactically or therapeutically active proteins, including obtaining blood from a patient, incubating the blood at a suitable temperature to induce production of prophylactically or therapeutically active proteins, and removing the prophylactically or therapeutically active proteins from the blood.... Agent:

20120264700 - Glycoside derivatives and uses thereof: m

20120264701 - Use of d-ribose for fatigued subjects: Low doses of D-ribose raise the level of fitness and lower the perception of fatigue in baby boomers aged 45-65 who perceive themselves as fatigued. The doses range from 0.100 grams to 3.0 grams, bid, for a total of 0.200 to 6.0 grams daily. Objective measures of cardiopulmonary parameters confirm... Agent: Bioenergy, Inc.

20120264703 - Methods and compositions for the treatment of anxiety disorders, including post traumatic stress disorder (ptsd) and related central nervous system (cns) disorders.: The present invention provides novel methods and formulations for treating anxiety disorders, including Post Traumatic Stress Disorder, in human subjects employing coordinate treatment using α and β blockers alone or in combination with additional psychotherapeutic medications to treat the anxiety disorder and reduce symptomology in treated subjects.... Agent:

20120264702 - Synthesis and use of glycoside derivatives of propofol: The present invention relates to methods and compositions for the synthesis, production, and use of pro-drug propofol analogs. This invention relates to a method for the production of a broad group of glycosylated propofol carbohydrate derivatives.... Agent: Nutek Pharma Ltd.

20120264704 - Substituted dihydropyrazolones and use thereof as hif-prolyl-4 -hydroxylase inhibitors: The present application relates to novel substituted dihydropyrazolone derivatives, processes for their preparation, their use for treatment and/or prophylaxis of diseases and their use for the preparation of medicaments for treatment and/or prophylaxis of diseases, in particular cardiovascular and hematological diseases and kidney diseases, and for promoting wound healing.... Agent:

20120264705 - Antimicrobial compositions comprising 15-hetre and methods of use thereof: The present disclosure provides compositions comprising fatty acids, or derivatives thereof (e.g., C1-C4 esters) including, for example, DGLA, 15-OHEPA and/or 15-HETrE, used alone or in combination with one or more antibiotic agents for the treatment of disease and/or disorders such as a skin infection or wound healing.... Agent: Dignity Sciences Limited

20120264810 - Compositions and methods for enhancing cellular uptake and intracellular delivery of lipid particles: Compositions, methods and compounds useful for enhancing the uptake of a lipid particle b\ a cell are described In particular embodiments, the methods of the invention include contacting a cell with a lipid particle and a compound that binds a Na+/K+ ATPase to enhance uptake of the lipid particle b\... Agent: The University Of British Columbia

20120264811 - Elongator proteins and use thereof as dna demethylases: The invention provides DNA demethylases comprising Elp1, Elp2, Elp3, Elp4, Elp5 and/or Elp6. The invention also provides methods of modulating gene expression, for example, for the treatment of cancer or to modify the cellular transcription program (e.g., for regenerative medicine). Also provided are methods of identifying compounds that modulate the... Agent: The University Of North Carolina At Chapel Hill

20120264805 - Medicament for the treatment and prevention of liver failure: Small inhibitory RNA (siRNA) molecules, which e.g. are purified and/or isolated, as an active in a medicament, which siRNA molecules are inhibitory RNA molecules that through RNA interference (RNAi) reduce or prevent expression of the p53 upregulated modulator of apoptosis (PUMA). The siRNA molecules can be administered as a medicament... Agent: Medizinische Hochschule Hannover

20120264807 - Method for introducing sirna into cells by photochemical internalisation: The present invention relates to a method for introducing an siRNA molecule into the cytosol of a cell, said method comprising i) contacting said cell with an siRNA molecule, a carrier and a photosensitising agent, and ii) irradiating the cell with light of a wavelength effective to activate the photosensitising... Agent: PCi Biotech As

20120264808 - Methods and compositions for modulating calcium channels: The present invention relates to methods and compositions for modulating calcium channels. In particular, the present invention provides methods and compositions for modulating (e.g., disrupting) Cav1.3a calcium channels for research and therapeutic methods (e.g., treating dopaminergic diseases and conditions).... Agent:

20120264806 - Oligomeric compounds and excipients: The present invention provides method of optimizing the efficacy and potency of antisense compounds. In certain embodiments, the invention provides assays useful for determining favorable oligonucleotide characteristics and excipients for improved cellular uptake.... Agent:

20120264809 - Rnai-mediated inhibition of histamine receptor h1-related conditions: RNA interference is provided for inhibition of histamine receptor H1 mRNA expression, in particular, for treating patients having an HRH1-related condition or at risk of developing an HRH1-related condition such as allergic conjunctivitis, ocular inflammation, dermatitis, rhinitis, asthma, or allergy.... Agent: Alcon Research, Ltd.

20120264813 - Sirna targeting cyclin-dependent kinase inhibitor 1b (p27, kip1) (cdkn1b): Efficient sequence specific gene silencing is possible through the use of siRNA technology. By selecting particular siRNAs by rational design, one can maximize the generation of an effective gene silencing reagent, as well as methods for silencing genes. Methods, compositions, and kits generated through rational design of siRNAs are disclosed... Agent: Dharmacon, Inc.

20120264812 - Treatment of nuclear respiratory factor 1 (nrf1) related diseases by inhibition of natural antisense transcript to nrf1: The present invention relates to antisense oligonucleotides that modulate the expression of and/or function of Nuclear Respiratory Factor 1 (NRF1), in particular, by targeting natural antisense polynucleotides of Nuclear Respiratory Factor 1 (NRF1). The invention also relates to the identification of these antisense oligonucleotides and their use in treating diseases... Agent: Curna, Inc.

20120264814 - Isolation, cloning, sequencing and functional analysis of ss-casein promoter along with the regions of exon1, intron1 and exon2 using mammary gland derived cell line of buffalo (bubulus bubalis): The present invention relates to a method of in vitro isolation of buffalo β-caesin promoter (buCSN2) along with the regions of exon1, intron1 and exon2 from the genomic DNA in vitro (Bubalus bubalis) and its functional activity in using mammary cell line. The novel buffalo β-caesin promoter along with exon1,... Agent: National Institute Of Immunology

20120264815 - Reversible platelet inhibition: The present invention relates, in general, to receptors and to platelet aggregation and, in particular, to a method of inhibiting platelet aggregation using an aptamer that binds to and inhibits the activity of a receptor, such as glycoprotein IIb/IIIa (gpIIb/IIIa), and to aptamers suitable for use in such a method.... Agent: Duke University

20120264816 - Sulfated oxysterol and oxysterol sulfation by hydroxysterol sulfotransferase promote lipid homeostasis and liver proliferation: Methods and compositions for the prevention and treatment of liver damage or disease in a subject in need thereof are provided. The methods involve providing the sulfated oxysterol 25-hydroxycholesterol-3-sulfate (25HC3S) to the subject e.g. by 1) administering 25HC3S to the subject; or 2) overexpressing, in the subject, the hydroxysterol sulfotransferase... Agent:

20120264707 - Beta-l-2'-deoxy-nucleosides for the treatment of hepatitis b: wherein R is selected from the group consisting of H, straight chained, branched or cyclic alkyl, CO-alkyl, CO-aryl, CO-alkoxyalkyl, CO-aryloxyalkyl, CO-substituted aryl, alkylsulfonyl, arylsulfonyl, aralkylsulfonyl, amino acid residue, mono, di, or triphosphate, or a phosphate derivative; and BASE is a purine or pyrimidine base which may be optionally substituted. The... Agent: Centre National De La Recherche Scientifique

20120264706 - Purine derivatives as adenosine a1 receptor agonists and methods of use thereof: The invention relates to Purine Derivatives; compositions comprising an effective amount of a Purine Derivative; and methods for reducing an animal's rate of metabolism, protecting an animal's heart against myocardial damage during cardioplegia; or for treating or preventing a cardiovascular disease, a neurological disorder, an ischemic condition, a reperfusion injury,... Agent: Inotek Pharmaceuticals Corporation

20120264708 - Method for treatment of macular degeneration by modulating p2y12 or p2x7 receptors: Provided is a method of treating or preventing age-related macular degeneration (AMD) in a patient subject to, or symptomatic of the disease, wherein the method comprises restoring normal lysosomal pH (pHL), or acidifying an abnormally elevated pHL, thus decreasing or preventing a damaging accumulation of lipofuscin or waste products in... Agent:

20120264709 - Nucleotide and oligonucleotide prodrugs: which exhibit antiviral properties. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject in need of anti-HBV treatment. The invention also relates to methods of treating a HBV infection in a subject by administering a pharmaceutical composition comprising the compounds of the... Agent: Spring Bank Pharmaceuticals, Inc.

20120264711 - Antiviral compounds: The invention is related to anti-viral compounds, compositions containing such compounds, and therapeutic methods that include the administration of such compounds, as well as to processes and intermediates useful for preparing such compounds.... Agent: Gilead Sciences, Inc.

20120264710 - Systems and methods for detecting hent1 expression in hematological disorders: This invention relates generally to methods, assays and systems for detecting hENT1 expression levels in hematological disorders, to methods, assays and systems for detecting hENT1 expression levels in hematological disorders using flow cytometry, and to methods, assays and systems for detecting hENT1 expression levels in myelodysplastic syndrome (MDS) and acute... Agent:

20120264712 - Caries risk test for predicting and assessing the risk of disease: Provided are methods, test devices, and diagnostic kits for predicting, assessing, and diagnosing the risk of a disease using salivary analysis. The methods comprise providing a whole (unfractionated) saliva sample from a subject; contacting an aliquot of the saliva with two or more lectins under conditions that allow the two... Agent: Proactive Oral Solutions, Inc.

20120264713 - Use of docosatrienes, resolvins, and their stable analogs in the treatment of airway diseases and asthma: The present invention is generally drawn to novel isolated therapeutic agents, termed resolvins, generated from the interaction between a dietary omega-3 polyunsaturated fatty acid (PUFA) such as eicosapentaenoic acid (EPA) or docosahexaenoic acid (DHA), cyclooxygenase-II (COX-2) and an analgesic, such as aspirin (ASA). Surprisingly, careful isolation of compounds generated from... Agent: The Brigham And Women's Hospital, Inc.

20120264714 - Boron-containing small molecules as anti-inflammatory agents: Methods of treating anti-inflammatory conditions through the use of boron-containing small molecules are disclosed.... Agent: Anacor Pharmaceuticals, Inc.

20120264716 - Phenyl bicyclic methyl amine derivatives as sphingosine-1 phosphate receptors modulators: The present invention relates to novel phenyl bicyclic methyl amine derivatives, processes for preparing them, pharmaceutical compositions containing them and their use as pharmaceuticals as modulators of sphingosine-1-phosphate receptors.... Agent:

20120264715 - Substituted bicyclic methyl amine derivatives as sphingosine-1 phosphate receptors modulators: The present invention relates to novel substituted bicyclic methyl amine derivatives which are useful as sphingosine-1-phosphate receptors modulators and useful for treating a wide variety of disorders associated with modulation of sphingosine-1-phosphate receptors.... Agent:

20120264717 - Compounds, compositions and methods comprising oxadiazole derivatives: The present invention relates to compositions and methods for treating a disease in an animal, which disease is responsive to inhibiting of functional cystic fibrosis transmembrane conductance regulator (CFTR) polypeptide by administering to a mammal in need thereof an effective amount of a compound defined herein (including those compounds set... Agent: Institute For Oneworld Health

20120264718 - Bicyclic methyl amine derivatives as sphingosine-1 phosphate receptors modulators: The present invention relates to novel bicyclic methyl amine derivatives, processes for preparing them, pharmaceutical compositions containing them and their use as pharmaceuticals as modulators of sphingosine-1-phosphate receptors.... Agent:

20120264719 - Dosage regimen of an s1p receptor modulator: S1P receptor modulators are administered following a dosage regimen providing a positive benefit-risk profile.... Agent:

20120264720 - Identification and treatment of cancer subsets: Methods of predicting whether or not a tumor will be responsive to IP6 treatment, methods of treating patients with cancer using IP6, methods of predicting the progression of a disease, and kits that facilitate these methods are disclosed.... Agent: Translational Genomics Research Institute

20120264721 - Analogues of cilostazol: This invention relates to novel compounds which are derivatives of the phosphodiesterase inhibitor, cilostazol and pharmaceutically acceptable salts thereof. This invention also provides pyrogen-free compositions comprising one or more compounds of the invention and the use of the disclosed compounds and compositions in methods of treating diseases and conditions that... Agent: Concert Pharmaceuticals, Inc.

20120264722 - Pharmaceutical formulations and uses thereof in the treatment of female sexual dysfunction: The present invention relates to the use of a combination of a PDE5-inhibitor and testosterone for the preparation of a medicament for the treatment of Female Sexual Dysfunction.... Agent: Emotional Brain B.v.

20120264723 - Process for the preparation of drospirenone: A process is described for the preparation of drospirenone, a synthetic steroid with progestogenic, antimineralocorticoid and antiandrogenic activity, useful for preparing pharmaceutical compositions with contraceptive action; comprising the oxidation of 17α-(3-hydroxypropyl)-6β,7β,15β,16β-dimethylene-5β-androstane-3β,5,17β-triol.... Agent:

20120264724 - Antimicrobial agents based on hemin derivatives: The invention relates to novel antimicrobial, including antibacterial and antifungal, agents and compositions based on hemin derivatives of general formula (I), and also to the production of novel hemin derivatives. The advantages of antibacterial agents based on hemin derivatives are their biocompatibility, biodegradability, high effectiveness against resistant bacteria and widespread... Agent: Obschestvo S Ogranichennoi Otvetstvennostiyu "pharmenterprises"

20120264725 - Substituted porphyrins: Substituted metalloporphyrin compounds are described, along with pharmaceutical compositions containing the same, and methods of use thereof in protecting cells from oxidant-induced toxicity and pathological conditions such as inflammatory lung disease, neurodegenerative conditions, radiation injury, cancer, diabetes, cardiac conditions and sickle cell disease. Mn(III) porphyrins bearing oxygen atoms within side... Agent:

20120264726 - Methods of sensitizing drug resistant microorganisms using methylsulfonylmethane (msm): Embodiments of the invention relate generally to formulations comprising methylsulfonylmethane (MSM) and one or more therapeutic agents, and uses of such formulations to treat, inhibit and/or sensitize infectious diseases. In several embodiments, such formulations are effective to treat, inhibit and/or sensitize drug-resistant bacterial microorganisms, for example, methicillin-resistant Staphylococcus aureus (MRSA).... Agent: Biogenic Innovations, LLC

20120264727 - Novel cephalosporin derivatives and pharmaceutical compositions thereof: According to the present invention, novel cephalosporin derivatives, a prodrug thereof, a hydrate thereof, a solvate thereof, an isomer thereof, or a pharmaceutically acceptable salt thereof as an effective ingredient for the broad spectrum of antibiotic resistant, low toxicity, particularly in Gram-negative bacteria, which can be useful with strong antimicrobial... Agent: Legochem Biosciences, Inc.

20120264734 - Aryl- or heteroaryl-substituted benzene compounds: The present invention relates to aryl- or heteroaryl-substituted benzene compounds. The present invention also relates to pharmaceutical compositions containing these compounds and methods of treating cancer by administering these compounds and pharmaceutical compositions to subjects in need thereof. The present invention also relates to the use of such compounds for... Agent:

20120264731 - Chromenone derivatives: or pharmaceutically-acceptable salts thereof, wherein each of R1, R2, R3, R4, R5, n and R6 has any of the meanings defined hereinbefore in the description; processes for their preparation, pharmaceutical compositions containing them and their use in the manufacture of a medicament for use in the treatment of cell proliferative... Agent: Astrazeneca Ab

20120264729 - Co-crystals and salts of ccr3-inhibitors:

20120264733 - Heterocyclic compound and use thereof:

20120264732 - Phenyl bicyclic methyl azetidine derivatives as sphingosine-1 phosphate receptors modulators: The present invention relates to novel phenyl bicyclic methyl azetidine derivatives, processes for preparing them, pharmaceutical compositions containing them and their use as pharmaceuticals as modulators of sphingosine-1-phosphate receptors.... Agent:

20120264730 - Substituted bicyclic methyl azetidines as sphingosine-1 phosphate receptors modulators: The present invention relates to novel substituted bicyclic methyl azetidine derivatives which are useful as sphingosine-1-phosphate receptors modulators and useful for treating a wide variety of disorders associated with modulation of sphingosine-1-phosphate receptors.... Agent:

20120264735 - Tyrosine kinase inhibitors: The present invention relates to pyridazin-4(1H)-one derivatives, that are useful for treating cellular proliferative diseases, for treating disorders associated with MET activity, and for inhibiting the receptor tyrosine kinase MET. The invention also related to compositions which comprise these compounds, and methods of using them to treat cancer in mammals.... Agent:

20120264736 - Benzenesulfonyl-chromane, thiochromane, tetrahydronaphthalene and related gamma secretase inhibitors: R2 and R3, or R2 and R4, or R3 and R4, together with the atoms to which they are bound, can form a fused cycloalkyl or fused heterocycloalkyl ring. The cycloalkyl ring or the heterocycloalkyl ring can be optionally substituted with one or more substituents. One or more compounds of... Agent: Schering Corporation

20120264728 - Amino-heteroaryl derivatives as hcn blockers: The invention relates to amino-heteroaryl derivatives having the general Formula I or a pharmaceutically acceptable salt thereof, to pharmaceutical compositions comprising the same, as well as to the use of these derivatives for the treatment of pain, such as neuropathic pain or inflammatory pain.... Agent:

20120264739 - Certain triazolopyridines and triazolopyrazines, compositions thereof and methods of use therefor: Provided are certain triazolopyridines and triazolopyrazines, compositions thereof and methods of use therefor.... Agent:

20120264738 - Dispiropyrrolidine derivatives: A compound that inhibits interaction between murine double minute 2 (Mdm2) protein and p53 protein and exhibits anti-tumor activity is provided. The present invention provides a dispiropyrrolidine derivative represented by the following formula (1), which has various substituents, inhibits interaction between Mdm2 protein and p53 protein and exhibits anti-tumor activity,... Agent:

20120264737 - Heterocyclic modulators of lipid synthesis: Compounds that are fatty acid synthesis modulators are provided. The compounds may be used to treat disorders characterized by disregulation of the fatty acid synthase function by modulating the function and/or the fatty acid synthase pathway. Methods are provided for treating such disorders including viral infections, such as hepatitis C... Agent: 3-v Biosciences, Inc.

20120264740 - Polycyclic heteroaryl substituted triazoles useful as axl inhibitors: Polycyclic heteroaryl substituted triazoles and pharmaceutical compositions containing the compounds are disclosed as being useful in inhibiting the activity of the receptor protein tyrosine kinase Axl. Methods of using the compounds in treating diseases or conditions associated with Axl activity are also disclosed.... Agent: Rigel Pharmaceuticals, Inc.

20120264741 - Pharmaceutical compositions and methods for preventing, treating, or reversing neuronal dysfunction: The present invention provides compositions and methods for preventing, treating or reversing neuronal dysfunction in a mammal resulting from exposure to organophosphate nerve agents, organophosphate insecticides and incapacitating agents of the central nervous system (CNS); CNS injury, including traumatic brain injury, neurologic complications of cardiac surgery, perinatal asphyxia, and stroke,... Agent:

20120264742 - Pharmaceutical composition for external use: A pharmaceutical composition for external use which is an organogel containing a fatty acid ester and a glycerolglycerin fatty acid ester, in particular, a novel transdermally absorbable pharmaceutical composition for external use which has a drug such as non-narcotic analgesics as an active ingredient made in organogel form containing a... Agent: Nihon University

20120264743 - Crystalline forms of (r)-8-chloro-1-methyl-2,3,4,5-thtrahydro-1h-3-benzazepine hydrochloride: The present invention is directed to crystalline forms of (R)-8-chloro-1-methyl-2,3,4,5-tetrahydro-1H-3-benzazepine, compositions containing the same and uses thereof.... Agent:

20120264744 - Oxazole and thiazole compounds as beta-catenin modulators and uses thereof: e

20120264745 - Methods and compositions for the delivery of a therapeutic agent: The present invention provides a liquid pharmaceutical composition comprising a therapeutic agent and an alkoxy-polyethylene glycol, for example, methoxy-polyethylene glycol, for administration of the therapeutic agent to the mammal. The compositions can be applied to a membrane, for example, a nasal membrane during intranasal administration. The invention also provides methods... Agent: Hananja Ehf

20120264746 - Cell migration modulating compounds: The described invention relates to compounds (I) which modulate cell migration, and find use in, for example, wound healing, cancer progression and angiogenesis. All definitions as in claim 1.... Agent:

20120264747 - Triazolopyridine jak inhibitor compounds and methods: A compound of Formula I, enantiomers, diasteriomers, tautomers or pharmaceutically acceptable salts thereof, wherein R1, R2, R3, R4 and R5 are defined herein, are useful as JAK kinase inhibitors. A pharmaceutical composition that includes a compound of Formula I and a pharmaceutically acceptable carrier, adjuvant or vehicle, and methods of... Agent:

20120264748 - Diaza-spiro[5.5]undecanes: The invention relates to compound of the formula (I), in which the substituents are as defined in the specification; in free form or in salt form; to its preparation, to its use as medicament and to medicaments comprising it.... Agent: Novartis Ag

20120264749 - Morpholine-spirocyclic piperidine amides as modulators of ion channels: The invention relates to morpholine spirocyclic piperidine amide compounds useful as inhibitors of ion channels. The invention also provides pharmaceutically acceptable compositions comprising the compounds of the invention and methods of using the compositions in the treatment of various disorders.... Agent:

20120264750 - Composition and method for controlling arthropod pests: The present invention provides: an arthropod pests control composition comprising, as active ingredients, a condensed heterocyclic compound and a diamide compound; a method for controlling arthropod pests which comprises applying effective amounts of a condensed heterocyclic compound and a diamide compound to the arthropod pests or a locus where the... Agent: Sumitomo Chemical Company, Limited

20120264751 - Pyrrolopyrazoles, potent kinase inhibitors: Pyrrole pyrazole compounds of formula I, compositions including these compounds and methods of their use are provided. Preferred compounds of formula I have activity as protein kinase inhibitors, including as inhibitors of PAK4.... Agent: Agouron Pharmaceuticals, Inc.

20120264752 - Dual-acting antihypertensive agents: wherein: Ar, r, Y, Z, Q, W, X, and R5-7 are as defined in the specification, and pharmaceutically acceptable salts thereof. These compounds have AT1 receptor antagonist activity and neprilysin inhibition activity. The invention is also directed to pharmaceutical compositions comprising such compounds; methods of using such compounds; and process... Agent: Theravance, Inc.

20120264753 - Novel 1-(biphenyl-4-yl-methyl)-1h-imidazole derivative and pharmaceutical product containing same: Disclosed is a novel 1-(biphenyl-4-yl-methyl)-1H-imidazole derivative represented by general formula (I), which has both angiotensin II receptor antagonist activity and PPAR-γ activating activity and is useful as a prophylactic and/or therapeutic agent for cardiovascular diseases and metabolic diseases. Also disclosed is a pharmaceutical composition which contains the novel 1-(biphenyl-4-yl-methyl)-1H-imidazole derivative.... Agent: Kowa Company, Ltd.

20120264754 - Cannabinoid receptor antagonists/inverse agonists useful for treating metabolic disorders, including obesity and diabetes: The present invention provides novel pyrazolines that are useful as cannabinoid receptor blockers and pharmaceutical compositions thereof and methods of using the same for treating obesity, diabetes, inflammatory disorders, cardiometabolic disorders, hepatic disorders, and/or cancers.... Agent: Jenrin Discovery

20120264755 - Pyridinyl derivatives as inhibitors of enzyme nicotinamide phosphoribosyltransferase: The present application discloses a compound of the formula (I) wherein Q is optionally substituted pyridyl; p is 0-6. Y is formulae (i), (ii) and (iii) where X is ═O, ═S and ═N—CN, r is 1-12, R is —Z-A, Z is a single bond, —S(═O)2—, >P═O, >C═O, —C(═O)NH—, and —C(═S)NH—;... Agent: Topotarget

20120264756 - Phosphatidylcholine transfer protein inhibitors: This invention relates to compounds of Formulas I, II, and III, and their use as inhibitors of phosphatidylcholine transfer protein (PC-TP). The invention further relates to pharmaceutical compositions and methods of treatment of disorders related to the inhibition of PC-TP using the compounds of Formulas I, II, and III. Such... Agent: The Brigham And Women's Hospital, Inc.

20120264757 - Composition and method for treating hemorrhoids and/or anorectal disorders: The invention provides an oil-in-water emulsion useful in the treatment of anorectal disorders comprising a local anesthetic, vasoconstrictor, glycerin and water, and method of preparation of the emulsion and a method for treating hemorrhoids using the composition of the invention.... Agent: Wyeth

20120264758 - Antimicrobial solutions and process related thereto: Disclosed are antimicrobial compositions for treating poultry and meat to substantially eliminate bacteria and microorganism harmful to human. The compositions include various combinations of an aliphatic heteroaryl salt, an aliphatic benzylalkyl ammonium salt, a dialiphatic dialkyl ammonium salt, a tetraalkyl ammonium salt and/or trichloromelamine.... Agent: Byocoat Enterprises, Inc.

20120264759 - Benzyl substituted triazine derivatives and their therapeutical applications: The invention provides triazine compounds and methods of their use to modulate protein kinases and to treat diseases mediated by said protein kinases.... Agent: California Capital Equity, LLC

20120264760 - Compounds and methods for treating mammalian gastrointestinal parasitic infections: One aspect of the present invention relates to compounds, and pharmaceutically acceptable salts and prodrugs thereof, that are useful as inhibitors of IMPDH. The invention also provides pharmaceutical compositions comprising the compounds of the invention which selectively inhibit parasitic IMPDH. In certain embodiments, the present invention relates to selective inhibition... Agent: Brandeis University

20120264761 - Aminobenzoquinazolinone m1 receptor positive allosteric modulators: The present invention is directed to aminobenzoquinazolinone compounds of formula (I) which are M1 receptor positive allosteric modulators and that are useful in the treatment of diseases in which the M1 receptor is involved, such as Alzheimer's disease, schizophrenia, pain or sleep disorders. The invention is also directed to pharmaceutical... Agent:

20120264762 - Heterocyclic compounds as ccr2 antagonists: e

20120264763 - Indoline anti-cancer agents: Indoline compounds having anti-mitotic activity, useful for the treatment of cancer and other proliferative disorders are provided.... Agent:

20120264764 - Oxabicycloheptanes and oxabicycloheptenes, their preparation and use: d

20120264765 - Cyclohexane-1,3-diones for use in the treatment of amyotrophic lateral sclerosis: The present invention relates to the identification of provided cyclohexane-1,3-diones (CHD compounds) and pharmaceutical compositions thereof for treating subjects with amyotrophic lateral sclerosis (ALS) and other neurodegenerative diseases. The invention also provides methods of preparing the provided CHD compounds.... Agent: Northwestern University

20120264766 - Pseudobase benzo[c]phenantridines with improved efficacy, stability and safety: are provided herein. The variables R, R1, R2, R3, and R4 are defined herein. Certain pseudobase benzo[c]phenanthridines provided herein act as prodrugs, targeting the parent benzo[c]phenanthridinium alkaloid to hydrophilic or hydrophobic regions in the body. Pharmaceutical compositions comprising a pseudobase benzo[c]phenanthridine and a carrier, excipient, or diluent are provided herein.... Agent: Marinus Pharmaceuticals Inc.,

20120264767 - Stable pharmaceutical composition of freeze-dried tetrodotoxin powder: This invention relates to a stable pharmaceutical composition of freeze-dried tetrodotoxin powder which contains trace amount of tetrodotoxin, substances which can stabilizes tetrodotoxin, including disaccharide(s) or polyglucose(s) or analogues thereof and solvent(s), and solvents which can help tetrodotoxin dissolve.... Agent: Wex Medical Limited

20120264768 - Bicyclic and tricyclic pyrimidine tyrosine kinase inhibitors with antitubulin activity and methods of treating a patient: Bicyclic and tricyclic pyrimidine tyrosine kinase inhibitors with antitubulin activity are provided in the present invention. The compositions of the present invention possess dual activity in a single agent of potent vascular endothelial growth factor receptor inhibitory activity as well as antitubulin activity. Water soluble salts of these compositions are... Agent:

20120264769 - Methanocarba adenosine derivatives and dendrimer conjugates thereof: Disclosed are (N)-methanocarba adenine nucleosides, e.g., of the formula (I): as A3 adenosine receptor agonists, pharmaceutical compositions comprising such nucleosides, and a method of use of these nucleosides, wherein A, a, R2, and R3 are as defined in the specification. These nucleosides are contemplated for use in the treatment a... Agent: The United States Of Americia, As Represented By The Secretary, Department Of Health And Human Serv

20120264770 - Hsp90 inhibitors: s

20120264771 - Method for treating androgen receptor positive cancers: Provided is a method of inhibiting growth of androgen receptor positive cancer cells. The method entails administering to an individual diagnosed with or suspected of having an androgen receptor positive cancer and administering to the individual a composition containing a compound that can inhibit the growth of the androgen receptor... Agent: Health Research Inc.

20120264772 - Antihypertensive pharmaceutical composition: Provided is an antihypertensive pharmaceutical composition containing Fimasartan, a pharmaceutically acceptable salt thereof, a solvate thereof or a hydrate thereof as an angiotensin II receptor blocker, and Amlodipine, an isomer thereof, a pharmaceutically acceptable salt thereof, a solvate thereof or a hydrate thereof as a calcium channel blocker.... Agent:

20120264773 - Organic compounds: o

20120264774 - Forms of rifaximin and uses thereof: Embodiments relate to Rifaximin polymorphic, salt, and hydrate forms, methods of producing polymorphic forms and to their use in medicinal preparations and to therapeutic methods using them.... Agent:

20120264775 - Oligomer-opioid agonist conjugates: The invention provides compounds that are chemically modified by covalent attachment of a water-soluble oligomer. A compound of the invention, when administered by any of a number of administration routes, exhibits characteristics that are different from those of the compound not attached to the water-soluble oligomer.... Agent: Nektar Therapeutics

20120264776 - Menthol liquids composition: A liquid antitussive composition comprising about 0.05 grams to about 0.2 grams of menthol per 100 ml of liquid antitussive composition, a solvent system, and a surfactant, wherein the composition has a maximum alcohol content of about 0.5 grams per 100 ml of the liquid antitussive composition, and wherein the... Agent:

20120264777 - Oxadiazole beta carboline derivatives as antidiabetic compounds: Beta-carboline derivatives of structural formula I are selective antagonists of the somatostatin sub-type receptor 3 (SSTR3) and are useful for the treatment of Type 2 diabetes mellitus and of conditions that are often associated with this disease, including hyperglycemia, insulin resistance, obesity, lipid disorders, and hypertension. The compounds are also... Agent: Merck Sharp & Dohme Corp.

20120264778 - Methods of treating dermatological disorders and inducing interferon biosynthesis with shorter durations of imiquimod therapy: Pharmaceutical formulations and methods for the topical and/or transdermal delivery of imiquimod, including creams, ointments and pressure-sensitive adhesive compositions to treat dermatological disorders, namelyl, viral infections, such as Type I or Type II Herpes simplex infections and genital and perianal warts, actinic deratosis and superficial basal cell carcinoma, and to... Agent: Medicis Pharmaceutical Corporation

20120264779 - Quinolinone-carboxamide compounds as 5-ht4 receptor agonists: The invention provides novel quinolinone-carboxamide 5-HT4 receptor agonist compounds. The invention also provides pharmaceutical compositions comprising such compounds, methods of using such compounds to treat diseases associated with 5-HT4 receptor activity, and processes and intermediates useful for preparing such compounds.... Agent: Theravance, Inc.

20120264781 - Method for the treatment, alleviation of symptoms of, relieving, improving and preventing a cognitive disease, disorder or condition: The present invention provides uses of a salt adduct comprising at least one positively charged moiety being a pyridoxine or a derivative thereof and at least one carboxylated 5- to 7-membered lactam ring, optionally additionally substituted, for the preparation of a medicament for the treatment, alleviation of symptoms of relieving,... Agent:

20120264780 - Solid compositions: The present invention features solid compositions comprising Compound IA, IB or IC, or a pharmaceutically acceptable salt thereof, in an amorphous form. In one embodiment, Compound IA, IB or IC, or a pharmaceutically acceptable salt thereof, is formulated in an amorphous solid dispersion which comprises a pharmaceutically acceptable hydrophilic polymer... Agent: Abbott Laboratories

20120264782 - Compositions for the treatment of cns-related conditions: The invention provides compositions comprising extended release memantine in combination with immediate release donepezil to a subject. Memantine in an extended release form containing 22.5 to 30 mg memantine or a pharmaceutically acceptable salt thereof in combination with donepezil achieves particular pharmacokinetic criteria such as change in plasma concentration of... Agent: Adamas Pharmaceuticals, Inc.

20120264783 - Methods for the treatment of cns-related conditions: The invention provides methods for administering extended release memantine in combination with immediate release donepezil to a subject. Memantine in an extended release form containing 22.5 to 30 mg memantine or a pharmaceutically acceptable salt thereof in combination with donepezil is administered to a patient suffering from a neurological condition,... Agent: Adamas Pharmaceuticals, Inc.

20120264784 - Methods of treating elevations in mtor signaling: Subjects having elevated signaling of a mammalian target of rapamycin (mTOR) are treated with compositions that include at least one compound that activates a Group 1 mGluR. In an embodiment, the subject has tuberous sclerosis complex (TSC). In an embodiment, the compound is a Group 1 mGluR agonist. In another... Agent:

20120264785 - Fluoro-substituted 3,5-dicyano-4-(1h-indazol-5-yl)-2,6-dimethyl-1,4-dihydropyridine derivatives and methods of use thereof: The present invention relates to novel fluoro-substituted 3,5-dicyano-4-(1H-indazol-5-yl)-2,6-dimethyl-1,4-dihy-dropyridine derivatives having protein tyrosine kinase inhibitory activity, to a process for the manufacture thereof and to the use thereof for the treatment of c-Met-mediated diseases or c-Met-mediated conditions, particularly cancer and other proliferative disorders.... Agent: Bayer Pharma Aktiengesellschaft

20120264787 - Respiratory disease treatment: There is provided a pharmaceutical composition that is adapted for pulmonary administration by inhalation, which composition comprises a glitazone, such as pioglitazone or rosiglitazone, and one or more pharmaceutically acceptable carriers and/or excipients, and wherein the glitazone content of the composition consists of at least 95% by weight of the... Agent: Pulmagen Therapeutics (inflammation) Limited

20120264786 - Use of thiazolidinediones for the partial inhibition of androgen binding to aromatase: A method for the treatment or prophylaxis of a disorder, wherein the disorder is affected by estrogen, comprising partially inhibiting aromatase activity or interfering with the binding of androgen to aromatase by administering a therapeutically effective amount of a thiazolidinedione to the patient. The use of rosiglitazone or pioglitazone to... Agent:

20120264788 - Animal parasite-control method using insect growth regulators: Methods and formulations for treating animal ectoparasites, effective against parasites such as fleas and ticks are provided. The methods comprise topically co-administering a non-mobile insect growth regulator and a mobile insect growth regulator to the animal. Parasiticidal formulations for treating animal ectoparasites are also provided, which can be safe to... Agent: The Hartz Mountain Corporation

20120264789 - Polymorphs of sorafenib acid addition salts: The present invention provides amorphous and crystalline forms of acid addition salts of sorafenib, pharmaceutical compositions comprising them and their use for the treatment of cancer. The present invention also provides processes for the preparation of acid addition salts of sorafenib.... Agent: Ranbaxy Laboratories Limited

20120264790 - Acylamino-substituted cyclic carboxylic acid derivatives and their use as pharmaceuticals: wherein A, Y, Z, R20 to R22 and R50 have the meanings indicated in the claims, which are valuable pharmaceutical active compounds. Specifically, they are inhibitors of the endothelial differentiation gene receptor 2 (Edg-2, EDG2), which is activated by lysophosphatidic acid (LPA) and is also termed as LPA1 receptor, and... Agent: Sanofi

20120264791 - Fatty acid niacin conjugates and their uses: The invention relates to fatty acid niacin conjugates; compositions comprising an effective amount of a fatty acid niacin conjugate; and methods for treating or preventing an metabolic disease comprising the administration of an effective amount of a fatty acid niacin conjugate.... Agent: Catabasis Pharmaceuticals, Inc.

20120264792 - Furazanobenzimidazoles as prodrugs to treat neoplastic or autoimmune diseases: e

20120264793 - Pharmaceutical use of 2',2-bis-thiazole non-nucleoside compounds as hepatitis c virus inhibitor: The present invention discloses the pharmaceutical use of a 2′,2-bis-thiazole non-nucleoside compound of formula I as an inhibitor of hepatitis C virus (HCV). The 2′,2-bis-thiazole non-nucleoside compound can inhibit the replication of HCV, and thus has an anti-HCV activity and is useful for treating hepatitis C.... Agent: Shanghai Institute Of Materia Medica, Chinese Academy Of Sciences

20120264794 - Method for preparing largazole analogs and uses thereof: Analogs of largazole are described herein. Methods of treating cancer and blood disorders using largazole and largazole analogs and pharmaceutical compositions comprising the same are additionally described herein. Methods for preparing largazole analogs are likewise described.... Agent: Colorado State University Research Foundation

20120264795 - Combination therapy with parp inhibitors: The present invention describes benzimidazole derivatives of Formula (I) which constitute potent PARD inhibitors in combination with temozolomide (TMZ).... Agent:

20120264796 - Methods for modulating circadian rhythms: This disclosure described the role of AMPK in circadian rhythms and methods of screening for agents that modulate such rhythms, compositions that are useful for modulating such rhythms and uses thereof.... Agent: The Salk Institute For Biological Studies

20120264797 - Cannabinoid receptor antagonists/inverse agonists useful for treating metabolic disorders, including obesity and diabetes: The present invention provides novel pyrazoles that are useful as cannabinoid receptor antagonists and pharmaceutical compositions thereof and methods of using the same for treating obesity, diabetes, hepatic disorders, and/or cardiometabolic disorders.... Agent: Jenrin Discovery

20120264799 - Indane-amine derivatives, their preparation and use as medicaments: The present invention relates to indane-amine derivatives, to processes for the preparation thereof, to medicaments comprising them as well as to their use for the preparation of a medicament for the treatment of 5HT7 receptor mediated diseases or conditions.... Agent: Laboratorios Del Dr. Esteve ,s.a.

20120264800 - Kinase inhibitors and method of treating cancer: e

20120264798 - Prodrugs of inhibitors of plasma kallikrein: This invention provides new pharmaceutically useful compounds that are prodrugs of inhibitors of plasma kallikrein and methods and compositions for preventing or treating plasma kallikrein dependent diseases or conditions, such as diabetic macular edema or hemorrhagic stroke, by administering prodrugs of the formula:... Agent: Activesite Pharmaceuticals, Inc.

20120264801 - 5-membered heterocycle-based p38 kinase inhibitors: Provided are 5-membered heterocycle-based p38 kinase inhibitors. Further provided are pyrazole and imidazole-based p38 kinase, including p38α, and p38β kinase, inhibitors. Pharmaceutical compositions containing the compounds are also provided. Methods of use of the compounds and compositions are also provided, including methods of treatment, prevention, or amelioration of one or... Agent: Novartis Ag

20120264802 - Photosensitizers for targeted photodynamic therapy: The present invention relates to photosensitizer compounds based on functionalized fullerenes useful in targeted photodynamic therapy (PDT), and methods of use thereof.... Agent: The General Hospital Corporation

20120264803 - Method for predicting therapeutic effects of chemotherapy on hepatocellular carcinoma patients: The present invention provides a method for predicting therapeutic effects of chemotherapy on hepatocellular carcinoma patients who have been treated with transarterial embolization and an antitumor agent for treating cancer patients who have been predicted to have a high probability of obtaining sufficient therapeutic effects from such chemotherapy. The present... Agent:

20120264804 - T type calcium channel blockers and the treatment of diseases: The present invention provides a method for treating a disease or condition in a mammal associated with influx of extracellular calcium via T type calcium channels, which comprises administering to the mammal a therapeutically effective amount of a T type calcium channel inhibitor, a prodrug thereof, or a pharmaceutically acceptable... Agent: University Of Virginia Patent Foundation

20120264817 - Solubilized formulation of docetaxel without tween 80: Lyophilizates containing docetaxel and the use thereof in preparing concentrated liquid formulations, and ready to use formulations for injection, as well as such concentrates and ready to use formulations themselves are disclosed in which Tween surfactants are avoided so that hypersensitivity reactions to Tween surfactants can be avoided and docetaxel... Agent:

20120264818 - Topical compositions with cannabis extracts: Various topical compositions including heat-treating mature, dried, powdered Cannabis sativa flower and bud leaves in carriers are disclosed. Various methods for the treatment of pain and methicillin-resistant Staphylococcus aureus (MRSA) infections are disclosed. Methods of making the topical composition, and patches, strips, bandages, and coverings containing the topical composition are... Agent:

20120264819 - Therapeutic uses of urolithins: The subject invention is drawn to ellagitannin metabolites (e.g., urolithin) that find use in treating or preventing a neoplastic disease in a subject.... Agent:

20120264820 - Synthetic flavonoids and pharmaceutical compositions and therapeutic methods of treatment of hiv infection and other pathologies: e

20120264821 - Use of equol for treating androgen mediated diseases: Equol (7-hydroxy-3(4′hydroxyphenyl)-chroman), the major metabolite of the phytoestrogen daidzein, specifically binds and blocks the hormonal action of 5α-dihydrotestosterone (DHT) in vitro and in vivo. Equol can bind circulating free DHT and sequester it from the androgen receptor, thus altering growth and physiological hormone responses that are regulated by androgens. These... Agent: Colorado State University Research Foundation

20120264822 - Method of improving animal tissue quality by supplementing the animal diet with oleic acid and selected tocols: A novel method for improving the meat quality of an animal is provided. The method comprises feeding the animal a diet supplemented with oleic acid and selected tocols in amounts effective to improve the meat quality. The method may be practiced on non-ruminants and ruminants.... Agent: E.i Du Pont De Nemours And Company

20120264823 - Substituted heteroaryl- and aryl-cyclopropylamine acetamides and their use: The invention relates to compounds of Formula (I): (A′)x-(A)-(B)—(Z)-(L)-C(═O)NH2 or pharmaceutically acceptable salts or solvates thereof, wherein: (A) is heteroaryl or aryl; each (A′), if present, is indepedently chosen from aryl, arylalkoxy, arylalkyl, heterocyclyl, aryloxy, halo, alkoxy, haloalkyl, cycloalkyl, haloalkoxy, and cyano, wherein each (A′) is substituted with 0, 1,... Agent: Oryzon Genomics S.a.

20120264824 - Compositions and methods for treating non-alcoholic steatohepatitis: Methods and compositions are disclosed comprising ethyl eicosapentanoate for the treatment of non-alcoholic steatohepatitis (NASH).... Agent: Mochida Pharmaceutical Co., Ltd.

20120264825 - Amino acid perhydrates, process for their preparation and uses thereof: The invention provides compounds which are -amino acid hydrogen peroxide solvates, wherein the side chain of the -amino acid has no basic nitrogen. A process for preparing the compounds and uses thereof are also described.... Agent:

20120264826 - N-acetyl beta alanine methods of use: Methods for increasing athletic performance, preventing paresthesia, increasing beta alanine absorption and cell membrane permeability through both passive diffusion and active transport, and increasing the half-life of beta alanine present in a blood stream in a human or animal are disclosed. Each method includes administering to the human or animal... Agent: Thermolife International, LLC

20120264827 - Sulfanylamide derivatives, uses thereof and compositions comprising them: The present invention concerns a family of sulfanilamide derivatives of formula (I) as anticonvulsant agents, where R is selected from optionally substituted C4-C9 alkyl, optionally substituted C6-C10 aryl, optionally substituted C6-C10 alkylenearyl and optionally substituted C5-C10heteroaryl; R2 is selected from —H and optionally substituted C1-C6 alkyl; each of R3 and... Agent: Yissum Research Development Company Of The Hebrew University Of Jerusalem, Ltd.

20120264828 - Polymorphic forms of o-desmethyl-venlafaxine succinate: The present invention discloses polymorphic forms of O-desmethyl-venlafaxine succinate and processes for the preparation thereof.... Agent: Cadila Healthcare Limited

20120264829 - Method for administering an nmda receptor antagonist to a subject: The invention provides methods for administering memantine to a subject. Memantine in an extended release form containing 22.5 to 30 mg memantine or a pharmaceutically acceptable salt is administered to a patient suffering from a neurological condition, such as Alzheimer's disease, Parkinson's disease or dementia. The extended release form achieves... Agent: Adamas Pharmaceuticals, Inc. A Delaware Corporation

20120264830 - Chondroitin sulfate-polycaprolactone copolymer, method for preparing the same and application thereof: A method for preparing a chondroitin sulfate-polycaprolactone copolymer includes subjecting a chondroitin sulfate component and a polycaprolactone polymer to an atom transfer radical polymerization reaction in the presence of a catalyst.... Agent: Kaohsiung Medical University

20120264832 - Low inflammatory blended oils: A low inflammatory oil composition and method for supplementing feed, nutrition and diet systems with omega-3 to omega-6 balanced oils comprised of a synergistic blend of at least two oils. The composition further comprises a synergistic blend of long chain omega-3 oil as a means to further increase the nutritional... Agent:

20120264831 - Rebaudioside-mogroside v blends: A composition includes Mogroside V and a Rebaudioside component in a weight ratio ≧1:1 and ≦6:1, wherein the Rebaudioside component consists of one or more compounds selected from the group consisting of Rebaudioside A, Rebaudioside B and Rebaudioside D. A method of purifying a Luo Han Guo extract includes contacting... Agent: Tate & Lyle Ingredients Americas LLC

20120264833 - Pharmaceutical compositions with enhanced performance: Disclosed are polymers of hydroxypropyl methyl cellulose acetate succinate (HPMCAS) and hydroxypropyl methyl cellulose acetate (HPMCA) with unique degrees of substitution of hydroxypropoxy, methoxy, acetyl, and succinoyl groups. When used in making compositions comprising a low-solubility drug and such polymers, the polymers provide enhanced aqueous concentrations and/or improved physical stability.... Agent:

20120264834 - Disodium salts, monohydrates, and ethanol solvates for delivering active agents: The inventors have discovered that the disodium salt of certain delivery agents has surprisingly greater efficacy for delivering active agents than the corresponding monosodium salt. Furthermore, the inventors have discovered that the disodium salts of these delivery agents form solvates with ethanol and hydrates with water. Preferred delivery agents include,... Agent: Emisphere Technologies, Inc.

  
10/11/2012 > 120 patent applications in 102 patent subcategories. categorized by USPTO classification

20120258905 - Vitamin receptor drug delivery conjugates for treating inflammation: Described herein are compositions, methods, compounds, conjugates, and kits for use in targeted drug delivery using drug delivery conjugates containing hydrophilic spacer linkers for use in treating disease states caused by pathogenic cell populations, such as inflammatory cells.... Agent: Endocyte, Inc.

20120258906 - Use of peptides as antidandruff agents: The present invention relates to compositions comprising peptides with antidandruff activity. The invention also relates to the use of these peptides as antidandruff agents, or in methodes for treating dandruff.... Agent: L'oreal

20120258907 - Treatment of fungal and/or protist infections: The present invention relates to the use of a polypeptides, comprising repeats of a peptide derived from a Heparan Sulphate Proteoglycan (HSPG) receptor binding region of an apolipoprotein, for treating or preventing a fungal and/or protist infection. The invention further relates to the use of such peptides for treating or... Agent: Ai2 Limited

20120258908 - Oligoadenylate synthetase (oas): The invention describes novel pharmaceutical compositions for the treatment of virus infections and cancer. The pharmaceutical compositions include mutant oligoadenylate synthetases (OAS) that have either enhanced cell permeability, reduced oxidative potential, improved antiviral activity, improved enzymatic activity, or absent enzymatic activity. The pharmaceutical compositions have improved drug properties and retain... Agent: Kineta Two, LLC

20120258909 - Solid compositions: The present invention features solid compositions comprising amorphous Compound I. For instance, Compound I may be formulated in an amorphous solid dispersion which comprises a pharmaceutically acceptable hydrophilic polymer and preferably a pharmaceutically acceptable surfactant.... Agent: Abbott Laboratories

20120258910 - Novel bacillus thuringiensis insecticidal proteins: The invention pertains to novel insecticidal compounds derived from Bacillus thuringiensis strains. New proteins designated Cry2Ae, Cry2Af, and Cry2Ag, and variants thereof are provided, as well as DNA sequences encoding these proteins or their variants. Further provided are recombinant hosts expressing such proteins, particularly plant cells and plants.... Agent: Bayer Cropscience N.v.

20120258912 - Pharmaceutical compositions and methods for delivering such compositions: The present invention provides pharmaceutical compositions comprising a pharmaceutically acceptable excipient and a conjugate having a degradable linkage. The conjugates include at least one of each the following: an aromatic moiety comprising an ionizable hydrogen atom, a spacer moiety, and a water-soluble polymer. Methods for delivering such compositions are also... Agent: Nektar Therapeutics

20120258911 - Phenylalkylcarboxylic acid delivery agents: The present invention provides phenylalkylcarboxylic acid compounds and compositions containing such compounds which facilitate the delivery of biologically active agents.... Agent: Emisphere Technologies, Inc.

20120258913 - Glucopyranoside compound: wherein Ring A and Ring B are: (1) Ring A is an optionally substituted unsaturated monocyclic heterocyclic ring, and Ring B is an optionally substituted unsaturated monocyclic heterocyclic ring, an optionally substituted unsaturated fused heterobicyclic ring, or an optionally substituted benzene ring, (2) Ring A is an optionally substituted benzene... Agent:

20120258914 - Coacervation process: Methods of forming compositions for the sustained release of water soluble active agents, including biologically active polypeptides and products produced by the process are described. Improved product characteristics and ease of scale-up can be achieved using a novel coacervation process wherein at least one coacervation agent is added to the... Agent: Alkermes, Inc.

20120258915 - Proteolysis resistant active vegf: The invention relates to endothelial growth factor (VEGF) in which the alanine at AA position 111 is replaced by proline. The arginine at AA position 110 may moreover be replaced by another amino acid. The invention also relates to derivatives of the VEGF according to the invention, nucleic acids, expression... Agent: Bayer Innovation Gmbh

20120258916 - Ophthalmic preparations based on bdnf (brain-derived neurotrophic factor) and their use: Said preparations can be administered topically to the intact eye surface, and are useful in the prevention and treatment of neurodegenerative disorders of the retina, optic nerve, lateral geniculate body and visual cortex, in order to prevent reduction of visual capacity and restore the normal visual function.... Agent: Hmfra Hungary Limited Liability Company

20120258917 - Peripheral administration of proteins including tgf-beta superfamily members for treatment of systemic disorders and disease: The present invention is directed to methods and compositions for accomplishing systemic delivery of minimally-soluble bioactive agents such as, but not limited to, proteins of the TGF-β superfamily via a peripheral mode of administration. According to the invention, an exemplary bioactive agent is BMP-7. The invention further provides for minimally-invasive... Agent:

20120258918 - Polypeptoid pulmonary surfactants: The present invention provides spreading agents based on sequence-specific oligomers comprising a peptoid, a peptide-peptoid chimera, a retropeptoid or a retro(peptoid-peptide) chimera, and methods for using the same, including for the treatment of respiratory distress of the lungs. The spreading agents are sequence-specific oligomers, including retrosequence-specific oligomers, based on a... Agent:

20120258919 - Collagen peptide, dipeptide and malady inhibitor: A problem that the present invention is to solve is to provide: a main body of a peptide molecule which is effective for inhibition of various maladies such as osteoporosis, osteoarthritis and pressure ulcer, particularly, a dipeptide which is easy to absorb into a body in an intestine; a collagen... Agent: Nitta Gelatin Inc.

20120258920 - Peptides and aptamers thereof as specific modulators of mutant p53 function: Mutations in the p53 tumor suppressor gene are frequently found in human tumors and mutant p53 proteins actively collaborate with tumor progression. Interfering with mutant p53 function may represent a valid strategy to block tumor growth and development of aggressive phenotypes. As a consequence of the characteristic of peptide aptamers... Agent: Universita' Degli Studi Di Trieste

20120258921 - Peptides for the treatment of hearing: Peptides for the treatment of inflammation, and therapeutic uses and methods of using the same are disclosed. Peptides including a transducing sequence are effective for inhibiting cytokine activity and TNF-α secretion through interaction with toll-like receptor signaling pathways. Experiments are described illustrating the efficacy of the compounds in treating otitis... Agent: 13therapeutics, Inc.

20120258922 - Synergistic inhibition of low-density lipoprotein oxidation: The invention provides use of a composition comprising a plant, plant parts, and extracts thereof having high levels of glucoraphanin and/or sulforaphane and tocopherols. Also provided are glucoraphanin and/or sulforaphane, in combination with tocopherols, where the overall composition synergistically inhibits oxidation of low-density lipoproteins. Methods of producing a food from... Agent: Seminis Vegetable Seeds, Inc.

20120258923 - Bioactivity composition of reevesia formosana: A series cardenolide derivatives including structure of formula I from the root of Reevesia formosana have provided. In formula (1) and (2), where R3, R5, R10 and R16 are as defined in the specification. The derivatives compounds showed potent cytotoxicity against MCF-7, NCI-H460, and HepG2 cancer cell lines.... Agent: Kaohsiung Medical University

20120258924 - Method of modulating stress-activated protein kinase system: Disclosed are methods of modulating a stress activated protein kinase (SAPK) system with an active compound, wherein the active compound exhibits low potency for inhibition of at least one p38 MAPK; and wherein the contacting is conducted at a SAPK-modulating concentration that is at a low percentage inhibitory concentration for... Agent: Intermune, Inc.

20120258925 - Antibacterial aminoglycoside analogs: s

20120258926 - Formulations of acadesine: This invention provides a buffered solution comprising acadesine, as well as compositions, formulations and kits containing said solution. The solution, compositions, formulation, and kits can be used to prevent morbidity/mortality in a patient or to treat an ischaemic condition, a condition regulated by adenosine, or a condition associated with reduced... Agent:

20120259001 - Duplex oligonucleotides with enhanced functionality in gene regulation: Disclosed are methods of enhancing functionality of duplex oligonucleotides and compositions made by the methods. The duplex oligonucleotides include siRNAs, miRNA mimics, and piRNA mimics which contain modified nucleotides and mismatches between the two strands of the molecule at specific nucleotide positions.... Agent: Dharmacon, Inc.

20120259000 - Epidermal differentiation microrna signature and uses thereof: The present invention concerns a method for determining the state of epidermal differentiation of a human keratinocyte in a sample of human epithelium, comprising determining the level of expression of at least one miRNA selected from hsa-miR-455-3p, hsa-miR-141, hsa-miR-148a, hsa-miR-182, hsa-miR-224, hsa-miR-26a, hsa-miR-26b, hsa-miR-361-5p, hsa-miR-425, hsa-miR-92b, hsa-let-7i, hsa-miR-22, hsa-miR-221, hsa-miR-222,... Agent: L'oreal

20120258998 - Fusion genes in gastrointestinal cancer: A method of treating or preventing a gastrointestinal cancer by inhibiting expression of a CD44-SLC1A2 fusion gene or a functional variant thereof, or by inhibiting the activity of a fusion protein expressed by the CD44-SLC1A2 fusion gene or the functional variant thereof.... Agent:

20120259002 - Molecule for treating an inflammatory disorder: The invention provides two types of oligonucleotides for treating an inflammatory disorder: an oligonucleotide which is able of altering the splicing of a pre-mRNA encoding a C5 in order to decrease the amount of a C5a and an oligonucleotide which is able of altering the splicing of a pre-mRNA encoding... Agent: Prosensa Technologies B.v.

20120258999 - Reagents, methods and systems to suppress pro-inflammatory cytokines: The present invention relates to reagents, methods and systems to treat inflammation and pain in a subject using small interfering RNA (siRNA) molecules targeted to either TNFα, IL1 IL6 and other pro-inflammatory cytokines.... Agent: Warsaw Orthopedic, Inc.

20120259003 - Anti-wssv and/or tsv nucleic acid drug: An anti-WSSV and/or TSV nucleic acid drug, the active ingredients of which are five nucleic acids whose nucleotide sequences are sequence 1, sequence 2, sequence 3, sequence 4 and sequence 5 in the sequence list, respectively. The nucleic acid drug of the present invention has no toxic or side effect... Agent: Nanjing Sen Nan Biotechnology Research Co., Ltd

20120258927 - Inhibitors of e1 activating enzymes: This invention relates to compounds that inhibit E1 activating enzymes, pharmaceutical compositions comprising the compounds, and methods of using the compounds. The compounds are useful for treating disorders, particularly cell proliferation disorders, including cancers, inflammatory and neurodegenerative disorders; and inflammation associated with infection and cachexia.... Agent: Millenium Pharmaceuticals, Inc.

20120258928 - Nucleoside cyclicphosphates: Cyclic phosphate of nucleoside derivatives for the treatment of viral infections in mammals, which is a compound, its stereoisomers, salts (acid or basic addition salts), hydrates, solvates, or crystalline forms thereof, represented by the following structure:... Agent: Gilead Pharmasset LLC

20120258929 - Agent that modulates physiological condition of pests, involved in insect peptidyl-dipeptidase a activity: The present invention provides an agent that modulates physiological condition of pests, wherein the agent has an ability to modulate the activity of an insect peptidyl-dipeptidase A; a method for assaying pesticidal activity of a test substance, which comprises a step of measuring the activity of a peptidyl-dipeptidase A in... Agent: Sumitomo Chemical Company, Limited

20120258931 - Regimens for intra-articular viscosupplementation: The invention provides viscosupplementation methods for treating osteoarthritis and joint injury with HA-based viscosupplements, particularly viscosupplements with an intra-articular residence half-life shorter than 3 weeks. Viscosupplements for use in the methods of the invention may be further characterized in that they contain less than 20 mg/ml HA, at least 5%... Agent:

20120258930 - The improvement of gastrointestinal health, immunity and performance by dietary intervention: This invention relates to the improvement of gastrointestinal health, immunity and performance by direct dietary intervention with a composition comprising a glucan and/or a fucan, and relates in particular to the transfer of associated health benefits to offspring via glucan and/or a fucan supplementation of the maternal diet. Accordingly the... Agent: Bioatlantis Ltd.

20120258932 - Combination of polychitosamine and hmg-coa reductase inhibitor for hyperlipidemia: Combinations of therapeutic compounds for prophylaxis or treatment of hyperlipidemia and hyperlipidemia related disorders, such as hypercholesterolemia and the resultant atherosclerosis in a mammal. The combinations are useful for reducing serum cholesterol, and/or cholesteryl ester, triglycerides, phospholipids and fatty acids in a mammal. The methods of the preferred embodiments comprise... Agent:

20120258933 - Combination: The present invention relates to a method of treating cancer in a human and to pharmaceutical combinations useful in such treatment. In particular, the method relates to a cancer treatment method that includes administering a proteasome inhibiting compound, and N-{(1S)-2-amino-1-[(3-fluorophenyl)methyl]ethyl}-5-chloro-4-(4-chloro-1-methyl-1H-pyrazol-5-yl)-2-thiophenecarboxamide, or a pharmaceutically acceptable salt thereof, and optional additional antineoplastic... Agent:

20120258934 - Fosfomycin pharmaceutical composition: e

20120258935 - Process for preparation of hiv protease inhbitors: A process for the synthesis of bisfuran intermediates useful for preparing antiviral HIV protease inhibitor compounds is hereby disclosed... Agent: Gilead Sciences, Inc.

20120258936 - Inositol hexakisphosphate analogs and uses thereof: Provided herein are analog and derivative compounds of inositol hexakisphosphate effective to treat a Clostridium difficile infection and to neutralize the bacterial toxins produced by the same. In addition, methods of treating the C. difficile infection and for neutralizing its toxins with the compounds are provided.... Agent: The Board Of Regents Of The University Of Texas System

20120258937 - Targeting estrogen receptors in the treatment of lymphangioleiomyomatosis: Methods for inhibiting estrogen hormone-induced pulmonary metastasis of smooth muscle cells that are capable of pulmonary metastasis comprise antagonizing the estradiol receptor on the smooth muscle cells such that pulmonary metastasis of the cells is inhibited.... Agent: Fox Chase Cancer Center

20120258938 - Enzymatic production or chemical synthesis and uses for 5,7-dienes and uvb conversion products thereof: Provided herein are steroidal compounds that are androsta-5,7-dienes or pregna-5,7-dienes and ultraviolet B (UVB) conversion products thereof and cholecalciferol derivatives hydroxylated at one or more of C1, C17, C20, C23, C24, C25, and C26 which includes pharmaceutical, cosmeceutical or nutraceutical compositions of the steroidal compounds as shown in Tables 1A,... Agent:

20120258940 - Method for treating haematological cancers: The present invention relates to a combination which comprises (a) a FGFR inhibitor and (b) a glucocorticoid receptor modulator, or a pharmaceutical acceptable salt thereof; the use of such a combination for the preparation of a medicament for the treatment of haematological cancers; a commercial package or product comprising such... Agent:

20120258939 - Pharmaceutical manufacturing process: The present invention provides a method for preparing a sterile suspension of a glucocorticosteroid. The glucocorticosteroids used in the invention are preferably antiinflammatory glucocorticosteroids. By making the last stage of product preparation be the sterilization process, the potential for contamination during manufacture and heat degradation of products is greatly reduced.... Agent: Norton Healthcare Limited

20120258941 - 17-hydroxy-17-pentafluorethyl-estra-4,9(10)-dien-11-aryl derivatives, methods for the production thereof and the use thereof for treating diseases: The invention relates to 17-hydroxy-17-pentafluoroethylestra-4,9(10)-diene 11-aryl derivatives of the formula I with progesterone-antagonising action and to processes for preparation thereof, to use thereof for treatment and/or prophylaxis of disorders and to the use thereof for production of medicaments for treatment and/or prophylaxis of disorders, especially of fibroids of the uterus... Agent: Bayer Pharma Aktiengesellschaft

20120258942 - Device for transdermal administration of drugs including acrylic polymers: A transdermal delivery system is provided where the drug delivery rates, onset and profiles of at least one active agent are controlled by selectively manipulating the monomeric make up of an acrylic-based polymer in the transdermal drug delivery system. The drug carrier composition may be comprised of (a) one or... Agent: Noven Pharmaceuticals, Inc.

20120258943 - Formulations of deoxycholic acid and salts thereof: The present application is directed to an aqueous pharmaceutical composition comprising from about 0.4% w/v to less than about 2% w/v of a salt of deoxycholic acid, wherein the composition is maintained at a pH from about 8.1 to about 8.5 such that the composition is stabilized against precipitation. Also... Agent: Kythera Biopharmaceuticals, Inc.

20120258944 - Antioxidants for use in therapy: Compounds based on the following structures: wherein each of R1, R2, R3 and R4 is independently selected from: hydrogen, alkyl, and substituted alkyl; and each of R5, R6 and R7 is independently selected from: hydrogen, alkyl, substituted alkyl, alkoxy, substituted alkoxy, N,N-dialkylamino, substituted N,N-dialkylamino, N-monoalkylamino, substituted N-monoalkylamino, and electron-donating substituents... Agent: Karolinska Institutet Innovations Ab

20120258945 - Association between ferroquine and an artemisinine derivative for treating malaria: This invention is directed to methods for the treatment and prevention of malaria comprising administering a combination of ferroquine, or a pharmaceutically acceptable salt, hydrate or solvate thereof, and an artemisinin derivative, and to pharmaceutical compositions comprising such combination.... Agent: Sanofi-aventis

20120258949 - Spirocyclic derivatives as histone deacetylase inhibitors: This invention is related to new histone deacetylase inhibitors according to the general formula (I), wherein: m and n are independently zero or an integer from 1 to 4; p is zero or an integer from 1 to 3, with the proviso that when p is zero, n and m... Agent: Dac S.r.i.

20120258948 - N-linked hydroxamic acid derivatives useful as antibacterial agents: i

20120258947 - Substituted 6-amino-nicotinamides as kcnq2/3 modulators: Substituted 6-amino-nicotinamides, pharmaceutical compositions containing these compounds and also use of these compounds in the treatment and/or prophylaxis of pain and further diseases and/or disorders.... Agent: Grunenthal Gmbh

20120258946 - Substituted phenylureas and phenylamides as vanilloid receptor ligands: Substituted phenylureas and phenylamides, processes for their preparation, pharmaceutical compositions containing these compounds, and the use of these compounds for preparing pharmaceutical compositions.... Agent: Gruenenthal Gmbh

20120258951 - Novel antiplatelet agent: b

20120258950 - Pyrrolo[2,3-d]pyrimidine tropomysin-related kinase inhibitors:

20120258952 - Substituted n-(1h-indazol-4-yl)imidazo[1,2-a]pyridine-3-carboxamide compounds as cfms inhibitors: Compounds of Formula (I): and pharmaceutically acceptable salts thereof in which R1, R2, R3, R4 and R5 have the meanings given in the specification, are inhibitors of cFMS and are useful in the treatment of bone-related diseases, cancer, autoimmune disorders, inflammatory diseases, cardiovascular diseases and pain.... Agent: Array Biopharma Inc.

20120258953 - Benzoxazepines as inhibitors of pi3k/mtor and methods of their use and manufacture: The invention is directed to Compounds of Formula (I): the invention provides compounds that inhibit, regulate, and/or modulate P13K and/or mTOR that are useful in the treatment of hyperproliferative diseases, such as cancer, in mammals. This invention also provides methods of making the compound methods of using such compounds in... Agent: Exelixis, Inc.

20120258954 - Arylsulfonamide based matrix metalloprotease inhibitors: said compound is inhibitor of MMP-2, and/or MMP-8, and/or MMP-9, and/or MMP-12 and/or MMP-13, and thus can be employed for the treatment of a disorder or disease characterized by abnormal activity of MMP-2, and/or MMP-8, and/or MMP-9, and/or MMP-12 and/or MMP-13. Accordingly, the compound of formula (I) can be used... Agent: Novartis Ag

20120258955 - Bicyclic thiazoles as allosteric modulators of mglur5 receptors: The present invention relates to novel bicyclic thiazoles which are positive allosteric modulators of the metabotropic glutamate receptor subtype 5 (“mGluR5”) and which are useful for the treatment or prevention of disorders associated with glutamate dysfunction and diseases in which the mGluR5 subtype of receptors is involved. The invention is... Agent: Janssen Pharmaceutica Nv

20120258956 - Use of a spirolide, analogues and derivatives for treating and/or preventing pathological conditions linked to the tau and beta-amyloid proteins: for preparing a drug for the prevention and/or treatment of a pathology related to the increase in β-amyloid protein and/or hyperphosphorylation of tau protein compared to control, where said spirolide compound is administered in the amount necessary to reach a concentration in the serum of equal to or less than... Agent:

20120258957 - Heterocyclic derivatives: wherein the variables are defined as in the specification, or to a pharmaceutically acceptable salt or solvate thereof. The present invention also relates to a pharmaceutical composition comprising said heterocyclic derivatives and to their use in therapy, for instance in the treatment or prevention of disorders or diseases influenced by... Agent:

20120258958 - Azaindoles useful as inhibitors of jak and other protein kinases: The present invention relates to inhibitors of protein kinases. The invention also provides pharmaceutical compositions comprising the compounds of the invention and methods of using the compositions in the treatment of various disorders.... Agent: Vertex Pharmaceuticals Incorporated

20120258959 - Pyridone gpr119 g protein-coupled receptor agonists: Novel compounds are provided which are GPR119 G protein-coupled receptor modulators. GPR119 G protein-coupled receptor modulators are useful in treating, preventing, or slowing the progression of diseases requiring GPR119 G protein-coupled receptor modulator therapy. These novel compounds have the structure Formula I or Formula IA.... Agent: Bristol-myers Squibb Company

20120258960 - Novel multifunctional peptidase inhibitors, especially for medical use: The invention relates to compounds of the general formula (1) or the acid addition salts thereof with organic and/or inorganic acids; as well as to the use of the compounds of the general formula (1) in medicine.... Agent: Imtm Gmbh

20120258961 - 4-amino-1,3-thiazine or oxazine derivative: The present invention provide a medicament for treating the diseases induced by production, secretion or deposition of amyloid-β proteins, for example, a compound of the following formula (I) wherein R1, R2a, R2b, R3a, R3b, R4a, R4b, ring A, Y and the dotted line are defined in the specification, its pharmaceutically... Agent: Shionogi & Co., Ltd.

20120258962 - 1,3-oxazines as bace1 and/or bace2 inhibitors: e

20120258963 - Hydroxymethyl pyrrolidines as beta 3 adrenergic receptor agonists: The present invention provides compounds of Formula (I), pharmaceutical compositions thereof, and method of using the same in the treatment or prevention of diseases mediated by the activation of β3-adrenoceptor.... Agent:

20120258964 - 2-heteroaryl carboxamides: The invention relates to novel 2-heteroaryl carboxamides and to the use thereof for producing medicaments for the treatment and/or prophylaxis of diseases and for improving perception, concentration, learning and/or memory.... Agent: Bayer Schering Pharma Ag

20120258965 - N-hydroxylsulfonamide derivatives as new physiologically useful nitroxyl donors: The invention relates to N-hydroxylsulfonamide derivatives that donate nitroxyl (HNO) under physiological conditions and are useful in treating and/or preventing the onset and/or development of diseases or conditions that are responsive to nitroxyl therapy, including heart failure and ischemia/reperfusion injury. Novel N-hydroxylsulfonamide derivatives release NHO at a controlled rate under... Agent: Cardioxyl Pharmaceuticals

20120258966 - Pharmaceutical compounds: wherein R1-R3, A and n have any of the values described in the specification; and pharmaceutically acceptable salts thereof; have activity as inhibitors of PI3K and may thus be used to treat diseases and disorders arising from abnormal cell growth, function or behaviour associated with PI3 kinase such as cancer,... Agent: Piramed Limited

20120258967 - Pi3 kinase inhibitors and uses thereof: The present invention provides compounds, compositions thereof, and methods of using the same.... Agent: Avila Therapeutics, Inc.

20120258968 - 4-phenylamino-pyrimidine derivatives having protein kinase inhibitor activity: Furthermore, the present invention is directed to pharmaceutical composition containing at least one compound of general formula (I) and/or pharmaceutically acceptable salts or solvates thereof and for the use of them for the preparation of pharmaceutical compositions for the prophylaxis and/or the treatment of protein kinase related, especially CDK9-related diseases... Agent:

20120258969 - Viral inhibitors: r

20120258970 - Compositions and methods for the treatment of drug-induced hand-foot syndrome: The present invention provides methods of treating, ameliorating or preventing hand-foot syndrome in a subject in need thereof comprising administering to the subject a therapeutically effective amount of a phosphodiesterase inhibitor.... Agent:

20120258971 - Therapeutic agent for chronic pain: This invention provides a novel therapeutic agent for chronic pain. The therapeutic agent for chronic pain comprises aripiprazole as an active ingredient.... Agent: Otsuka Pharmaceutical Co., Ltd.

20120258972 - Composition and methods for treating hair loss: A method for treating hair loss caused by androgenic alopecia and/or male pattern baldness. The method, which not only slows hair loss but causes hair re-growth, includes approximately daily application to a subject's scalp of a novel composition comprising finasteride (Propecia® or Proscar®), dutasteride (Avodart®), and minoxidil (Rogaine®) as active... Agent:

20120258973 - Disubstituted heteroaryl-fused pyridines: The invention relates to compound of the formula (I′) in which the substituents are as defined in the specification; in free form or in salt form; to its preparation, to its use as medicament and to medicaments comprising it.... Agent: Novartis Ag

20120258974 - Use of a2b adenosine receptor antagonists for treating heart failure and arrhythmia in post-myocardial infarction patients: Provided are methods of improving the cardiac condition of post-myocardial infarction (MI) patients and reducing cardiovascular death and hospitalization due to heart failure or arrhythmias, by administering a therapeutically effective amount of an A2B adenosine receptor antagonist.... Agent: Gilead Sciences, Inc.

20120258975 - Potent small molecule inhibitors of autophagy, and methods of use thereof: Certain aspects of the invention relates to small molecule autophagy inhibitors of the formula (I), and their use for treatment and prevention of cancers and acute pancreatitis. As disclosed herein, a small molecule inhibitor of autophagy was been identified from an image-based screen in a known bioactive library. It was... Agent: President And Fellows Of Harvard College

20120258976 - Crystalline pyrrolo[2,3-d]pyrimidine compounds: The present invention discloses novel crystalline and non-crystalline forms of 3-((3R,4R)-4-methyl-3-[methyl-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-amino]-pip-eridin-1-yl)-3-oxopropionitrile, pharmaceutical composition containing the same, preparations thereof and the uses thereof.... Agent: Pfizer Inc.

20120258977 - Inhibitors of e1 activating enzymes: This invention relates to compounds that inhibit E1 activating enzymes, pharmaceutical compositions comprising the compounds, and methods of using the compounds. The compounds are useful for treating disorders, particularly cell proliferation disorders, including cancers, inflammatory and neurodegenerative disorders; and inflammation associated with infection and cachexia.... Agent: Millennium Pharmaceuticals, Inc.

20120258978 - Nitrogen-containing six-membered aromatic ring derivatives and pharmaceutical products containing the same: in which Nx group is preferably a 6-membered aromatic ring containing two nitrogen atoms; R0, R1 and R2 are each independently a hydrogen atom, an alkyl group, or an amino group; E is an oxygen atom or an —NR8 group (wherein R8 is an alkyl group or the like); n... Agent: Daiichi Sankyo Company, Limited

20120258979 - Substituted piperidine spiro pyrrolidinone and piperidinone, preparation and therapeutic use thereof: wherein R1, R2, R3, m, n and p are as described herein. More specifically, the compounds of this invention are modulators of H3 receptors and are, therefore, useful as pharmaceutical agents, especially in the treatment and/or prevention of a variety of diseases modulated by H3 receptors including diseases associated with... Agent:

20120258980 - Antibacterial agent for drug-resistant bacteria, method for screening for same, and use of same: A method for treating an individual infected with drug-resistant bacteria resistant to at least one drug, the method including: administering to the individual an antibacterial agent for drug-resistant bacteria which comprises at least one of a nybomycin and a derivative thereof, wherein the antibacterial agent for drug-resistant bacteria is effective... Agent:

20120258981 - Process for the synthesis of quaternary amine compounds: The invention relates to a process for the synthesis of quaternized compounds of formula:... Agent: Alkermes, Inc.

20120258982 - Adamantyl compounds: wherein the variables are as defined herein. The compounds and compositions disclosed herein are useful to modulate the activity of JNK and treat diseases associated with JNK activity. Disclosed are methods and formulations for inhibiting JNK and treating JNK-mediated disorders, and the like, with the compounds, and processes for making... Agent:

20120258983 - Pharmaceutical composition and administrations thereof: The present invention relates to pharmaceutical compositions comprising a solid dispersion of N-[2,4-Bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide, methods of manufacturing pharmaceutical compositions of the present invention, and methods of administering pharmaceutical compositions of the present invention.... Agent: Vertex Pharmaceuticals Incorporated

20120258984 - 5-htp combination therapy: The present invention relates to combination therapies and pharmaceutical compositions comprising a combination of 5-hydroxytryptophan and a serotonin reuptake inhibitor. The present invention provides a pharmaceutical composition comprising (i) a serotonin reuptake inhibitor and (ii) 5-hydroxytrytophan. The present invention further provides a pharmaceutical composition comprising (i) 5-hydroxytryptophan in an amount... Agent: H. Lundbeck A/s

20120258985 - Stabilized polymeric thiol reagents: Disclosed are water soluble polymeric conjugates comprising the structure POLY-[Y—S—S-A]x, where POLY is a water soluble polymer; Y is a hydrocarbon-based spacer group, x is 1 to 25, S—S is a disulfide group attached to an sp3 hybridized carbon of Y; and A is a covalently linked residue of a... Agent: Nektar Therapeutics

20120258987 - Lysophosphatidic acid receptor antagonists: Described herein are compounds that are antagonists of lysophosphatidic receptor(s). Also described are pharmaceutical compositions and medicaments that include the compounds described herein, as well as methods of using such antagonists, alone and in combination with other compounds, for treating LPA-dependent or LPA-mediated conditions or diseases.... Agent: Amira Pharmaceuticals, Inc.

20120258986 - Olefin containing nuclear transport modulators and uses thereof: The invention generally relates to the field of nuclear transport modulators, e.g., CRM1 inhibitors, and more particularly to new substituted-heterocyclic azole compounds, the synthesis and use of these compounds and their pharmaceutical compositions, e.g., in the treatment, modulation and/or prevention of physiological conditions associated with CRM1 activity such as in... Agent: Karyopharm Therapeutics, Inc.

20120258988 - Therapeutic or prophylactic agent for diabetes: A therapeutic or prophylactic agent for diabetes includes a thiazolidine derivative as a PPAR-γ agonist as an effective component which exhibits a reduced side effect of the PPAR-γ agonist. The therapeutic or prophylactic agent for diabetes includes a particular IP agonist such as beraprost sodium (BPS), and a thiazolidine derivative... Agent: Toray Industries, Inc.

20120258989 - Use of succinate dehydrogenase inhibitors for extending shelf life of fruits and vegetables: The present invention relates to the use of succinate dehydrogenase Inhibitors for extending shelf life and storage stability of fruits and vegetables, to a method for extending shelf life of fruits and vegetables by applying a succinate dehydrogenase inhibitor to the crops prior to the harvest of the fruits or... Agent: Bayer Cropscience Ag

20120258990 - Pyrazole derivatives: The present invention relates to heterocyclic compounds of formula (I) which have microbiocidal activity, in particular fungicidal activity: formula (I) wherein G1 and G2 are independently O or S; T is —C(R9R10)—, —C(R11)═C(R12)—, —C≡C—, NR13 or O; Y1 and Y2 are independently CR14 or N; Q is —C(═O)—N(R15)-z, —C(═S)—N(R16)-z, —C(═O)—O-z,... Agent: Syngenta Crop Protection, LLC

20120258991 - Method of treating a cancer by administering a specified drug: A method of treating a cancer selected from the group consisting of breast cancer, pancreatic cancer, kidney cancer, prostate cancer, medulloblastoma, rhabdomyosarcoma, Ewing sarcoma, liposarcoma, multiple myeloma or leukemia. An effective amount of 5-(4-(6-(4-amino-3,5-dimethyl-phenoxy)-1-methyl-1H-benzimidazol-2-ylmethoxy)-benzyl)-thiazolidine-2,4-dione.dihydrochloride is administered to a patient having said cancer.... Agent: Daiichi Sankyo Company, Limited

20120258992 - Dual-acting antihypertensive agents: wherein: Q, W, Y, Z, r, and Ar are as defined in the specification, and pharmaceutically acceptable salts thereof. These compounds have AT1 receptor antagonist activity and neprilysin inhibition activity. The invention is also directed to pharmaceutical compositions comprising such compounds; methods of using such compounds; and process and intermediates... Agent: Theravance, Inc.

20120258993 - Non-natural macrocyclic amide hdac6 inhibitor compounds and their uses as therapeutic agents: The present invention relates to novel amide compounds of formula I, and their use as anti-tumoral and pro-apoptotic agents. The invention includes the use of such compounds in medicine, in relation to cancer disease as well as other diseases where an inhibition of HDAC6 is responsive, and the pharmaceutical composition... Agent: Sigma-tau Industrie Farmaceutiche Riunite S.p.a.

20120258994 - Preparation and use of (+)-1-(3,4-dichlorophenyl)-3-azabicyclo[3.1.0]hexane in the treatment of conditions affected by monoamine neurotransmitters: The present invention relates to (+)-1-(3,4-dichlorophenyl)-3-azabicyclo[3.1.0]hexane and pharmaceutically acceptable active salts, polymorphs, glycosylated derivatives, metabolites, solvates, hydrates, and/or prodrugs of (+)-1-(3,4-dichlorophenyl)-3-azabicyclo[3.1.0]hexane and their use alone or in combination with additional psychotherapeutic compositions in the treatment of conditions affected by monoamine neurotransmitters, including treatment of refractory individuals.... Agent:

20120258995 - New indolinone protein kinase inhibitors: The present invention relates to new indolinone compounds and their pharmaceutically acceptable salts and prodrugs for treating and preventing VEGFR related cellular disorders such as cancer.... Agent: Beta Pharma, Inc

20120258996 - Novel ligands that modulate rar receptors: e

20120258997 - New application of 2-pyrrolidone derivatives: The invention is related to the new application of selected derivatives of 2-pyrrolidone to inhibition of protein glycation and to prevention and treatment of diabetes complications, such as atherosclerosis, nephropathy, retinopathy, cataract or neuropathy.... Agent:

20120259004 - Anti-cancer extract and compounds: The preset invention relates to a new approach for treating a cancer or fibrosis, such as Hepatocellular carcinoma, or liver fibrosis using an extract from a plant of Graptopetalum sp., Rhodiola sp. or Echeveria sp., and prepared by extracting the plant with Dimethyl sulfoxide (DMSO), its fraction or the compound... Agent: National Yang-ming University

20120259005 - Brca1-based breast or ovarian cancer prevention agents and methods of use: A pharmaceutical composition for use in treating, inhibiting, and/or preventing breast and/or ovarian cancer can include: a molecule having a structure of one of Compounds 1-38, pharmaceutically acceptable salt thereof, or analog thereof; and a pharmaceutically acceptable carrier containing the compound. The pharmaceutically acceptable carrier can be configured for oral,... Agent: University Of Kansas

20120259006 - Novel benzofuran type derivatives, a composition comprising the same for treating or preventing cognitive dysfunction and the use thereof: The present invention relates to the novel benzofuran derivatives, the preparation thereof and the composition comprising the same. The benzofuran derivatives of the present invention showed potent inhibiting activity of beta-amyloid aggregation and cell cytotoxicity resulting in stimulating the proliferation of neuronal cells as well as recovering activity of memory... Agent: Medifron Dbt Co., Ltd.

20120259007 - Anticoagulant compounds and their use: According to the invention there is provided a compound of formula (I): wherein R1, R2, R3 and n have meanings given in the description, or a pharmaceutically acceptable solvate, salt or prodrug thereof for use as an anticoagulant.... Agent: Haoma Medica Limited

20120259008 - Method for treating asthenopia: The present invention relates to a method for treating asthenopia, accommodative dysfunction or ocular pain comprising an administration of a specific prostaglandin compound to a mammalian subject. The present invention also relates to a composition for treating asthenopia, accommodative dysfunction or ocular pain comprising a specific prostaglandin compound.... Agent: Sucampo Ag

20120259009 - Polymer composition and molded articles shaped of the same: The present invention relates to a polymer composition comprising 100 parts by weight of an olefin-based polymer, and 0.01 to 100 parts by weight of terpenoid and 0.01 to 200 parts by weight of a releasable active compound per 100 parts by weight of said olefin-based polymer.... Agent: Sumitomo Chemical Company, Limited

20120259010 - Cationic cosmetic composition: A cosmetic composition is provided which includes a diester quit and a small amount of a potassium salt in an aqueous carrier. Preferably the compositions are lotions and creams which have the benefit of smooth spreadability in topical application onto the skin.... Agent: Conopco, Inc., D/b/a Unilever

20120259011 - Personal care compositions with cationic diesters and dihydroxypropyl quaternary ammonium salts: A personal care composition is provided which includes a diester quat and a polyhydroxy quaternary ammonium salt. Preferably the composition is a lotion or cream which exhibits a dragginess in topical application onto the skin.... Agent: Conopco, Inc., D/b/a Unilever

20120259012 - Treatment for amyotrophic lateral sclerosis: Provided are certain methods of screening, identifying, and evaluating neuroprotective compounds useful for treatment of neurological diseases, such as, e.g., multiple sclerosis (MS). The compounds described upregulate the cellular cytoprotective pathway regulated by Nrf2. Also provided are certain methods of utilizing such compounds in therapy for neurological disease, particularly, for... Agent: Biogen Idec Ma Inc.

20120259013 - Liquid dosage forms of isotretinoin: The present invention relates to a pharmaceutical solution comprising isotretinoin or salts thereof. The present invention further relates to the processes for preparing such compositions.... Agent: Ranbaxy Laboratories Limited

20120259014 - Topical retnoid solutions: The present invention relates to a topical solution comprising a retinoid or its pharmaceutically acceptable salts thereof and a process of preparing it.... Agent: Ranbaxy Laboratories Limited

20120259015 - Medicament for prophylactic and/or therapeutic treatment of hepatic steatosis or non-alcoholic steatohepatitis: A medicament for prophylactic and/or therapeutic treatment of hepatic steatosis or non-alcoholic steatohepatitis, which comprises a polyprenyl compound (e.g., 3,7,11,15-tetramethyl-2,4,6,10,14-hexadecapentaenoic acid) as an active ingredient.... Agent: Kowa Company, Ltd.

20120259016 - Compositions comprising ornithine and phenylacetate or phenylbutyrate for treating hepatic encephalopathy: The present invention relates to use of ornithine in the manufacture of a medicament for use in combination with at least one of phenylacetate and phenylbutyrate for preventing or treating liver decompensation or hepatic encephalopathy. The invention also relates to use of at least one of phenylacetate and phenylbutyrate in... Agent: Ucl Business PLC

20120259017 - Use of propionic acid as an antimicrobial: Propionic acid is used to curb the growth of Candida albicans, Aspergillus niger, Escherichia coli, Pseudomonas aeruginosa and Staphylococcus aureus in personal care products. Carnosic acid may be substituted for some of the propionic acid to provide a synergistic combination.... Agent: Kemin Industries, Inc.

20120259018 - Composition of dexibuprofen transdermal hydrogel: Stable non-alcoholic transdermal hydrogel of dexibuprofen was prepared by using a simple manufacturing process, and the experimental trials showed that the pH modifying agent, antioxidant and water miscible solvent are the essential excipients to obtain stable non-alcoholic transdermal hydrogel of dexibuprofen. The dexibuprofen hydrogel prepared using carbopol as a gelling... Agent:

20120259019 - Composition and application process for liquid antifungal: Embodiments of the present invention relate to a non-aqueous antifungal composition that comprises an alcoholic solvent, a preservative, a wetting agent and a flavoring agent, which can be used in the bakery industry when applied on the surface of products by spraying. Embodiments of the present invention result in food... Agent:

20120259020 - Transdermal therapeutic systems containing 4-n-butylresorcinol: Transdermal therapeutic systems that contain 4-n-butylresorcinol as an active ingredient.... Agent: Beiersdorf Ag

20120259021 - Self-assembled particles from zwitterionic polymers and related methods: Zwitterionic block copolymers and zwitterionic conjugates that advantageously self-assemble into particles, particles assembled from the zwitterionic block copolymers and zwitterionic conjugates, pharmaceutical compositions that include the self-assembled particles, and methods for delivering therapeutic and diagnostic agents using the particles.... Agent: University Of Washington Through Its Center For Commercialization

20120259022 - Pharmaceutical compositions providing enhanced drug concentrations: A drug in a solubility-improved form is combined with a concentration-enhancing polymer in a sufficient amount so that the combination provides substantially enhanced drug concentration in a use environment relative to a control comprising the same amount of the same solubility-improved form of drug without the concentration-enhancing polymer.... Agent:

20120259023 - Novel plant gum-modified food starch conjugate as emulsifying agent for fat soluble ingredients: The present invention relates to novel conjugates based on plant gums and modified food starch, a process for the manufacture thereof, as well as to compositions containing active ingredients, preferably fat-soluble active ingredients, and/or colorants in a matrix based on these conjugates, and to a process for preparing these compositions.... Agent:

20120259024 - Pod for processing used cooking oils and processing apparatus: A pod for processing used cooking oils is disclosed that allows a higher energy efficiency of the process and better quality of the final result obtained, in view of different possible uses. This increase in terms of energy efficiency makes it possible to use an apparatus of the domestic appliance... Agent:

  
10/04/2012 > 191 patent applications in 129 patent subcategories. categorized by USPTO classification

20120252718 - Compositions and methods for regulating cytochrome c-mediated apoptosis by trna: The invention relates to the discovery that tRNA is a potent regulator of cell survival, tRNA regulates the interaction between cytochrome c and Apaf-1 and subsequently Apaf-1 oligomerization into an apoptosome which in turn recruits and oligomerizes the caspase cascade which ultimately leads to cell death. Accordingly, the present invention... Agent: The Trustees Of The University Of Pennsylvania

20120252717 - Conjugates of biologically active proteins having a modified in vivo half-life: Disclosed are biologically active protein conjugates that comprise a biologically active polypeptide coupled via a peptide bond to a polypeptide comprising from 2 to about 500 units of a repeating peptide motif, wherein the biologically active protein conjugate exhibits a modified plasma half-life compared to the intrinsic half-life of the... Agent: Cell Therapeutics, Inc.

20120252719 - Water soluble membrane proteins and methods for the preparation and use thereof: The present invention is directed to water-soluble membrane proteins, methods for the preparation thereof and methods of use thereof.... Agent: Massachusetts Institute Of Technology

20120252720 - Compositions for treatment of ear disorders and methods of use thereof: The present invention relates to compositions and methods useful for the treatment of ear disorders, administered to a treated ear in the form of a foam or a mousse. Administering a medicament in such forms will increase the residence time of the medicament in the ear canal, provide relatively uniform... Agent: Otic Pharma Ltd.

20120252721 - Methods for treating drug-resistant hepatitis c virus infection with a 5,5-fused arylene or heteroarylene hepatitis c virus inhibitor: Provided herein are methods for treating or preventing drug-resistant hepatitis C virus infection in a subject, which comprises administering to the subject a 5,5-fused heteroarylene hepatitis C virus inhibitor compound, for example, of Formula I, IA, or IB.... Agent: Idenix Pharmaceuticals, Inc.

20120252722 - Metal-binding therapeutic peptides: The present invention is related methods of delivering MBD peptide-linked agents into live cells. The methods described herein comprise contacting MBD peptide-linked agents to live cells under a condition of cellular stress. The methods of the invention may be used for therapeutic or diagnostic purposes.... Agent:

20120252723 - Regulating the amino acid pool used for the acute-phase protein synthesis: The present invention is directed at a combination of (i) serine, (ii) cysteine, (iii) arginine and (iv) at least one branched amino acid, for use in the therapeutic or prophylactic treatment of inflammation or infection, wherein the combination is to be administered enterally and at a combination of (i) serine,... Agent: N.v. Nutricia

20120252724 - Insulin preparations containing methionine: The invention relates to an aqueous pharmaceutical formulation having insulin, an insulin analog, or an insulin derivative, and methionine; and to the production thereof, to the use thereof for treating diabetes mellitus, and to a medication for treating diabetes mellitus.... Agent: Sanofi-aventis

20120252725 - Use of 1,3-diphenylprop-2-en-1-one derivatives for treating liver disorders: The invention provides 1,3-diphenylprop-2-en-1-one derivatives and pharmaceutical compositions comprising the same for treating liver disorders, in particular those requiring the reduction of plasma level of biochemical markers such as amino-transferases. The 1,3-diphenylprop-2-en-1-one derivatives of General Formula (I) have hepatoprotective properties and can be used in methods for treating liver disorders... Agent:

20120252726 - Novel neurotrophic factors: The invention relates to neublastin neurotrophic factor polypeptides, nucleic acids encoding neublastin polypeptides, and antibodies that bind specifically to neublastin polypeptides, as well as methods of making and methods of using the same.... Agent: Nsgene A/s

20120252727 - Mucosal delivery of therapeutic molecules, proteins, or particles coupled to ceramide lipids: Described herein are compositions and methods useful for allowing for the absorption (passage) of agents of interest, such as therapeutic agents, across epithelial and mucosal barriers and/or into certain subcellular compartments of the cell, such as the recycling endosome (RE), Golgi, and the endoplasmic reticulum (ER).... Agent: Children's Medical Center Corporation

20120252728 - Val (8) glp-1 composition and method for treating functional dyspepsia and/or irritable bowel syndrome: A method of treating functional dyspepsia and/or irritable bowel syndrome in mammals in need of treatment is disclosed herein. The method comprises administering to the mammal a formulation by inhalation, wherein the formulation avoids first pass metabolism of the active ingredient. The method comprises administering a formulation by pulmonary inhalation... Agent:

20120252729 - Pth-containing therapeutic/prophylactic agent for osteoporosis, characterized in that pth is administered once a week in a unit dose of 100 to 200 units: A method of treating osteoporosis by PTH that has excellent safety and high efficacy is disclosed, along with a method for inhibiting/preventing bone fractures by PTH that has excellent safety, as well as providing a drug to do this. A drug containing PTH as the active ingredient is disclosed, characterized... Agent: Asahi Kasei Pharma Corporation

20120252730 - Platelet aggregation inhibitors: Peptides and cyclized analogs thereof that are useful as platelet aggregation inhibitors in the treatment of cardiac disease, including acute coronary syndrome are disclosed.... Agent: University Of Chicago

20120252731 - Co-administration of an agent linked to an internalization peptide with an anti-inflammatory: The invention provides methods of delivering pharmacologic agents linked to an internalization peptide, in which an inflammatory response inducible by the internalization peptide is inhibited by co-administration of an anti-inflammatory or by linking the internalization peptide to biotin or similar molecule. Such methods are premised in part on the results... Agent: Nono, Inc.

20120252732 - Albumin fusion proteins: The present invention encompasses albumin fusion proteins. Nucleic acid molecules encoding the albumin fusion proteins of the invention are also encompassed by the invention, as are vectors containing these nucleic acids, host cells transformed with these nucleic acids vectors, and methods of making the albumin fusion proteins of the invention... Agent: Human Genome Sciences, Inc.

20120252733 - Use of targeted nitroxide agents in bone healing: Provided herein are compositions and related methods useful for accelerating bone healing and growth. The compounds comprise a nitroxide-containing group attached to a mitochondria-targeting group. The compounds can be cross-linked into dimers without loss of activity.... Agent: University Of Pittsburgh - Of The Commonwealth System Of Higher Education

20120252734 - Inhibitors of antigen presentation by mhc class ii molecules: The present invention relates to compounds, pharmaceutical compositions containing such compounds and methods for their use. In particular, the compounds of the invention are useful for the treatment or prevention of diseases associated with T cell proliferation such as autoimmune diseases and disorders.... Agent:

20120252735 - Treatment of skin conditions by dickkopf1 (dkk1): The present disclosure is generally related to methods of inducing non-palmoplantar skin to develop a palmoplantar phenotype, for example, methods for increasing skin thickness, decreasing skin pigmentation, and/or decreasing hair growth. In particular, disclosed herein are methods of using topical administration of DKK1 to increase skin thickness, decrease skin pigmentation,... Agent: The Govt. Of The U.s.a. As Represented By The Secretary Of The Dept. Of Health & Human Services

20120252737 - Methods for diagnosing and treating cancer: The invention provides methods for decreasing one or more symptoms of cancer in a patient requiring the steps of determining the activation or inactivation of the MK2 signaling pathway and, based on these determinations, administering either a MK2 inhibitor or a combination of a MK2 inhibitor and a chemotherapeutic agent,... Agent: Massachusetts Institute Of Technology

20120252736 - Methods involving pdgfrbeta inhibitors: The invention refers to PDGFRbeta inhibitor for use in the antiproliferative treatment of T-cell lymphoma, in particular NHL, ALCL and PTCL.... Agent: Medizinische Universitaet Wien

20120252738 - Tubulin inhibitors: The present invention relates to novel tubulin binding molecules of formula (I) and their use for the treatment of cancer and other diseases.... Agent: R & D Biopharmaceuticals Gmbh

20120252739 - Tubulin inhibitors: The present invention relates to novel tubulin binding molecules of formula (I) and their use for the treatment of cancer and other diseases.... Agent: R&d Biopharmaceuticals Gmbh

20120252740 - Hdac inhibitors and therapeutic methods of using same: Histone deacetylases inhibitors (HDACIs) and compositions containing the same are disclosed. Methods of treating diseases and conditions wherein inhibition of HDAC provides a benefit, like a cancer, a neurodegenerative disorder, a neurological disease, traumatic brain injury, stroke, malaria, an autoimmune disease, autism, and inflammation, also are disclosed.... Agent:

20120252742 - Human single-chain t cell receptors: A soluble human single-chain T cell receptor (TCR) having the structure: Vα2-L-Vβ or Vβ-L-Vα2, wherein L is a linker peptide that links Vβ with Vα, Vβ is a TCR variable β region, and Vα2 is a TCR variable α region of the family 2 is provided. The provided scTCR is... Agent:

20120252741 - Novel semi-synthetic glycopeptides as antibacterial agents: Provided herein are semi-synthetic glycopeptides having antibacterial activity. The semi-synthetic glycopeptides described herein are made by chemical modification of a glycopeptide by hydrolyzing the disaccharide moiety of the amino acid-4 of the parent glycopeptide in acidic medium to give the amino acid-4 monosaccharide; conversion of the monosaccharide to the amino-sugar... Agent: Biomarin Pharmaceutical Inc.

20120252743 - Trypsin-like serine protease inhibitors, their preparation and use as selective inhibitors of the clotting factors iia and xa: wherein p is an integer between 0 and 2 inclusively, Y is selected from the group consisting of —O—, —S—, —S(═O)—, —SO2—, methylene, —CH(OH)—, —CH(NH2)—, —CH(CH2—OH)—, —CH(CH2—NH2)— or —N(R6)—, R5 is selected from the group consisting of —H or a simple (C1-C3) alkyl and R6 is selected from the group... Agent: The Medicines Company (leipzig) Gmbh

20120252744 - Pharmaceutical composition and method for neoangiogenesis/revascularization useful in treating ischemic heart disease: A pharmaceutical composition and a method of treating ischemic heart diseases by growing new blood vessels that supply oxygen and nutrients to infarcted heart tissues throughout the entire infarct zone and for preventing cardiomyocyte apoptosis in ischemic events. The pharmaceutical composition contains an active ingredient compound with a backbone structure... Agent: Lead Billion Limited

20120252745 - Novobiocin analogues having modified sugar moieties: The disclosure provides novobiocin analogues with noviose replacements which are useful as Hsp90 inhibitors in the treatment of cancer.... Agent:

20120252746 - Methods for internally controlling or treating equine bot larvae: Provided are novel methods and formulations for orally controlling bot larvae in the gastrointestinal tract of equine animal.... Agent: Eli Lilly And Company

20120252747 - Macrocyclic compounds and methods of making and using the same: o

20120252748 - Methods and compositions for determining the responsiveness of cancer therapeutics: The present invention relates to methods for predicting the responsiveness of a patient to a breast cancer treatment regimen by assaying a biological sample to determine the level of expression of the long-chain fatty acyl-CoA synthetase 4 (ACSL4) in the biological sample. The present invention also provides ACSL4 inhibitors and... Agent: New York University

20120252749 - Methods of treating cancer with glut inhibitors: Methods of treating cancer comprising administering inhibitors of glucose transporters (GLUTs) are provided. Methods of predicting whether a cancer will respond to treatment with a GLUT inhibitor also are provided.... Agent: Northwestern University

20120252871 - Diagnosis and treatment of chronic lymphocytic leukemia (cll): New markers in the form of miRNA levels in plasma are provided for indicating the presence of CLL in a subject as well as suggesting routes of therapeutic treatment.... Agent: Institute For Systems Biology

20120252870 - Indian hedgehog (ihh) as a marker to predict osteoarthritis (oa) and methods for the prevention and treatment of oa: Methods of diagnosing osteoarthritis are carried out by measuring levels of Ihh, and methods of treating osteoarthritis comprise inhibiting Ihh to reduce or prevent cartilage degradation.... Agent: Rhode Island Hospital

20120252867 - Method of therapy and diagnosis of atherosclerosis: There is provided a method of therapy of atherosclerosis, by providing microRNA let-7g, an analogue thereof or modified let-7g to organisms to inhibit the expression of lectin-like oxidized low density lipoprotein receptor-1 (LOX-1), and the binding of LOX-1 and oxidized low-density lipoprotein (oxLDL), so as to block the pathogenesis of... Agent:

20120252875 - Methods and compositions for treating diseases, disorders or injury of the cns: The present invention relates to non-invasive methods for treating diseases, disorders and injury to the central nervous system (CNS), and in particular to otic compositions and to methods of use thereof.... Agent:

20120252874 - Methods for delivery of sirna to the spinal cord and therapies arising therefrom: The present application relates at least in part to methods for the administration of small interfering RNAs (siRNAs) to the spinal cord of a human or animal patient and also to a method of treatment for spinal cord injury and other diseases and disorders of the CNS. In particular, the... Agent:

20120252868 - Novel means and methods for the treatment of hearing loss and phantom hearing: This invention relates to modulators of NADPH oxidase as a medicament for the treatment and/or prevention of hearing loss and/or phantom hearing. Such modulators preferably act by inhibiting NADPH oxidase activity, wherein the NADPH oxidase comprises or consists of the amino acid sequence of any one of SEQ ID NO:... Agent:

20120252872 - Rnai modulation of apob and uses thereof: The invention relates to compositions and methods for modulating the expression of apolipoprotein B, and more particularly to the downregulation of apolipoprotein B by chemically modified oligonucleotides.... Agent: Alnylam Pharmaceuticals, Inc.

20120252873 - Sirna targeting interleukin-1 receptor-associated kinase 4 (irak4): Efficient sequence specific gene silencing is possible through the use of siRNA technology. By selecting particular siRNAs by rational design, one can maximize the generation of an effective gene silencing reagent, as well as methods for silencing genes. Methods, compositions, and kits generated through rational design of siRNAs are disclosed... Agent: Dharmacon, Inc.

20120252869 - Treatment of sirtuin (sirt) related diseases by inhibition of natural antisense transcript to a sirtuin (sirt): The present invention relates to antisense oligonucleotides that modulate the expression of and/or function of a Sirtuin (SIRT), in particular, by targeting natural antisense polynucleotides of a Sirtuin (SIRT). The invention also relates to the identification of these antisense oligonucleotides and their use in treating diseases and disorders associated with... Agent: Opko Curna, LLC

20120252882 - Cardiac-specific nucleic acid regulatory elements and methods and use thereof: The present invention relates to nucleic acid regulatory elements that are able to enhance cardiac-specific expression of genes, methods employing these regulatory elements and uses of these elements. Expression cassettes and vectors containing these nucleic acid regulatory elements are also disclosed. The present invention is particularly useful for applications using... Agent:

20120252883 - Method and composition to increase radiation-induced tumor therapeutic effects: Disclosed herein are methods and compositions for treating cancer by increasing radiation-induced damage to cancer without increasing radiation-induced side effects by increasing secretory ASMase levels specifically in tumor endothelium, and inducing apoptosis of tumor endothelial cells by treating the tumor with radiation. ASMase levels are increased in tumor endothelium by... Agent: Memorial Sloan-kettering Cancer Center ("mskcc")

20120252877 - Methods and compositions for treatment of tuberous sclerosis complex: The present disclosure relates to a method of treating Tuberous Sclerosis Complex (TSC). The present disclosure further provides an isolated polynucleotide molecule comprising, a polynucleotide comprising an AAV9 vector; a polynucleotide encoding a TSC1 or a TSC2, or variant thereof; and a promoter. The present disclosure further provides a pharmaceutical... Agent: Theramind Research, LLC

20120252884 - Modified and stabilized gdf propeptides and uses thereof: Modified and stabilized propeptides of Growth Differentiation Factor proteins, such as GDF-8 and Bone Morphogenetic Protein-11, are disclosed. Also disclosed are methods for making and using the modified propeptides to prevent or treat human or animal disorders in which an increase in muscle tissue would be therapeutically beneficial. Such disorders... Agent: Wyeth LLC

20120252879 - Modulation of huntingtin expression: Provided herein are methods, compounds, and compositions for reducing expression of huntingtin mRNA and protein in an animal. Such methods, compounds, and compositions are useful to treat, prevent, delay, or ameliorate Huntington's disease, or a symptom thereof.... Agent:

20120252880 - Oligonucleotide complex compositions and methods of use as gene alteration tools: Compositions and methods of treatments of cells are provided for altering the phenotype of a cell by administering an oligonucleotide complex to the cell, the complex having two strands and chemical modifications.... Agent: The General Hospital Corporation

20120252881 - Therapeutic agent for tumor: The present invention provides a therapeutic agent for a tumor, particularly a therapeutic agent for drug-resistant cancer, an agent for suppression or prophylaxis of tumor metastasis, and an agent for suppression or prophylaxis of cancer recurrence, containing a nucleic acid containing miR27b or a nucleotide having a nucleotide sequence having... Agent: National Cancer Center

20120252876 - Trans-acting rna switches: Disclosed are RNA constructs which function to activate or inactivate a biological process, e.g., may be designed for attachment to a polypeptide coding region. Such RNA constructs modulate translation of a polypeptide from the coding region in response to the presence of a target polynucleotide in an expression environment. Such... Agent:

20120252878 - Use of cathepsin h: Present invention concerns the use of Cathepsin H. Other aspects of the invention concern methods for screening pharmaceuticals, for diagnosing pain susceptibility and for the treatment of pain.... Agent: Sanofi

20120252751 - Anti-viral nucleoside analogs and methods for treating viral infections, especially hiv infections: e

20120252750 - Formulations for reducing neuronal degeneration: Nutriceutical and pharmaceutical formulations for treating neurodegenerative disorders such as Alzheimer's disease are provided. Nutriceutical formulations include two or more of folate, vitamin E, and acetyl-L-carnitine (ALCAR). Pharmaceutical formulations include two or more of 3-deaza-adenosine (DZA), N-acetyl-L-cysteine (NAC), and S-adenosylmethionine (SAM).... Agent: University Of Massachusetts

20120252752 - Compositions, methods and kits for repressing virulence in gram positive bacteria: Bacterial virulence is repressed by compositions and methods for activating permanently a repressor of virulence factors. Compositions provided contain at least one non-metabolizable analog of guanine, guanosine, isoleucine and valine.... Agent:

20120252753 - Therapeutic target for pancreatic cancer cells: This invention provides a therapeutic target for pancreatic cancer. The invention further provides methods of screening of new therapeutic agents using the target. The invention also provides a pharmaceutical composition comprising fasudil or derivatives thereof for pancreatic cancer treatment, and a kit comprising such a pharmaceutical composition.... Agent: Translational Genomics Research Institute

20120252754 - Candy cakes: Hyperkalemic Periodic Paralysis is a disease in mainly stock type horses that can be treated by giving the horse light corn syrup. Currently, the easiest way to do this is with a syringe, which is actually very difficult. The invention is a treat that will deliver a specific amount of... Agent:

20120252755 - Compositions and methods for disinfecting materials: The present invention relates to methods for disinfecting or decontaminating a material or for preventing an infection or contamination of a material. The invention further relates to compositions which are suitable for disinfecting a material or for preventing an infection or contamination of a material and to uses of such... Agent: Medoderm Gmbh

20120252756 - Pharmaceutical compositions and methods for treating, controlling, ameliorating, or reversing conditions of the eye: A pharmaceutical composition comprises a polyethylene glycol having a molecular weight in the range from about 1,000 to about 10,000, and a water-soluble cellulose derivative having a molecular weight in the range from about 50,000 to 120,000. The composition can further comprise boric acid and/or phosphate, a non-ionic surfactant, and/or... Agent:

20120252758 - Novel bicyclic pyridinones: p

20120252760 - Novel pyridopyrazines and their use as modulators of kinases: The invention relates to novel pyrido[2,3-b]pyrazine derivatives of the general formulae (I) and (II), and to their preparation and use as medicaments, especially for the treatment of malignant disorders and other disorders based on pathological cell proliferations.... Agent: Zentaris Gmbh

20120252757 - Organopolysiloxane and cosmetic containing it: e

20120252759 - Thiazole derivatives for the treatment of diseases such as cancer: Compounds of the formula Ia and Ib, in which R1, R1′, R2, R3, R5, R6 and R7 have the meanings indicated in claim 1, are kinase inhibitors and can be employed, inter alia, for the treatment of tumours.... Agent: Merck Patent Gesellschaft Mit Beschranker Hafting

20120252761 - Kinase inhibitors: m

20120252762 - Anti-cancer agent: The anti-cancer agent of the present invention contains at least one kind of phosphine transition metal complex selected from a group of compounds represented by the following Formulae (1a) to (1d). According to this anti-cancer agent, an anti-cancer agent is provided which has a higher anti-cancer activity and lower toxicity... Agent: Nippon Chemical Industrial Co., Ltd.

20120252763 - Novel group of stat3 pathway inhibitors and cancer stem cell pathway inhibitors: The present invention relates to the use of a novel class of cancer stem cell pathway (CSCP) inhibitors; to methods of using such compounds to treat refractory, recurrent, or metastatic cancers; to methods of selective killing cancer cells by using such compounds with specific administration regimen; to methods of targeting... Agent: Boston Biomedical, Inc.

20120252764 - Compositions and methods for protecting cells from toxic exposures: The present invention provides compositions and methods for protecting cells and tissues from damage associated with therapeutic treatments of cancers and other diseases and conditions where reactive oxygen species are produced. The present invention also provides compositions useful as research reagents.... Agent: Perscitus Biosciences, LLC

20120252766 - Co-crystal of 4-furan-2(5h)-one with salicylic acid and use thereof as pesticide: The invention relates to a new co-crystal of 4-{[(6-chloropyrid-3-yl)methyl](2,2-difluoroethyl)amino}furan-2(5H)-one (I) with salicylic acid, and also to processes for preparation thereof and use thereof.... Agent: Bayer Itechnology Services Gmbh

20120252765 - Use of irbesartan for the preparation of a medicament for the prevention of hospitalization for heart failure: Use of irbesartan or one of its pharmaceutically acceptable salts for the preparation of a medicament for the prevention of hospitalization for heart failure.... Agent: Sanofi

20120252768 - Composition containing protopanaxatriol and protopanaxadiol: A composition including: at least one mixture selected from the group consisting of a mixture of (A) panaxatriol and (B) protopanaxatriol and a mixture of (C) panaxadiol and (D) protopanaxadiol, wherein a ratio (A)/(B) of a mass of the (A) panaxatriol to a mass of the (B) protopanaxatriol is 1... Agent: Lion Corporation

20120252767 - Methods of hormonal treatment utilizing ascending-dose extended cycle regimens: The present invention provides ascending-dose extended cycle regimens in which a female is administered an estrogen and a progestin for a period of greater than 30 or 31 consecutive days, optionally followed by a hormone-free period or by a period of administration of estrogen. The disclosed regimens can be administered... Agent: Teva Women's Health, Inc.

20120252769 - 2-phenyl-1-[4-(2-aminoethoxy)-benzyl]-indole and estrogen formulations: The present invention relates to new formulations containing one or more estrogens and 2-Phenyl-1-[4-(2-Aminoethoxy)-Benzyl]-Indole compounds which are useful as estrogenic agents, as well as pharmaceutical compositions and methods of treatment utilizing these compounds, which have the general structures below:... Agent: Wyeth LLC

20120252770 - Chemical compounds 572: e

20120252771 - Implants and methods for treating inflammation-mediated conditions of the eye: Methods for treating inflammation-mediated conditions of the eye are described, comprising: implanting into the vitreous of the eye of an individual a bioerodible implant comprising a steroidal anti-inflammatory agent and a bioerodible polymer, wherein the implant delivers the agent to the vitreous in an amount sufficient to reach a concentration... Agent: Allergan, Inc.

20120252772 - Cucurbitane-triterpenoid compounds, pharmaceutical composition, use and preparation method thereof: wherein a single bond or a double bond is formed between C5 and C10, and a single bond or a double bond is fromed between C8 and C9; when a single bond is formed between C5 and C10, the R1 is oxygen; while a single bond is formed between C8... Agent: National Taiwan University

20120252773 - Method and composition for inhibiting cell proliferation and angiogenesis: e

20120252774 - Steroid tetrol solid state forms - 2: The invention relates to solid state forms of androst-5-ene-3α,7β,16β,17β-tetrol, formulations containing or prepared from such solid state forms and use of these materials for modulating unwanted inflammation including acute and chronic non-productive inflammation. The formulations can be used to prevent, treat or slow the progression of conditions related to autoimmunity... Agent:

20120252775 - Method for diagnosing, preventing, and treating neurological diseases: The invention provides for methods of treating autism associated with Desulfovibrio overgrowth in the gastrointestinal tract of a patient, said method comprising administering to the patient suffering from said autism a treatment course of aztreonam in an amount effective to treat autism in the patient, thereby treating autism.... Agent:

20120252776 - C4 monomethyl triterpenoid derivatives and methods of use thereof: e

20120252781 - Benzodiazepine bromodomain inhibitor:

20120252780 - Bicyclic pyridines and analogs as sirtuin modulators: Provided herein are novel sirtuin-modulating compounds and methods of use thereof. The sirtuin-modulating compounds may be used for increasing the lifespan of a cell, and treating and/or preventing a wide variety of diseases and disorders including, for example, diseases or disorders related to aging or stress, diabetes, obesity, neurodegenerative diseases,... Agent:

20120252779 - Heterocyclyl pyrazolopyrimidine analogues as jak inhibitors: wherein X1 to X5, Y, Z1 to Z3, and R have the meaning as cited in the description and the claims. Said compounds are useful as JAK inhibitors for the treatment or prophylaxis of immunological, inflammatory, autoimmune, allergic disorders, and immunologically-mediated diseases. The invention also relates to pharmaceutical compositions including... Agent:

20120252778 - Pyrazolo pyrimidine derivatives: The present invention relates to pyrazolo pyrimidine derivatives, to methods of preparing these, to combinations and pharmaceutical composition comprising these, and to their use in the treatment of diseases and disorders which may for example involve autoimmune diseases, angiogenesis, pain, and/or inflammatory diseases.... Agent: Novartis Ag

20120252777 - Thiazolopyrimidine compounds: e

20120252783 - Xanthine derivatives, the preparation thereof and their use as pharmaceutical compositions:

20120252782 - Xanthine derivatives, the preparation thereof and their use as pharmaceutical compositions:

20120252784 - 2,3,4-benzothiadiazepine-2,2-dioxide derivatives: Novel 2,3,4-benzothiadiazepines-2,2-dioxides and processes for the preparation thereof are disclosed. The compounds influence the central nervous system and may be used to treat or prevent Alzheimer's disease, Parkinson's disease or Huntington's disease, senile dementia not of the Alzheimer's type, vascular dementia, post-stroke dementia, Korsakoff's syndrome, Down's syndrome, schizophrenia, panic disorder,... Agent:

20120252785 - Staurosporine derivatives as inhibitors of flt3 receptor tyrosine kinase activity: The present invention relates to the use of staurosporines derivatives for the preparation of a drug for the treatment of diseases involving deregulated FLT3 receptor tyrosine kinase activity, especially for the curative and/or prophylactic treatment of leukemias and myelodysplastic syndromes, and to a method of treating diseases involving deregulated FLT3... Agent: Novartis Ag

20120252786 - 5ht2c receptor modulator compositions and methods of use: The present invention relates to a composition comprising phentermine and a selective 5HT-2C receptor agonist. In addition, the invention relates to a composition comprising phentermine and a selective 5HT-2C receptor agonist having Formula (I): or a pharmaceutically acceptable salt, solvate or hydrate thereof. These compositions are useful in pharmaceutical compositions... Agent:

20120252788 - 5ht2c receptor modulators: e

20120252787 - Administration of an anti-obesity compound to individuals with renal impairment: The present disclosure relates to methods for weight management in an individual in need thereof by determining the level of renal sufficiency of the individual and prescribing or administering a therapeutically effective amount of (R)-8-chloro-1-methyl-2,3,4,5-tetrahydro-1H-3-benzazepine or a pharmaceutically acceptable salt, solvate or hydrate thereof to the individual, provided that the... Agent:

20120252789 - Inhibitors of sphingosine kinase: The present invention relates to compounds of the formula (I), in which R1, R2, R3, R4, R5, R6, R7, R8, R9, R10, R11, R12, R13, R14, R15, R16, R17, M1, M2, M3, M4, Y1, Y2, V, W, n, m and o have the meanings given in Claim 1, and physiologically... Agent: Merck Patent Gesellschaft Mit Beschrankter Haftung

20120252790 - Amino-derivatives as novel inhibitors of histone deacetylase: e

20120252791 - Heterocyclic gtp cyclohydrolase 1 inhibitors for the treatment of pain: The present invention relates to the field of small molecule heterocyclic inhibitors of GTP cyclohydrolase (GCH-I), or a tautomer, prodrug, or pharmaceutically acceptable salt thereof. The invention also features pharmaceutical compositions of the compounds and the medical use of these compounds for the treatment or prevention of pain (e.g., inflammatory... Agent:

20120252792 - Methods and compositions for modulating rho-mediated gene transcription: The invention provides methods, compositions, and kits for the inhibition of members of the Rho GTPase family. Specifically, the invention provides methods, compositions and kits for the inhibition of RhoA and/or RhoC transcriptional signalling. The invention finds use in treatment of Rho-mediated disease states (e.g., tumor metastasis, inflammation, inflammatory disease),... Agent: The Regents Of The University Of Michigan

20120252793 - Intranasal benzodiazepine pharmaceutical compositions: The present invention generally relates to intranasal pharmaceutical compositions comprising a benzodiazepine and methods of use thereof that can provide a therapeutic effect without a decrease in blood pressure and/or pulse after administration of the pharmaceutical composition.... Agent:

20120252794 - Analgesic combination of opioid analgesic and cyclooxygenase-2 inhibitor: The invention relates to the use of a combination of an opioid analgesic together with a COX-2 inhibitor.... Agent: Purdue Pharma L.p.

20120252795 - Oral lysophilisates containing pvp/va: The present invention relates to novel oral pharmaceutical compositions in lyophilized form, in which the dissolution and the bioavailability of the active ingredient that they contain are improved. The compositions according to the invention comprise in particular a polyvinyl acetate/polyvinylpyrrolidone copolymer. The oral lyophilisates according to the invention are particularly... Agent: Cephalon France

20120252796 - Compounds for the treatment of dyslipidemia and related diseases: e

20120252797 - Isoxazole compounds as inhibitors of heat shock proteins:

20120252798 - Indole compounds as an inhibitor of cellular necrosis: The present invention relates to new indole compounds, pharmaceutically acceptable salts or isomers thereof which are useful for the prevention or treatment of cellular necrosis and necrosis-associated diseases. The present invention also relates to a method and a composition for the prevention or treatment of cellular necrosis and necrosis-associated diseases,... Agent:

20120252799 - Heterocyclic aromatic compounds useful as growth hormone secretagogues: e

20120252800 - Bicyclic thiazoles as allosteric modulators of mglur5 receptors: The present invention relates to novel bicyclic thiazoles which are positive allosteric modulators of the metabotropic glutamate receptor subtype 5 (“mGluR5”) and which are useful for the treatment or prevention of disorders associated with glutamate dysfunction and diseases in which the mGluR5 subtype of receptors is involved. The invention is... Agent: Janssen Pharmaceutica N.v.

20120252801 - Antifungal compounds: The present invention relates to a series of novel compounds which have been shown to possess antifungal activity. The invention therefore relates to the new compounds, methods for their preparation, pharmaceutical compositions comprising them and to the compounds for use as a medicament, more in particular antifungal medicament.... Agent: Katholieke Universiteit Leuven, K.u.leuven R&d

20120252802 - (alpha-substituted aralkylamino and heteroarylalkylamino) pyrimidinyl and 1,3,5-triazinyl benzimidazoles, pharmaceutical compositions thereof, and their use in treating proliferative diseases: Provided herein are (alpha-substituted aralkylamino or heteroarylalkylamino) pyrimidinyl and 1,3,5-triazinyl benzimidazoles, e.g., a compound of Formula I, and their pharmaceutical compositions, preparation, and use as agents or drugs for treating proliferative diseases.... Agent: Pathway Therapeutics Inc.

20120252803 - Composition and method for controlling arthropod pests: The present invention provides: an arthropod pests control composition comprising, as active ingredients, a condensed heterocyclic compound and a pyrethroid compound; a method for controlling arthropod pests which comprises applying effective amounts of a condensed heterocyclic compound and a pyrethroid compound to the arthropod pests or a locus where the... Agent: Sumitomo Chemical Company, Limited

20120252804 - Composition and method for controlling arthropod pests: The present invention provides: an arthropod pests control composition comprising, as active ingredients, a condensed heterocyclic compound and pyriproxyfen; a method for controlling arthropod pests which comprises applying effective amounts of a condensed heterocyclic compound and pyriproxyfen to the arthropod pests or a locus where the arthropod pests inhabit; and... Agent: Sumitomo Chemical Company, Limited

20120252805 - Novel compounds: The present invention relates to novel NADPH oxidase II inhibitors and their use in the treatment of diseases mediated by the NADPH oxidase II enzyme.... Agent:

20120252806 - Inhibitors of akt activity: The instant invention provides for compounds that inhibit Akt activity. In particular, the compounds disclosed selectively inhibit one or two of the Akt isoforms. The invention also provides for compositions comprising such inhibitory compounds and methods of inhibiting Akt activity by administering the compound to a patient in need of... Agent:

20120252807 - Arbovirus inhibitors and uses thereof: The present invention relates to chemical compounds, methods for their discovery, and their therapeutic use. In particular, the present invention provides compounds as inhibitors of arboviruses.... Agent: The Regents Of The University Of Michigan

20120252808 - Quinoline amide m1 receptor positive allosteric modulators: The present invention is directed to quinoline amide compounds of formula (I) which are M1 receptor positive allosteric modulators and that are useful in the treatment of diseases in which the M1 receptor is involved, such as Alzheimer's disease, schizophrenia, pain or sleep disorders. The invention is also directed to... Agent:

20120252810 - Fatty acid non-flushing niacin derivatives and their uses: The invention relates to fatty non-flushing acid niacin derivatives; compositions comprising an effective amount of a fatty acid non-flushing niacin derivative; and methods for treating or preventing an metabolic disease comprising the administration of an effective amount of a fatty acid non-flushing niacin derivative.... Agent: Catabasis Pharmaceuticals, Inc.

20120252809 - Substituted 3-heteroaroylamino-propionic acid derivatives and their use as pharmaceuticals: wherein A, D, E, L, G, R10, R30, R40, R50 and R60 have the meanings indicated in the claims, which are valuable pharmaceutical active compounds. They are inhibitors of the protease cathepsin A, and are useful for the treatment of diseases such as atherosclerosis, heart failure, renal diseases, liver diseases... Agent: Sanofi

20120252811 - Combinations of therapeutic agents for treating cancer: The invention relates to a combination comprising a Bcr-Abl, c-Kit and PDGF-R tyrosine kinase inhibitor; and one or more pharmaceutically active agents; pharmaceutical compositions comprising said combination; methods of treatment comprising said combination; processes for making said combination; and a commercial package comprising said combination.... Agent:

20120252812 - 6-pyrimidinyl-pyrimid-4-one derivative: e

20120252813 - Crystalline forms of certain 3-phenyl-pyrazole derivatives as modulators of the 5-ht2a serotonin receptor useful for the treatment of disorders related thereto: Provided are certain solvates of 3-methoxy-N-[3-(2-methyl-2H-pyrazol-3-yl)-4-(2-morpholin-4-yl-ethoxy)-phenyl]-benzamide or a pharmaceutically acceptable salt thereof. Also provided are pharmaceutical compositions comprising such solvates and methods for their use.... Agent:

20120252814 - Glucokinase activators: o

20120252815 - Inhibitors of sphingosine kinase: The present invention relates to compounds of the formula (I), in which R1, R2, R3, R4, R5, R6, R7, R8, R9, R10, R11, R12, R13, R14, R15, R16, R17, M1, M2, M3, Y1, Y2, V, W, n, m and o have the gleanings given herein, and physiologically acceptable salts, derivatives,... Agent: Merck Patent Gesellschaft Mit Beschrankter Haftung

20120252816 - Use of phosphodiesterase inhibitors for treating multidrug resistance: The present invention relates to methods of treating multidrug resistance in cancerous cells with phosphodiesterase (PDE) inhibitors, e.g., PDE5 inhibitors. More specifically, the invention relates to methods of treating multidrug resistance that arises, e.g., during administration of chemotherapeutic/antineoplastic (anticancer) agents for treatment of cancer, with a PDE5 inhibitor (e.g., sildenafil,... Agent:

20120252817 - Derivatives of 6,7-dihydro-5h-imidazo[1,2-a]imidazole-3-carboxylic acid amides: Derivatives of 6,7-dihydro-5H-imidazo[1,2-a]imidazole-3-carboxylic acid amide exhibit good inhibitory effect upon the interaction of CAMs and Leukointegrins and are thus useful in the treatment of inflammatory disease.... Agent: Boehringer Ingelheim International Gmbh

20120252818 - Heat shock protein binding compounds, compositions, and methods for making and using same: The present subject matter relates to a compound represented by the general formula (I) or (I′) or a pharmacologically acceptable salt thereof; pharmaceutical compositions containing at least one of these compounds; methods of making at least one of these compounds; methods of using at least one of these compounds for... Agent: Memorial Sloan-kettering Cancer Center

20120252820 - Methods of treating fungal infections: Methods of identifying compounds that potentiate the activity of antifungal agents, potentiators identified by these methods, and methods of using potentiators to treat fungal infections are disclosed.... Agent: Northeastern University

20120252819 - Solid dispersion formulations and methods of use thereof: The present invention relates to formulations and methods for increasing the bioavailability of 1-(4-benzhydrylpiperazin-1-yl)-3,3-diphenylpropan-1-one, 1-(3,3-diphenylpropanoyl)piperazine, or a salt thereof. In particular, the formulation can include one or more pharmaceutically acceptable matrix polymers to form a solid dispersion, e.g., a spray dried dispersion or a hot melt extrusion.... Agent: Zalicus Pharmaceuticals Ltd.

20120252821 - Inhibitors of bruton's tyrosine kinase: Disclosed herein are compounds that form covalent bonds with Bruton's tyrosine kinase (Btk). Also described are irreversible inhibitors of Btk. Methods for the preparation of the compounds are disclosed. Also disclosed are pharmaceutical compositions that include the compounds. Methods of using the Btk inhibitors are disclosed, alone or in combination... Agent: Pharmacyclics, Inc.

20120252822 - Inhibitors of bruton's tyrosine kinase: Disclosed herein are compounds that form covalent bonds with Bruton's tyrosine kinase (Btk). Also described are irreversible inhibitors of Btk. Methods for the preparation of the compounds are disclosed. Also disclosed are pharmaceutical compositions that include the compounds. Methods of using the Btk inhibitors are disclosed, alone or in combination... Agent: Pharmacyclics, Inc.

20120252824 - Drug combinations and uses in treating a coughing condition: The present specification discloses compositions comprising a plurality of therapeutic compound having antitussive activity and methods and uses for treating a coughing condition with such compositions.... Agent:

20120252823 - Adenosine receptor agonists, partial agonists, and antagonists: wherein R1 to R5 are as described herein, as well as pharmaceutical compositions thereof and methods of use thereof. The A3 AR antagonists or partial agonists find use in treating a number of diseases such as cancer, glaucoma, and inflammatory diseases, as well as in preventing cardiac ischemia. Also disclosed... Agent: The United States Of America, As Represented By The Secretary, Department Of Health And Human

20120252825 - Beneficial effects of combination therapy on cholesterol: The present invention discloses pharmaceutical combination therapies for the treatment or prevention of diseases in a mammal comprising a Janus Kinase inhibitor or a pharmaceutically acceptable salt thereof and a HMG-CoA reductase inhibitor or a pharmaceutically acceptable salt thereof. Pharmaceutical compositions containing the same and kits for achieving a therapeutic... Agent: Pfizer Inc.

20120252827 - Combination of therapy comprising zd6474 and a taxane: The present invention relates to a method for the production of an antiangiogenic and/or vascular permeability reducing effect in a warm-blooded animal such as a human, particularly a method for the treatment of a cancer involving a solid tumour, which comprises the administration of ZD6474 in combination with a taxane;... Agent:

20120252826 - Combination therapy: The present invention relates to a method for the production of an antiangiogenic and/or vascular permeability reducing effect in a warm-blooded animal such as a human, which is optionally being treated with ionising radiation, particularly a method for the treatment of a cancer, particularly a cancer involving a solid tumour,... Agent: Astrazeneca Ab

20120252828 - Pyridoquinazolinone m1 receptor positive allosteric modulators: The present invention is directed to quinolinone-pyrazolone compounds of formula (I) which are M1 receptor positive allosteric modulators and that are useful in the treatment of diseases in which the M1 receptor is involved, such as Alzheimer's disease, schizophrenia, pain or sleep disorders. The invention is also directed to pharmaceutical... Agent:

20120252830 - Substituted aminobutyric derivatives as neprilysin inhibitors: e

20120252829 - Tivozanib and capecitabine combination therapy: A method of treating a tumor in a subject using a combination of tivozanib and capecitabine is disclosed.... Agent:

20120252832 - Abuse-resistant controlled-release opioid dosage form: Abuse-resistant, controlled release opioid tablets are a combination containing an opioid antagonist such as naloxone at a level above that needed to suppress the euphoric effect of the opioid, if the combination were crushed to break the controlled release properties causing the opioid and opioid antagonist to be released as... Agent: Endo Pharmaceuticals Inc.

20120252831 - Compositions of opioid antagonists and methods for treating scleroderma therewith: Provided are compositions comprising opioid antagonists, such as naltrexone naloxone, or nalmefene, or their pharmaceutically acceptable salts, and methods for treating scleroderma, including systemic sclerosis, therewith.... Agent: Mustafa Nevzat Ilac Sanayii A.s.

20120252833 - Sustained-release product comprising a combination of a non-opioid amine and a non-steriodal anti-inflammatory drug: Sustained-release oral pharmaceutical compositions and methods of use, wherein the compositions are in a single dosage form and include an amine-containing compound (including salts thereof), a salt of a non-steroidal anti-inflammatory drug (NSAID), and a hydrophilic matrix.... Agent: Upsher-smith Laboratories, Inc.

20120252834 - Novel use and method of rapamycin to treat toxic shock: Rapamycin is used for prevention and treatment of toxic shock. The toxic shock is induced, for example, by a toxin, such as Staphylococcal enterotoxin A (SEA), Staphylococcal enterotoxin B (SEB), toxic shock syndrome toxin 1 (TSST-I), streptococcal pyrogenic exotoxin A (SPEA), and streptococcal pyrogenic exotoxin C (SPEC).... Agent: The Government Of United States, As Represented By The Secretary Of The Army

20120252835 - Stable temsirolimus composition and process of preparing same: The present disclosure describes a stable composition of Temsirolimus for parenteral administration. The composition includes BHA or BHT as anti-oxidants and alcoholic solvent. The pH of the composition is below 5.0. The composition also can include a chelating agent and/or a surfactant. A method of producing the composition is also... Agent: Astron Research Limited

20120252836 - 1,3-dioxanes and their uses: The present invention relates to compounds containing 1,3-dioxane moiety, pharmaceutical compositions thereof, and the use of the compounds and compositions for the modulation of thromboxane A2 or a peroxisome proliferator-activated receptor. The compounds, analogs, and pharmaceutically acceptable salts thereof, and pharmaceutical compositions can be used in the treatment and prevention... Agent: Evolva Sa

20120252837 - Bicyclic derivatives of azabicyclic carboxamides, preparation thereof and therapeutic use thereof: e

20120252838 - Tetrahydrotriazolopyridine compounds as selective mglu5 receptor potentiators useful for the treatment of schizophrenia: The present invention provides certain tetrahydrotriazolopyridine derivatives, pharmaceutical compositions thereof, methods of using the same and processes for preparing the same. Formula (I) wherein R1 is hydrogen, fluoro, chloro, or methyl; and R2 is C4-CS branched alkyl.... Agent: Eli Lilly And Company

20120252839 - Gain-of-function bcl-2 inhibitors: Compounds are described that are useful for treating an apoptosis-associated disease, which are specifically cytotoxic to tumor cells that are overexpressing Bcl-xL, and are much less cytotoxic in isogenic cells that are not overexpressing Bcl-xL. Also described is a method for treating an apoptosis-associated disease in a subject in need... Agent: Fred Hutchinson Cancer Research Center

20120252840 - Method of treating cancer: This invention is directed to the treatment of cancer, particularly ocular melanoma, with a dual inhibitor of MET and VEGF such as Compound 1.... Agent: Exelixis, Inc.

20120252841 - Substituted 2-mercaptoquinoline-3-carboxamides as kcnq2/3 modulators: The invention relates to substituted 2-mercaptoquinoline-3-carboxamides, methods for the preparation thereof, medicaments containing these compounds and the use of these compounds for the preparation of medicaments.... Agent: Drunenthal Gmbh

20120252842 - Compositions, synthesis, and methods of using indanone based cholinesterase inhibitors: The present invention provides novel indanone derivatives which can be advantageously used for treating and/or preventing of a medical condition for which inhibition of a cholinesterase is desired.... Agent: Reviva Pharmaceuticals, Inc.

20120252843 - Isoindoline compounds and methods of their use: Provided herein are isoindoline compounds, pharmaceutical compositions comprising one or more of such compounds, and methods of their use for treating, preventing, or managing various diseases.... Agent:

20120252844 - 2,6-dioxo-3-deutero-piperdin-3-yl-isoindoline compounds: The present application describes 2-(2′,6′-dioxo-3′-deutero-piperidin-3′-yl)isoindoles, deuterated derivatives thereof, stereoisomers thereof, pharmaceutically acceptable salt forms thereof, and methods of treating using the same.... Agent: Deuteria Pharmaceuticals, Inc.

20120252846 - Buccal, polar and non-polar spray or capsule containing drugs for treating pain: Buccal aerosol sprays or capsules using polar and non-polar solvent have now been developed which provide biologically active compounds for rapid absorption through the oral mucosa, resulting in fast onset of effect. The buccal polar compositions of the invention comprise formulation I: aqueous polar solvent, active compound, and optional flavoring... Agent:

20120252845 - Composition for sustained drug delivery comprising geopolymeric binder: The present invention relates to a sustained release medical composition comprising an active pharmaceutical ingredient and a geopolymeric binder. Preferably the active pharmaceutical ingredient is combined with the geopolymeric binder during the formation of that binder.... Agent:

20120252848 - Liquid dosage forms of non-enterically coated acid-labile drugs: Provided herein are formulations of acid labile drugs, such as proton pump inhibitors (PPI). The formulations comprise a PPI and a liquid vehicle typically having a pH greater than 6.5 and a viscosity sufficient to maintain a uniform suspension of the PPI for 15 minutes.... Agent:

20120252847 - Novel form of s-omeprazole: The present invention relates to a novel form of the (−)-enantiomer of 5-methoxy-2-[[(4-methoxy-3,5-dimethyl-2-pyridinyl)-methyl]sulfinyl]-1H-benzimidazole, i.e. S-omeprazole. More specifically, it relates to a novel form of the magnesium salt of the S-enantiomer of omeprazole trihydrate. The present invention also relates to processes for preparing such a form of the magnesium salt of... Agent:

20120252849 - Cyclopropyl dicarboxamides and analogs exhibiting anti-cancer and anti-proliferative activities: e

20120252850 - Niacin conjugated fatty acid mixtures and their uses: The invention relates to niacin conjugated fatty acid mixtures; compositions comprising an effective amount of a niacin conjugated fatty acid mixture; and methods for treating or preventing an metabolic disorder comprising the administration of an effective amount of a niacin conjugated fatty acid mixture.... Agent: Catabasis Pharmaceuticals, Inc.

20120252851 - Delivery system for sustained release of a calcium-channel blocking agent: A delivery system for sustained release of a calcium-channel blocking agent is adapted for introduction in the cerebrospinal fluid of a subject. The delivery system comprises a solid dispersion product of a calcium-channel blocking agent in a mixture of a (i) first poly(lactide-co-glycolide) having a molecular weight distribution centered around... Agent:

20120252852 - Otamixaban formulations with improved stability: The invention relates to a pharmaceutical composition comprising methyl (2R,3R)-2-{3-[amino(imino)methyl]benzyl}-3-{[4-(1-oxidopyridin-4-yl)benzoyl]amino}butanoate or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable acidic reacting compound or to an aqueous solution or dispersion of the composition as well as a process for the preparation of the same, methods of using such compositions to... Agent: Sanofi

20120252853 - Positive allosteric modulators of nicotinic acetylcholine receptor: The present invention relates to compounds useful in therapy, to compositions comprising said compounds, and to methods of treating diseases comprising administration of said compounds. The compounds referred to are positive allosteric modulators (PAMs) of the nicotinic acetylcholine α7 receptor.... Agent: H. Lundbeck A/s

20120252854 - Crystalline forms of thiazolidinedione compound and its manufacturing method: e

20120252855 - Methods for treating degenerative diseases/injuries: Invented is a method of treating cardiovascular disease/injury, in a mammal, including a human, in need thereof which comprises the administration of a therapeutically effective amount of a non-peptide TPO receptor agonist to such mammal.... Agent:

20120252856 - Pi3k/akt pathway subgroups in cancer: methods of using biomarkers for diagnosis and therapy: The present invention relates to methods of dividing cancer into subgroups based upon Akt pathway gene expression. In one embodiment, the present invention provides a method of diagnosing glioblastoma multiforme (GBM) subtype in an individual by determining the presence of an abnormal expression of an Akt pathway gene cluster and... Agent: Dignity Health

20120252858 - Compounds, compositions, and methods for the treatment of beta-amyloid diseases and synucleinopathies: Dihydroxyaryl compounds and pharmaceutically acceptable esters, their synthesis, pharmaceutical compositions containing them, and their use in the treatment of β-amyloid diseases, such as observed in Alzheimer's disease, and synucleinopathies, such as observed in Parkinson's disease, and the manufacture of medicaments for such treatment.... Agent:

20120252857 - Genotype specific methods for treating human subjects using 4-methylpyrazole: Provided herein are methods of administering 4-methylpyrazole (4-MP), or physiologically acceptable salts thereof, to subjects of genetic subpopulations expressing specific polymorphisms of the alcohol dehydrogenase and aldehyde dehydrogenase genes. Also provided herein are methods to prevent or ameliorate ethanol intolerance, reduce or ameliorate symptoms associated with acetaldehyde accumulation accompanying ethanol... Agent:

20120252859 - Tricyclic indeno-pyrrole derivatives as serotonin receptor modulators: The present invention generally relates to a series of compounds, to pharmaceutical compositions containing the compounds, and to use of the compounds and compositions as therapeutic agents. More specifically, compounds of the present invention are tricyclic indeno-pyrrole compounds. These compounds are serotonin receptor (5-HT) ligands and are useful for treating... Agent: Athersys, Inc.

20120252861 - Medical compositions for intravesical treatment of bladder cancer: Anti-cancer coating compositions comprising 3-hydroxymethyl-5-aziridinyl-1-1-methyl-2-[1H-indole-4,7-dione]propenol (E09) are disclosed. More specifically, the coating compositions comprise EO9 and a formulation vehicle. The formulation vehicle improves the solubility and stability of EO9. Additionally, the coating compositions can include coating agents that provide better adhesion of the coating composition to the bladder wall during... Agent: Spectrum Pharmaceuticals, Inc.

20120252860 - Novel n, n'-hydrazino-bis-isatin derivatives with selective activity against multidrug-resistant cancer cells: wherein R is selected from the group consisting of hydrogen atom and unsubstituted or substituted phenyl group; R1 is selected from the group consisting of hydrogen atom and unsubstituted or substituted phenyl group; X is selected from the group consisting of hydrogen atom or halogen atom; and Y is selected... Agent: King Saud University

20120252862 - Dissolvable film strip comprising natural components: The present invention relates to film strips which comprise natural product formulations and can be absorbed from oral mucosa. The said film strip can be used with the aim of preventing and treating diseases in a short time, by being absorbed rapidly when it is applied from the oral mucosa... Agent: Yeditepe Universites

20120252863 - Triptans for the treatment of psoriasis: The present invention provides for a composition comprising a tryptamine based drug that acts as a 5-hydroxytryptamine-1 inhibitor in an amount sufficient to reduce the effects of psoriasis and wherein the composition is formulated for topical or oral administration.... Agent:

20120252864 - Substituted isoindoline-1,3-dione derivatives: This invention relates to novel substituted isoindoline-1,3-dione derivatives and pharmaceutically acceptable salts thereof. More specifically, the invention relates to novel substituted isoindoline-1,3-dione derivatives that are analogues of apremilast. This invention also provides compositions comprising a compound of this invention and a carrier and the use of disclosed compounds and compositions... Agent: Concert Pharmaceuticals Inc.

20120252866 - Age inhibitors: The invention relates to a compound having general formula I, wherein: X represents CH2, C═O, C═S or CHOH, R1 represents an amino acid optionally substituted by one or more halogen atoms, or by one or more CF3 groups and n=0.1 or 2, or R1 represents a peptide containing two amino... Agent: Pharmamens

20120252865 - Carbamate derivatives in particular for the treatment of neurological disorders: The present invention relates to new carbamate derivatives of formula I, processes for their preparation, and to pharmaceutical compositions containing them for the treatment of neurological disorders, such as neuropathic pain and anxiety.... Agent: Sigma-tau Industrie Farmaceutiche Riunite S.p.a.

20120252885 - Dronabinol treatment for migraines: In various embodiments, the present invention provides pharmaceutical compositions comprising delta-9-tetrahydrocannabinol and methods of administering such compositions to treat migraines.... Agent:

20120252886 - Catechins for the treatment of amyloidosis: A method of treating an amyloid disease characterized by AL amyloid fibrillogenesis, in a mammalian subject. The method includes administering to the mammal a therapeutically effective amount of a various disclosed catechins. The therapeutic amount of the catechin is selected for efficacy in treating AL amyloid fibrillogenesis in a mammalian... Agent:

20120252887 - Composition and method for treating diabetes and metabolic disorders: A composition and method for treating diabetes and metabolic disorders, and for achieving weight loss in a subject comprising a combination of naturally occurring compounds is provided.... Agent: Atm Metabolics Lllp

20120252888 - Compositions and methods for treating neurologic disorders: The present invention relates to compositions comprising DHA, EPA, LA and GLA. The compositions may further comprise other omega-3 PUFAs, MUFAs, SFAs, gamma tocopherol, Vitamin A and Vitamin B. The compositions are useful for treating neurologic disorders. The compositions are administered chronically for the prevention and/or treatment of multiple sclerosis... Agent: Palupa Medical Ltd.

20120252889 - Polyketide molecules as anticancer agents: e

20120252890 - Process and compounds for the manufacture of oseltamivir and analogs thereof, and new antiviral agents: The present application relates to processes for the preparation of intermediates useful in the manufacture of oseltamivir and the H3PO4 salt of oseltamivir, Tamiflu®. The application further relates to novel intermediate and compounds and oseltamivir analogs and to pharmaceutical compositions comprising said analog compounds. The application further relates to a... Agent: Brock University

20120252891 - Vanilloid fatty hydroxamates as therapeutic anti-inflammatory pharmaceuticals: Three unique subtypes of N-hydroxyamides and N-hydroxycarbamates containing both the vanilloid moiety (4-hydroxy-3-methoxybenzyl) and a lipophilic aliphatic moiety. Also disclosed are direct syntheses of these vanilloid fatty hydroxamates. The compounds possess inhibitory activity against the enzymes fatty acid amide hydrolase (FAAH) and matrix metallo-proteinase 9 (MMP-9). In addition, these substances... Agent: Rutgers, The State University Of New Jersey

20120252892 - Methods for treating fibromyalgia syndrome: The invention is directed to a method of treating fibromyalgia syndrome in a subject, comprising administering a therapeutically effective amount of a carbamoyl compound, or pharmaceutically acceptable salt thereof.... Agent:

20120252893 - Antimicrobial formulation: e

20120252894 - Compounds for alleviating pain and stress in fetus and newborn: The invention relates to a compound which inhibits the importation of chloride into neurons or a compound which improve the outflow of chloride from neurons thereby promoting the inhibitory actions of GABA and alleviating pain and stress of the fetus during delivery and the newborn. The invention also relates to... Agent:

20120252896 - Methods and compositions for modulation of t-cells via the kynurenine pathway: The present invention provides methods for the modulation of T cells and T cell responses, particularly of Th17 effector cells. The invention provides methods of and compositions for modulating T cells, particularly T cells expressing IL-17, particularly Th17 effector cells, via the tryptophan metabolism pathway, particularly using tryptophan metabolites, kynurenines... Agent:

20120252895 - Therapeutic methods employing nitric oxide precursors: Isolated polynucleotide molecules and peptides encoded by these molecules are used in the analysis of human carbamyl phosphate synthetase I phenotypes, as well as in diagnostic and therapeutic applications, relating to a human carbamyl phosphate synthetase I polymorphism. By analyzing genomic DNA or amplified genomic DNA, or amplified cDNA derived... Agent: Vanderbilt University

20120252897 - Combination composition comprising benzoyl peroxide and adapalene: An aqueous gel composition of the present invention comprising about 0.1 to 0.3 wt % adapalene and about 2.5 to 5.0 wt % benzoyl peroxide, as active ingredients, wherein both the active ingredients are stabilized in hydrophilic gelling matrix of pH dependent gelling agent comprising crosslinked, acrylic acid-based polymer(s).... Agent: Glenmark Generics Limited

20120252898 - Method of producing a stabilized naturally occuring hydroxycitric acid (hca) from garcinia indica fruit: A method of producing a stabilized naturally occurring hydroxycitric acid is provided. In one embodiment, the method comprises combining an aqueous liquid with Garcinia indica fruit to provide an aqueous extract containing hydroxycitric acid and mixing the aqueous extract containing hydroxycitric acid with a liquid quaternizing agent wherein the aqueous... Agent:

20120252899 - Method of removing e. coli bacteria from an aqueous solution: The method of removing Escherichia coli (E. coli) bacteria from an aqueous solution includes the step of mixing multi-walled carbon nanotubes functionalized with a dodecylamine group (C12H27N) into an aqueous solution containing E. coli bacteria. The multi-walled carbon nanotubes functionalized with a dodecylamine group have an antimicrobial effect against the... Agent: King Fahd University Of Petroleum And Minerals

20120252900 - Grease-like gel for repelling insects and preventing undesirable behavior in hoofed animals: Grease-like compositions are provided for repelling insects and preventing undesirable behavior in hoofed animals. The compositions utilize nontoxic mineral, synthetic, or vegetable oil based gels containing silica, clay, urea, polytetrafluoroethylene, or metallic soap thickeners and capsaicin.... Agent: Pignx, Inc.

20120252901 - Agomelatine and pharmaceutical compositions thereof: Agomelatine crystal, which is a drug for treating depression, and pharmaceutical compositions thereof are provided. The X-ray powder diffraction spectra of such agomelatine crystal, which is irradiated by Cu-Kα and showed by 2θ(degree), has characteristic diffraction peaks at 12.84, 13.84, 16.14, 18.56, 19.12, 20.86, 21.20, 23.84; its IR absorption pattern... Agent: Tianjin Taipu Pharmaceutical Science & Technology Development Co., Ltd

20120252902 - Treatment of adhd: A method is provided for treating a subject in need of therapy for attention deficit hyperactivity disorder (ADHD) and related CNS disorder symptoms of impaired learning, impaired planning, impaired problem solving, impulsiveness attention deficit and aggression comprising administering to said subject an amount of a ketogenic material sufficient to produce... Agent: Btg International Limited

20120252903 - Cholesterol control agent: There is proposed a method for using a preparation for lowering the cholesterol level of a patient. In preferred embodiments, the preparation essentially consists of an active substance being an aqueous solution of formaldehyde with a concentration of 36.5-40%, the active substance constitutes 2-6 weight units, and an additive being... Agent:

20120252904 - Mitf as a marker for predisposition to cancer: The present invention relates to a mutant of MITF which is useful as a marker for predisposition to the development of cancer and to uses thereof in diagnosis and preventive treatments, sumoylation being reduced or absent in this mutant.... Agent: Inserm (institut National De La Sante Et De La Recherche Medicale )

20120252905 - Drug delivery from rapid gelling polymer composition: Compositions are disclosed that afford drug delivery from two-part polymer compositions that rapidly form covalent linkages when mixed together. Such compositions are particularly well suited for use in a variety of tissue related applications when rapid adhesion to the tissue and gel formation is desired along with drug delivery. For... Agent: Angiotech International Ag

20120252906 - Bioavailability enhancement delivery composition: A composition for increasing the bioavailability of an active pharmaceutical ingredient (“API”) in humans and animals, comprising a first water soluble surfactant having a cloud point greater than about 37° C., a second water soluble surfactant having a cloud point greater than about 37° C., wherein a mixture of the... Agent:

20120252907 - Diagnostic methods and kit for detecting cancer: The present disclosure is directed to compositions and methods for detecting elevated microRNA U6 concentrations in serum relative to a standard microRNA (e.g. SNORD44) as a diagnostic indicator of metastatic disease. In one embodiment the methods of the present disclosure are used to diagnose the existence of, or assess the... Agent: Indiana University Research And Technology Corporation

Previous industry: Perfume compositions
Next industry: Colloid systems and wetting agents; subcombinations thereof; processes of


######

RSS FEED for 20140710: xml
Integrate FreshPatents.com into your RSS reader/aggregator or website to track weekly updates.
For more info, read this article.

######

Thank you for viewing Drug, bio-affecting and body treating compositions patents on the FreshPatents.com website. These are patent applications which have been filed in the United States. There are a variety ways to browse Drug, bio-affecting and body treating compositions patent applications on our website including browsing by date, agent, inventor, and industry. If you are interested in receiving occasional emails regarding Drug, bio-affecting and body treating compositions patents we recommend signing up for free keyword monitoring by email.



Results in 2.97563 seconds

PATENT INFO